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Abstract 
The effect of inositol-hexakisphosphate (phytate) on urinary risk factors for calcium 
oxalate urolithiasis in South African population groups with different kidney stone risk 
profiles: theoretical modelling, in vitro crystallisation experiments and in vivo human 
studies. 
Saajidah Fakier 
August 2015 
 
The principal aims of this thesis were to establish whether soluble calcium-phytate 
complexes inhibit calcium oxalate crystallisation and whether a higher dietary intake of 
phytate in South African black subjects compared to white subjects may contribute to the 
relative rarity of urolithiasis in this group.  
 
Potentiometric titrations were conducted to determine thermodynamic binding constants of 
soluble calcium-phytate complexes. Binding constants of seven complexes were identified. 
These were included in the data base of the Joint Experts Speciation System computer 
program to model the effect of phytate on the urinary supersaturation of calcium salts. 
Physiological concentrations of phytate failed to decrease ionized calcium and hence the 
urinary supersaturation of calcium salts.  
 
These theoretical predictions were then tested in an in vitro model. Calcium oxalate 
crystallisation experiments were conducted in simple salt solutions, artificial urine and real 
urine of the respective groups. The following parameters were measured: ionized calcium; 
calcium oxalate metastable limit; calcium oxalate particle volume-size distribution; calcium 
oxalate crystal nucleation, aggregation and growth kinetics. Deposited crystals were 
examined by scanning electron microscopy. The results confirmed those of the theoretical 
modelling. Furthermore, the results demonstrated that the inhibitory capacity of phytate is of 
a kinetic nature rather than a thermodynamic one. Phytate inhibited calcium oxalate crystal 
aggregation and the inhibition of calcium oxalate crystal growth was found to be independent 
of the physiological concentration of phytate.  
 
In vivo studies were conducted in which phytate-deficient, phytate-rich diets and a phytate 
supplement were administered in healthy black and white male volunteers. The baseline 
intake of phytate was assessed using food frequency questionnaires; urinary phytate was 
determined using a novel assay; biochemical and physiochemical urinary risk factors were 
measured. The black group had a significantly higher baseline intake of phytate culminating 
in a significantly higher urinary phytate excretion. No significant difference in urinary 
crystallisation kinetics was observed as being due to phytate per se.  
 
The findings of this thesis contribute to the pool of knowledge on urolithiasis and provide 
insight on the relative rarity of this disease in South Africa’s black population.   
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Kidney stone disease, also referred to as urolithiasis, renal stone disease and 
nephrolithiasis, dates back to centuries ago.1, 2 This disease is multifactorial and is governed 
by urinary risk factors, dietary factors as well as epidemiological & etiological factors, all of 
which will be described in greater detail in the subsequent paragraphs. The occurrence of 
kidney stone disease in South Africa is of interest in the context of the work presented in this 
thesis because its prevalence in the black population is less than 1 % whereas 15 % of the 
white population are prone to this disease.3-5 Thus, the coexistence of a stone-prone and a 
relatively stone-free population group provides added interest to research involving this 
disease.   
Composition of stones 
Essential body fluids are supersaturated with slightly soluble materials that can crystallise.6 
These crystals can be deposited in the body and is known as mineralization or calcification, 
since calcium is one of the major minerals that can be deposited in the human body.6 
Examples of calcification under physiological conditions are tooth and bone formation.7, 8 The 
aforementioned processes are well-defined and limited, unlike pathological crystallisation of 
salts in the urinary tract which may lead to the formation of kidney stones. Different types of 
crystals are precipitated in different parts of the nephron.9, 10 The most common types of 
crystals observed in the urine are as follows: calcium oxalate (CaOx), calcium phosphate 
(CaP), uric acid and struvite.11-14 Kidney stones are composed of these crystalline materials 
and often contain a mixture of several types with one or two that are predominant.   
Calcium Oxalate stones 
Approximately 80 % of kidney stones contain calcium, of which most are calcium oxalate 
(CaOx).15-17 This type of crystal has three different forms namely CaOx monohydrate (COM), 
CaOx dihydrate (COD) and CaOx trihydrate (COT).18 COM is most common in stones 
whereas the latter does not occur in stones. This is because COT is not thermodynamically 
stable and is thus transformed into COM and COD. Stones of this type may also contain 
CaP.19, 20 
Calcium Phosphate stones  
2- 20% of kidney stones are CaP stones.21, 22 These stone types are present as apatite (also 
reported as carbonate apatite) or calcium hydrogen phosphate (brushite).23, 24 The frequency 
of brushite stones is less than apatite.21, 22 Stones of this type may be found in combination 
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with CaOx or struvite but never with uric acid as the latter precipitates at a much lower pH.25, 
26 
Uric Acid Stones 
Approximately 8% of stones are uric acid stones.23 This type of stone forms when urine is 
supersaturated with uric acid, an acidic urine pH (less than 5.5) or a combination of the 
two.23, 27  Abnormal purine metabolism also causes uric acid stone formation.23, 27 
Struvite 
1% of stones are struvite stones, also known as “triple phosphate” and magnesium-
ammonium-phosphate-carbonate-apatite.23, 27 These stones are formed in the presence of 
urease-producing bacteria (eg. Proteus mirabilis) due to urinary tract infections and is more 
common in females than in males.28, 29 
The mechanism of stone formation 
Crystals in urine, known as crystalluria, is common to both stone formers and healthy 
people.30-32 This process involves two physicochemical facets namely a thermodynamic and 
a kinetic process.33-35 The former aspect includes urinary supersaturation which in turn leads 
to the nucleation of smaller crystals and the latter refers to the rates of crystal nucleation, 
growth, aggregation and phase transformation. The use of human tissue biopsies and 
intraoperative imaging led to the identification of three pathways for kidney stone formation.36-
38 These pathways include overgrowth on interstitial apatite plaques (Randall’s plaque 
theory39-42), growth on plugs of dilated ducts of Bellini (BD) and free solution crystallisation.36-
38 These concepts are described in detail in the paragraphs which follow.  
Supersaturation 
Supersaturation is the driving force for crystallisation and is the free energy necessary for 
this physicochemical process.33, 43 Supersaturation can be expressed by the following 
equation ΔG= RTln(Ai/A0) where R is the gas constant, T is the temperature and Ai & A0 
refers to the activity product of the salt at specific conditions and at equilibrium, 
respectively.33 The ratio of Ai to A0 is known as the relative supersaturation (RS). When this 
ratio is greater than 1, the urine is said to be supersaturated.23, 33 Although supersaturation is 
essential for the formation of crystals which may lead to the subsequent formation of stones, 
it is not always sufficient to differentiate between stone formers and healthy people.43-46 
Nucleation 
Nucleation is defined as the initial step in the formation of a solid phase from a 
supersaturated solution.47, 48 This crystallisation process will occur when the RS is greater 
than 1 and when the metastable limit (MSL, defined as the ability of a solution to resist 
spontaneous crystallisation6, 49, 50) is surpassed. Two types of nucleation processes exist 
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namely homogeneous and heterogeneous nucleation.6, 47 Homogeneous nucleation is 
spontaneous and occurs in a pure solution (i.e no foreign surfaces) at relatively low RS 
values.6, 43, 47 Homogenous nucleation is very unlikely to occur in urine since this medium is a 
complex solution containing many foreign surfaces which may serve as a platform for the 
formation of new crystals. The latter this is known as heterogeneous nucleation which occurs 
at RS values lower than that of a pure solution.6, 47 
Growth 
Nucleation may lead to crystal growth when a nucleus of a critical size has been established 
and when the RS remains above 1.6, 43, 48 Crystal growth is an intricate process involving the 
adsorption of new substances into the crystal lattice of existing crystals.6, 43, 48 These crystals 
may then adhere to each other to form larger particles via a process known as aggregation6, 
48 which is described below.  
Aggregation 
This mechanism is also referred to as agglomeration and involves the adhesion of particles 
in solution to form larger particles as mentioned above. Of the three essential processes that 
are required for stone formation, crystal aggregation is considered the most important 
mechanism in the context of kidney stone formation.6, 33 This is because the rate of 
aggregation is rapid relative to nucleation and growth and may lead to large crystalline 
particles in renal tubules.6, 33  
Overgrowth on interstitial apatite plaque (Randall’s plaque theory) 
This theory is defined as interstitial papillary and medullary deposits of apatite (plaque) which 
may serve as a nidus of a relatively large concretion.39-42 This pathway of stone formation 
has been postulated by Randall in 1937 where he examined several kidneys at post-mortem 
and found plaque in 20% of the kidneys, some of which had stones attached to them.39 More 
recently, endoscopic mapping of kidneys in CaOx stone formers revealed large amounts of 
Randall’s plaque which were prominent in CaOx stone formers with hypercalciuria.51, 52 
Another study confirmed that plaque is composed of apatite and that its origin is in the 
basement membrane of the thin limb of Henle’s loop in idiopathic CaOx stone formers (ICSF) 
only.53 Other studies have also demonstrated that Randall’s plaque is common in ICSF.54-58 
These studies showed that stones of ICSF were attached to Randall’s plaque56-58; the plaque 
surface area on kidneys was significantly higher in ICSF than in controls54 and that a 
correlation between the mean plaque surface area and the number of stone events exists55.  
Growth on plugs from dilated ducts of Bellini 
This pathway is common in brushite and primary hyperthyroid stone formers.36-38 Apatite 
deposits are found in ducts of Bellini (BD) and inner medullary collecting ducts (IMCD) of 
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these stone formers.36-38 These deposits “plug” the ducts leading to dilation of the ducts. 36-38 
Stones may grow from plugs which protrude from the dilated ducts into the urinary space. 36-
38 CaP stones were found to grow via this pathway.36, 37 
Free solution crystallisation 
This pathway refers to kidney stones which are free in the renal pelvis and were never 
attached. 36, 37 Stones which form via this pathway are composed of cystine. 36, 37 The latter is 
poorly soluble and supersaturated in the urine in BD which leads to stone formation.36 
Risk factors associated with stone formation 
There are several risk factors associated with CaOx stone formation. These may be divided 
into urinary risk factors, dietary habits and epidemiological and etiological aspects.  
Urinary Risk Factors 
Urinary calcium 
An excessively high urinary excretion of calcium (greater than 250 mg/ 24 hr in women and 
300 mg/ 24 hr in men) is known as hypercalciuria.59-61 Hypercalciuria is defined as a risk 
factor for calcium stone formation as it increases the urinary supersaturation of CaOx and 
CaP salts.59, 62, 63 In 30 – 50 % of calcium stone formers, hypercalciuria is often accompanied 
by normal serum calcium levels and in the absence of known causes of increased urinary 
calcium such as hyperthyroidism, cancer, sarcoidosis and an increase in vitamin D intake.59, 
64, 65 This is referred to as primary or idiopathic hypercalciura (IH). Three mechanisms for IH 
have been classified, namely absorptive hypercalciuria, resorptive hypercalciuria and renal 
leak hypercalciuria.59, 61, 66  
Absorptive hypercalciuria is the most common mechanism and is associated with elevated 
levels of 1,25-hydroxyvitamin D3.59, 67-69 The latter molecule (as well as the parathyroid 
hormone (PTH)) regulates the synthesis and activity of transporters responsible for the 
translocation of calcium from the intestine, kidney and bone during calcium homeostasis. 
Thus, elevated levels of 1,25-hydroxyvitamin D3 results in an increase in the absorption and 
subsequent excretion of urinary calcium.  
Resorptive hypercalciuria is caused by an increase in bone turnover which occurs due to an 
overproduction of PTH.70, 71 As mentioned above, this hormone is responsible for the 
regulation of calcium homeostasis.  
Renal leak hypercalciuria occurs due to an abnormality in renal tubular calcium 
reabsorption.59, 66 
Chapter 1                                                                                                General introduction 
5 
 
Increased urinary calcium excretion is also correlated to an increase in dietary calcium and 
dietary sodium intake.49, 72-75 
Urinary oxalate 
An elevated urinary oxalate excretion of greater than 45 mg/ 24 hr is classified as 
hyperoxaluria.63, 64 Urinary calcium was previously regarded as the most important risk factor 
for CaOx kidney stone formation.76-78 However, urinary oxalate is now regarded as the 
limiting risk factor since it has a greater effect on the urinary saturation of CaOx.79, 80 A 
correlation between urinary oxalate and stone disease has been reported.81, 82 These studies 
have shown that stone formers have a higher urinary oxalate concentration than healthy 
controls. Increased levels of urinary oxalate may be caused by a high dietary intake thereof16, 
83, hyperabsorption84, increased endogenous production84 as well as a deficiency of oxalate-
degrading bacteria.16, 85-87 
Urinary Uric Acid 
An abnormally high excretion of uric acid (greater than 800 mg/ 24 hr in men and 750 mg/ 24 
hr in females) is known as hyperuricosuria.64, 88, 89 This poses a risk for the formation, growth 
and aggregation of calcium oxalate crystals.89, 90 High urinary concentrations of uric acid 
were found in a third of CaOx stone formers which was postulated to be as a result of the 
over consumption of dietary protein or the endogenous overproduction of uric acid.91 Other 
researchers have hypothesized that the relationship between uric acid and CaOx may be as 
a result of the “salting-out” effect, whereby uric acid acts as a catalyst for CaOx crystal 
aggregation.92 Allopurinol therapy has been recommended for patients with high urinary uric 
acid.93 More recently an in vitro study has demonstrated that theobromine inhibits uric acid 
crystal nucleation and growth suggesting its potential therapeutic application in patients with 
uric acid nephrolithiasis.94   
Urinary pH 
Urinary pH is also a risk factor for the crystallisation of CaOx, CaPs as well as uric acid.25, 49, 
95-97 Urine with an alkaline pH is less susceptible to the formation of CaOx crystallisation; 
phosphate and citrate are ionised at this pH which may then bind calcium thus decreasing 
the saturation of CaOx.25, 95, 96 However, an increased complexation of calcium and 
phosphate at an alkaline pH (pH > 6) may increase the risk of CaP crystallisation if 
hypercalciuria is present.25, 96, 98 Patients undergoing therapeutic alkalinisation to reduce 
CaOx formation should therefore be monitored for the risk of CaP formation. At a pH less 
than 5.5, uric acid crystallisation occurs.95, 99 Thus, in order to decrease the risk of the 
formation of the aforementioned salts, it is recommended to maintain a urinary pH between 6 
and 7.16, 97, 100 
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Other urinary risk factors include that of a decrease in the urinary excretion of inhibitors such 
as citrate and magnesium. These are described later on page 11. 
Dietary risk factors 
Dietary oxalate 
Research has shown that urinary oxalate excretion is correlated to its dietary intake.83, 101-104 
The amount of dietary oxalate that is excreted in the urine ranges from 10-20 %105 to 40-53 
%.83, 106 Studies have also shown that an increase in dietary oxalate ingestion with a 
concomitant decrease in dietary calcium intake, increased the excretion of urinary oxalate.83 
77, 107-110 As dietary oxalate is directly related to its urinary excretion, CaOx stone formers are 
advised to reduce their intake of oxalate rich foods to less than 100 mg/ day.25 These foods 
include beetroot, chocolates, parsley, rhubarb, spinach, strawberries, tea and wheat bran.83, 
101, 104, 105, 111 
Dietary calcium 
As urinary calcium was thought to be the most important risk factor for CaOx stone 
formation, stone formers were advised to decrease their intake of this mineral.112-114 
However, recent studies have discovered that this practice is inappropriate and potentially 
harmful.49, 74, 115-117 A study in which a large cohort of men was investigated after decreasing 
the ingestion of dietary calcium over a period of 4 years showed that 8.7 % of the participants 
developed stones.115 Another study showed that the restriction of dietary calcium increased 
the relative supersaturation of CaOx.49 A decrease in the intake of dietary calcium therefore 
has an inverse effect on the formation of CaOx; this is because less calcium is available for 
the binding of oxalate in the gut which in turn leads to an increase in the absorption of 
oxalate and its subsequent excretion in urine.16 As mentioned previously, increasing urinary 
oxalate is a risk factor for CaOx stone formation. Patients are therefore advised to consume 
800 – 1200 mg of calcium per day.83, 118   
Dietary Protein 
Dietary protein has also been shown to influence CaOx urolithiasis. Epidemiological studies 
have shown a correlation between the incidence of urolithiasis and the consumption of 
animal protein (purine-rich).115, 119-122 Studies investigating the effect of dietary protein on 
urinary risk factors associated with CaOx urolithiasis showed that urinary calcium and uric 
acid increased whereas urinary citrate decreased when a diet with a high proportion of meat 
was consumed.115, 123-127 The mechanism of action for the increase in urinary calcium after 
animal protein consumption is as a result of an increase in endogenous acid production.128-130 
This leads to metabolic acidosis which increases calcium reabsorption from the bone leading 
Chapter 1                                                                                                General introduction 
7 
 
to an increase in urinary calcium excretion. An animal protein intake of 0.8- 1.2 g/ kg body 
weight per day is therefore recommended for kidney stone patients.118, 131  
Dietary sodium 
Research has shown that dietary sodium intake is directly proportional to urinary calcium 
excretion.72-74, 132, 133  A recent study showed that urinary calcium decreased in idiopathic 
hypercalciuric stone formers (n= 210) when a diet low in sodium was consumed.134 Thus, 
CaOx stone formers are advised to maintain a sodium intake of 2-3 g per day.25, 134, 135  
Dietary fatty acids 
Studies have shown that CaOx stone formers have an abnormal renal phospholipid 
composition which results in hyperoxaluria and hypercalciuria.136-138 A higher concentration of 
arachidonic acid (AA, a polyunsaturated omega-6 fatty acid) in the membrane phospholipids 
is present in stone formers.136-138 This fatty acid facilitates intestinal calcium absorption, 
hypercalciuria and alters the urinary excretion of prostaglandin 2 (PGE2, a phospholipid 
metabolite).137, 139 AA and PGE2 can be reduced by essential fatty acid supplementation. 
These essential fatty acids contains eicosapentaenoic and docosahexaenoic 
polyunsaturated acids (omega-3 fatty acids) which increases the cell membrane’s fluidity, 
flexibility and permeability to the regulation of ion transport such as calcium, sodium and 
potassium and to the transmembrane exchange of substances like oxalate.136, 140 Research 
has confirmed that fatty-acid supplementation reduces calcium, oxalate and PGE2 in urine of 
CaOx stone formers.139, 141-143 CaOx stone formers are therefore advised to consume omega-
3 fatty acids daily.139, 141, 143 Sources of this fatty acid are fish, fish oil, flax seed oil, walnut oil 
and it can also be consumed in supplemental form.   
Fluid intake 
One of the most common dietary measures for the prevention of stone formation is to 
maintain dilute urine by adequate fluid intake; this reduces the supersaturation of stone-
froing salts.  
Although “fluid intake” usually refers to water intake, other beverages such as lemon juice,144-
147 cranberry juice,148 orange juice,146 grape juice and apple juice145 were also studied in the 
context of urolithiasis. These beverages were however administered not only to increase 
urinary volume but to increase the urinary concentration of inhibitors such as citrate as well 
as to increase urinary pH. While some of these beverages increased urinary citrate and pH 
(lemon, cranberry and orange juice) others (grape and apple juice), have increased the risk 
of kidney stone formation. Thus, caution should be exercised with regard to the type of 
beverage used to increase urinary volume. Beverages such as cola and hot chocolate are 
also not advised due to their high oxalate content.104, 149 Notwithstanding these adverse 
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effects of beverages, the intake of water as source of fluid intake has been shown to 
decrease the risk of stone formation in studies consisting of both stone formers and healthy 
individuals.117, 150-155 Stone formers are therefore advised to drink water as a source of fluid 
intake between 2.5- 3 L per day to maintain a urinary volume of 2 L. 156-158   
Epidemiological and etiological risk factors 
Climate and geographical distribution 
The risk of CaOx urolithiasis is higher in the western hemisphere where the prevalence is 
5-9 % in Europe, 12% in Canada and 13-15 % in the USA than in the eastern 
hemisphere 1-5 %.27 However, a higher risk is present in Saudi Arabia (20.1%).27 The higher 
incidence in Arabia is due to socio-economic factors, local dietary intake habits which is high 
in oxalate as well as environmental factors such as the hot climate.159 Hot climates contribute 
to dehydration and decreased urinary volume, increased urine osmolality, and increased 
concentration of calcium and oxalate.160, 161 A recent study in which the 24 hr urine 
compositions of 50 marines were monitored before mobilization to the desert, after 30 days 
in the desert and 2 weeks after returning from the desert was conducted.162 This study 
showed that the daily urine output decreased significantly after being in the desert. The 
urinary excretion of calcium, uric acid, sodium, magnesium and potassium as well as pH 
decreased and small changes were observed for citrate and oxalate in this study. The 
researchers hypothesized that the kidneys preserved water and electrolytes while in the 
desert; however, the relative supersaturation of uric acid and sodium urate increased 
significantly which indicates an increased risk for stone formation when exposed to desert 
conditions. In Saudi Arabia, a correlation between stone incidence and both temperature and 
atmospheric pressure has been reported.163 Two recent studies have also demonstrated that 
an increase in stone incidence with global warming is evident; showing that temperature is 
correlated to stone incidence.164, 165  
Occupation 
Research has shown that an increase in risk factors associated with urolithiasis is associated 
with certain occupations.166, 167 This is most common in sedentary occupations such as 
aviation pilots or truck drivers167-169 whereas individuals doing manual work such as farming 
and forestry have a lower risk of forming stones.170 A recent study also demonstrated that 
workers in the steel industry who are exposed to hot temperatures have an increased risk for 
kidney stone formation.171 Hypocitraturia and low urine volumes were observed in this study 
which are risk factors for CaOx urolithiasis.171  
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Gender 
Epidemiological studies have shown that the prevalence of urolithiasis in males is higher 
than in females with a ratio of 2:1.120, 172 Studies also showed that males have a higher 
urinary excretion of oxalate.173, 174 These differences may be attributed to sex hormones in 
which oestrogen is thought to play a protective role in females by lowering the urinary 
supersaturation of stone-forming salts.173, 175 Testosterone, in males, on the other hand may 
increase urinary oxalate resulting in an increased risk for kidney stone formation.176, 177 
Race 
The relationship between race and the occurrence of CaOx urolithiasis has been investigated 
for many years.4, 178, 179 These studies were conducted to identify clinical and/or 
epidemiological factors within each group that will account for the difference in the 
occurrence of stone formation between the groups.180 Differences in the occurrence of stone 
formation between two race groups within the same country have been observed.16 For 
example, in the US the occurrence of idiopathic stone disease is more prevalent in whites 
than in blacks.181-183 Similarly in South Africa the prevalence of CaOx kidney stone disease in 
whites is 15 % whereas less than 1% of the black population are prone to this disease.3, 4 
Some studies showed that certain urine parameters may account for the difference in the 
racial prevalence of this disease.4, 5, 182, 184, 185 Several studies have been done to elucidate 
the rarity of CaOx urolithiasis in South African blacks and will be discussed in greater detail 
towards the end of this chapter.     
Modulators of stone formation 
Crystals formed in the urine are normally excreted harmlessly in non-stone formers.31, 186 
Other mechanisms that may also lead to stone formation such as Randall’s plaques remain 
as such in non-stone formers.51 These phenomena indicate that urine contains certain 
substances that modulate the mechanisms essential for stone formation i.e. supersaturation, 
nucleation, growth and aggregation.187 There are two types of modulators: high molecular 
weight (HMW) modulators such as proteins and glycosaminoglycans (GAGs) and low 
molecular weight (LMW) compounds such as citrate and pyrophosphate.187 These 
modulators influence crystal formation and retention by direct interaction with the crystal or 
indirectly by influencing the urinary environment.187 It should be noted that these modulators 
may either inhibit or promote the mechanisms associated with kidney stone formation. As 
CaOx is the major type of kidney stone, the modulators associated with this type will be 
described below. 
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High molecular weight modulators 
GAGs 
GAGs are polyanionic compounds composed of repeating disaccharide units that consist of 
N-acetylated or sulphated glucosamine or galactosamine amino sugar and a glucuronic acid 
N-free monosaccharide.188 Urinary GAGs include heparan sulfate (HS), chondroitin sulphate 
A, B and C (CS-A, CS-B, CS-C), dermatan sulphate (DS), keratan sulphate (KS) and 
hyaluronic acid (HA).189-191 These GAGs have been shown to inhibit certain mechanisms of 
CaOx crystallisation due to their ability to bind to CaOx crystal surfaces.192 In vitro studies 
showed that CS is able to inhibit crystal aggregation193-195 and growth193. HS was also 
reported to inhibit crystal growth and aggregation.196 However, the inhibitory effects in in vitro 
experiments do not always reflect the effects in vivo. An in vivo study showed that CS 
promotes nucleation and aggregation197 whereas another showed that HS promotes CaOx 
crystal nucleation (which may be seen as favourable since urinary supersaturation is 
decreased) and inhibits aggregation.198 Furthermore, some studies investigating the 
excretion of GAGs in stone-formers showed that the concentration is significantly less when 
compared to healthy individuals88, 199, 200 whereas others found no significant difference201-203. 
These differences may however be as a result of different techniques used for the 
quantification of GAGs as well as different patient selection criteria employed. Another study 
showed that recurrent CaOx stone formers excreted fewer GAGs than non-stone formers.204 
Thus, increasing the excretion of GAGs may enhance the inhibitory activity of urine. 
Proteins 
Proteins are excreted in urine in relatively small quantities at concentrations less than 
150 mg per day in normal urine.205 Tamm-Horsfall protein (THP), nephrocalcin (NC), 
osteopontin (OPN) and urinary prothrombin fragment 1 (UPTF1) have been studied 
extensively and are believed to play an inhibitory role in CaOx stone formation.205, 206 THP is 
the most abundant protein found in urine at concentrations between 20-200 mg/ day. In vitro 
studies on this protein in undiluted, ultra-filtered urine showed that it inhibits CaOx crystal 
aggregation due to steric hindrance as opposed to adsorption to the crystal surface.198 This 
protein does not show any major inhibitory activity with respect to CaOx crystal growth or 
nucleation.205 NC on the other hand was shown to inhibit CaOx crystal growth207, 
nucleation208 and aggregation209, 210. OPN was also shown to inhibit CaOx crystal nucleation 
in supersaturated solutions208, 211 as well as aggregation212. This protein is also capable of 
modulating the adhesion of COM crystals to renal epithelium cells208 thus preventing their 
retention and subsequent formation of stones. UPTF1 was also reported to be a powerful 
inhibitor of CaOx crystal growth and aggregation in human urine.213  
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Low molecular weight inhibitors 
Pyrophosphate 
Pyrophosphate, found at concentrations between 15- 100 µM in urine, was the first urinary 
crystallisation inhibitor discovered.214 This LMW compound was shown to inhibit CaOx crystal 
nucleation215, growth and aggregation216-218 due to its ability to irreversibly bind to the CaOx 
crystal surface. It was also shown to inhibit the formation of calcium phosphates.219, 220 
Furthermore, it also favours the more preferential form of CaOx i.e. COD221 which is less 
retained on the renal epithelium and also more common in normal urine than in urine of 
stone formers.222 The effect of pyrophosphate in undiluted urine however, is not comparable 
to that found in inorganic media. For example, pyrophosphate had no effect on the amount of 
oxalate required to induce CaOx crystal nucleation and aggregation in urine.206 The effect of 
pyrophosphate on CaOx crystallisation under physiological conditions is therefore difficult to 
elucidate.  
The role of pyrophosphate in kidney stone disease was also investigated by comparing its 
concentration in urine of normal individuals and stone formers. Although some studies 
showed that the urinary excretion of pyrophosphate in stone formers was significantly less 
than in healthy individuals223, 224, others showed that there was no significant difference.225, 226 
However, even though no significant difference in the urinary excretion of pyrophosphate is 
observed between stone formers and non-stone formers, it is possible that increasing the 
excretion of pyrophosphate may increase the inhibitory activity of urine.187  
The oral administration of orthophosphate was shown to increase the excretion of 
pyrophosphate however, this therapy was not proven effective in preventing stone 
formation.227 Potassium phosphate (Urophos-K) also increased the excretion of 
pyrophosphate.228 This treatment increased urinary citrate and inhibited crystal aggregation; 
it also decreased the nucleation of brushite. The effect of Urophos-K on the inhibition of 
crystal growth has not however been shown.  
Citrate 
In vitro studies in aqueous media showed that citrate is able to inhibit CaOx crystal 
nucleation215, 229, 230, growth193, 216, 231 and aggregation193, 232. It was also shown to inhibit CaOx 
deposition in undiluted233 and concentrated234 urine. The inhibitory activity of this low 
molecular weight compound is due to its ability to chelate calcium as well as its ability to bind 
to the CaOx crystal surface. Furthermore, in vivo studies have shown that hypocitraturia is 
common in stone formers235-240 and that, upon the administration of alkali therapy, the 
inhibition of crystal aggregation was increased241-243. Clinical trials have investigated the 
efficacy of several citrate-containing compounds such as potassium citrate244-246, calcium 
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citrate247, 248 and sodium-citrate-bicarbonate-tartrate249. These studies showed a decrease in 
the risk factors associated with urolithiasis and as such citrate has become an accepted form 
of stone therapy.  
Magnesium 
Magnesium is able to form ion complexes with oxalate which accounts for its inhibitory effect 
on CaOx crystallisation.17 In vitro experiments, in inorganic aqueous solutions as the reaction 
medium, demonstrated magnesium’s ability to inhibit CaOx crystal nucleation250, growth215 
and aggregation.193, 251 Another mechanism by which it may inhibit CaOx crystallisation is by 
binding to the surface of the crystals and becoming incorporated into the crystal lattice.252 On 
the other hand, other studies showed that magnesium has no effect on CaOx crystal 
nucleation215, growth216-218 and combined growth and aggregation.253 In vitro studies in urine 
showed that magnesium inhibits growth254, 255 and increases the CaOx MSL but has no effect 
on aggregation.254   
Phytate is another LMW inhibitor of CaOx urolithiasis and is described below. 
Phytate 
Phytate, also known as myo-inositol-hexakisphosphate, IP6 or phytic acid (in its fully 
protonated form), is of plant origin where it serves as a storage form of phosphorus and 
minerals and has a molecular weight of 660 g.mol-1.256-258 It is mainly found in whole-grains, 
legumes, oil seeds and nuts.259 This molecule is the central focus of the current thesis and as 
such will be discussed in detail in the paragraphs that follow and will henceforth be referred 
to as IP6. 
Structure of phytate 
IP6 consists of a myo-inositol ring and 6 phosphate groups hence the name “myo-inositol-
hexakisphosphate”.256, 258, 260, 261 The prefix “myo” refers to the configuration of the 6 hydroxyl 
groups on the inositol ring in which 5 may be in the axial position and 1 in the equatorial 
position (5axial / 1 equatorial) or alternatively with 5 in the equatorial position and 1 in the 
axial position (5 equatorial/ 1 axial). Each phosphate group is esterified to the inositol ring. 
Conformational studies on the structure of IP6 demonstrated that the 5 axial/ 1 equatorial 
conformer is predominant at physiological pH (6- 7) as shown in Figure 1.1.     
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Figure 1.1 Structure of IP6 at physiological pH (6-7)259. Conformation: 5 axial/ 1 equatorial. 
 
Bioavailabity of phytate in living organisms 
One of the first reports indicating the absorption of IP6 was demonstrated in 1980 whereby 
radiolabelled IP6 was administered to rats and recovered in blood, organs, bones and 
urine.262 A later study also administered radiolabelled IP6 to rats and found a large amount of 
radioactivity in the liver, kidneys and trace amounts in blood and urine.263 A more recent 
study in which IP6 was administered to rats for 7 days showed that both plasma and urinary 
IP6 was significantly higher than in the control rats.264 Furthermore, the IP6 levels in organs 
such as the brain and kidney was also higher than in the control rats.264 Similar results were 
also observed in other studies indicating that dietary IP6 increases the concentration of this 
substance in plasma, urine and organs of rats.265-267  
In humans, a study investigating the pharmacokinetic profile of IP6 was conducted.268 This 
study consisted of 7 individuals and the administration of 3 different doses of IP6 between 
400- 3200 mg/ day was investigated. All IP6 rich foods such as whole-grains, rice and 
legumes were restricted for 15 days. This study demonstrated that both plasma and urinary 
IP6 decreased within 15 days of an IP6 deficient diet. Furthermore, the same urinary 
excretion profile of IP6 was observed for the 3 different doses of IP6 leading the authors to 
speculate that urinary IP6 excretion reaches a plateau which  cannot be exceeded by an 
Equatorial 
position 
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excess intake of dietary IP6. Other studies also demonstrated the correlation between dietary 
IP6 and its bioavailability in humans.265, 269  
The above indicates that the bioavailability of IP6 in both humans and rats is dependent on 
its dietary intake to maintain its normal concentrations in plasma, urine and tissues.    
Nutrient or antinutrient 
As mentioned above, IP6 has six phosphate groups (each with hydroxyl moieties) giving it a 
large negative charge under physiological conditions.258 This molecule is therefore able to 
chelate ions such as Zn2+, Fe2+, Mg2+ and Ca2+.258 Therefore, during gastro-intestinal 
passage, IP6 may inhibit the absorption of these essential trace elements and minerals 
(when a mineral- deficient diet is consumed with an IP6- rich diet) leading to deficiencies of 
these minerals in the organism.270-272 IP6 was therefore regarded as an antinutrient for many 
decades. As a result, research has been done to remove IP6 from food by proper processing 
to improve the bioavailability of essential trace elements and minerals.259 This consequently 
led to a decrease in the intake of IP6 in more affluent societies. However, in the last 2 
decades, beneficial properties of IP6 have been reported. These properties include 
antioxidant273 and anticancer activities274, positive effects on blood glucose and blood 
cholesterol275, 276 as well as the inhibition of CaOx and CaP crystallisation and the prevention 
of urolithiasis.277  
Phytate and urolithiasis 
This molecule’s ability to chelate multivalent cations such as Ca2+ is of relevance in CaOx 
urolithiasis. The administration of IP6 as a prophylactic treatment of urolithiasis dates back to 
1958 where high doses of IP6 as the sodium salt (8.8 g/ day) was used to treat stone-
formers with hypercalciuria.278 This study demonstrated a significant decrease in urinary 
calcium which occurred due to the formation of insoluble calcium-phytate complexes in the 
intestinal tract culminating in a decrease in calcium absorption.278 Other studies also showed 
that the consumption of rice bran279 and unprocessed bran280 (source of IP6) decreased the 
urinary excretion of calcium in patients with idiopathic hypercalciuria. More recently, 
however, research has been focused on the administration of lower doses of IP6 with the aim 
of increasing its urinary excretion to increase the urine’s inhibitory activity towards CaOx and 
CaP crystallisation as cited in a review article by Schlemmer et al.259 Both in vitro as well as 
in vivo experiments in animals and humans have been conducted. Research in this field has 
been conducted principally by Grases and his co-workers (University of Balearic Islands, 
Spain). The outcome of these studies are described below.  
In vitro studies showed that IP6 has the ability to inhibit the crystallisation of both CaOx and 
CaP. The effect of IP6 on the early stages of COM crystallisation on the urothelium was 
Chapter 1                                                                                                General introduction 
15 
 
studied. 281 This was investigated by adding synthetic urine containing different 
concentrations of IP6 onto three different inert substrates, namely wax, CaP and CaP-mucin 
to determine its effect on the heterogeneous nucleation of COM. It was found that IP6 
inhibited the nucleation of COM on all three substrates at a concentration as low as 
7.15 x 10-7 M. The effect of IP6 on the development of COM crystals have also been studied 
on living substrates such as the urothelium of the pig urinary bladder.282, 283 These studies 
showed that IP6 prevented the development of COM and CaP deposits. Recent studies have 
also investigated the in vitro effect of IP6 on crystallisation kinetics in artificial urine.220, 284-287 
These studies showed that IP6 inhibited the nucleation of brushite at concentrations as low 
as 1.21 x 10-5 M and hydroxyapatite at a concentration of 3x10-6 M220;  inhibited the growth 
rate of COM crystals on hydroxyapatite crystal surfaces at a concentration of 2.27x10-6 M 
under normocalciuric conditions and at 9.09x 10-6 M under hypercalciuric conditions284; 
inhibited the growth rate of artificial stones in the presence of 2.5x10-6 M IP6285 and inhibited 
the regrowth of COM286 and COD fragments of post extracorporeal shock wave lithotripsy 
(ESWL)287 in the presence of 3.03 x 10-6 – 9.09 x 10-6 M IP6.  
In vivo studies in rats showed that the number of calcifications on kidneys in lithogenic rats 
was reduced when the rats were treated with IP6 (1.08 x 10-4 M).288 Similar results were 
obtained in another study in which rats were treated with vitamin D to induce the calcification 
of renal tissues.284 This study showed that a significant reduction in calcium deposits was 
observed when rats were treated with IP6.284 This was confirmed in another study in which 
rats fed with a purified diet, free of IP6, were more susceptible to kidney calcifications than 
those fed with a diet containing 1% Na-IP6.289 Urine analysis of these rats revealed that 
those fed with IP6 had a higher excretion of this substance than those consuming the purified 
diet.289 Furthermore, the concentration of both calcium and phosphorous in the kidneys of the 
control group of rats (fed with the purified diet) were greater than in the kidneys of the rats 
fed with 1% Na-IP6.289 Previous studies also demonstrated a decrease in urinary calcium 
excretion, in lithogenic rats, after the administration of IP6.279, 290 More recently, a study 
investigated the effect of four different salt forms of IP6 , namely calcium-magnesium-IP6, 
magnesium-potassium-IP6, sodium-IP6 and potassium-IP6 on the urinary excretion of 
calcium in lithogenic rats.291 Results of this study showed that calcium-magnesium IP6 had 
no effect on the excretion of urinary calcium whereas the other three salts decreased the 
amount of calcium significantly and that potassium- IP6 was the most effective.291   
In vivo studies in humans demonstrated that the normal urinary concentration of IP6 
oscillates between 0.757- 4.54 x 10-6 M as cited in a review article by Schlemmer et al.259 
Furthermore, the urinary excretion of IP6 was found to be significantly lower in stone formers 
than in normal individuals.265 An in vivo study investigated the effect of IP6 ingestion in CaOx 
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stone formers.292 In this study, a lithogenic test (a test developed by Grases et al to evaluate 
crystallisation propensity in urine293) was performed prior to and post administration of 120 
mg of IP6 for 15 days (n= 12 CaOx stone formers).292 This study had a control group 
consisting of 13 CaOx stone formers. After 15 days of IP6 ingestion, the lithogenic test was 
negative for 50 % of the stone formers whereas only 7 % of the control group tested 
negative. This study demonstrated that an increase in urinary IP6 has the potential to reduce 
the risk of CaOx stone formation.  
In summary, both in vitro and in vivo experiments have demonstrated the inhibitory capacity 
of IP6 towards CaOx and CaP crystallisation.         
CaOx urolithiasis in South Africa 
As mentioned earlier, the occurrence of kidney stone disease in the black population is 
relatively rare (1 %) whereas its occurrence in the white population (%15) is comparable to 
other western countries.3-5 It was hypothesised that various factors, including urine 
composition4, 5, 294-298, renal handling of lithogenic and antilithogenic substances16, 295, 296, 299-301 
as well as dietary habits5, 294-298, 302 may account for the rarity of CaOx urolithiasis in the 
former group.  
Several differences in urinary risk factors associated with CaOx urolithiasis were observed 
between the two groups. Urinary calcium4, 5, 294-296, 298, 299, 302, phosphate4, 5, 295, 296, 299, 302 and 
urate296, 299, 302 was found to be lower in the black group. However, all were within the normal 
range. Furthermore, although a lower urinary concentration of these risk factors may 
decrease the risk of kidney stone formation, it cannot account for the absolute rarity of the 
disease in this group. Other differences such as a higher urinary oxalate295, 297 and lower 
urinary citrate4, 294, 297, 302 and magnesium298, 302 excretion in the black group are 
counterintuitive as it suggests that the black group has a higher risk of forming CaOx kidney 
stones compared to the white group. Other urinary parameters such as sodium have been 
reported to be higher in the black group4, 5, 294 whereas inconsistent or no differences have 
been found in urinary pH4, 295. The rarity of CaOx urolithiasis in the black population can 
therefore not be attributed to the traditional urinary risk factors associated with this disease.  
The composition of urinary macromolecules (proteins and GAGs) in the respective groups 
has also been investigated. A study investigating the inhibitory activity of crystal matrix 
extract (CME) isolated from urine of black and white males showed that CaOx crystal 
nucleation was inhibited in artificial urine and that the inhibitory activity of CME derived from 
the urine of blacks was greater.303 It was speculated that the inhibitory activity was due to a 
protein called UPTF1. A follow up study investigating the effect of UPTF1 (in real urine) 
isolated from urine of black and white subjects, showed that it promoted nucleation.304 In the 
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same study, CaOx crystal size was decreased in the presence of UPTF1 and its inhibitory 
activity was shown to be synergistically dependent on urine composition.304 The inhibitory 
activity of UPTF1 was greater in its endogenous urine. Furthermore, the inhibitory activity of 
UPTF1 in the urine of black males was superior, suggesting that its conformation may be 
influenced by the urine composition.304 Structural analysis showed that UPTF1 derived from 
urine of black individuals have more ɣ-carboxyglutamic acid and sialic acid which may 
influence its modulatory capacity.305 
Other studies included the investigation of albumin306, 307, bikunin308, 309 and THP310, 311. 
Albumin isolated from urine of black individuals inhibited CaOx crystal growth and 
aggregation to a greater extent compared to those isolated from urine of white individuals.306 
The greater inhibitory activity of the albumin isolated from the urine of the former group may 
be due to the presence of higher negative charges on this molecule compared to albumin 
isolated from urine of white individuals.307  
Bikunin isolated from urine of the two groups showed that CaOx crystal growth and 
nucleation was inhibited in the presence of this substance.308 Bikunin derived from urine of 
black individuals inhibited CaOx crystal aggregation to a greater extent compared to the 
bikunin isolated from the urine of white individuals.308 
THP isolated from the urine of black subjects demonstrated a greater inhibitory capacity of 
CaOx crystal aggregation compared to THP isolated from the urine of white subjects.310, 311 
Furthermore, the THP derived from the urine of the former group inhibited CaOx crystal 
growth in its endogenous urine as well as in the urine of white subjects.310, 311 In contrast, 
THP derived from the urine of white subjects promoted CaOx crystal growth in its 
endogenous urine and showed inhibition in the urine of black subjects.310, 311 It was 
speculated that the difference in inhibitory activity may be due to structural differences such 
as a higher molecular weight, more cysteine and glycine, and less alanine, valine, leucine 
and phenylalanine in the THP of the black group.297  
The role of GAGS was also investigated.312 Chondroitin sulphate and dermatan sulphate 
were found to be higher in urine of black individuals.312 Crystallisation experiments 
demonstrated that GAGs from the respective race groups promoted CaOx crystal nucleation 
and inhibited aggregation in both artificial and real urine.312 Furthermore, GAGs isolated from 
the urine of black subjects inhibited CaOx crystal aggregation and growth in real urine to a 
greater extent than those isolated from the urine of white subjects.312 This suggested that 
GAGs may play a protective role against kidney stone formation in the black group. 
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In addition to the investigation and comparison of urinary parameters between the South 
African black and white population groups, dietary studies have also been conducted. These 
studies showed that dietary sodium intake is greater in the black group compared to the 
white group.5, 294 This correlates with the higher urinary sodium found in the former group.4, 5, 
294 However, despite the well-known fact that an increase in dietary sodium leads to an 
increase in urinary calcium, the latter is lower in the black group as stated earlier. Dietary 
calcium was reported to be lower in the black group which may account for its lower urinary 
excretion in this group, however this does not explain the lower incidence of CaOx 
urolithiasis in this group.297, 298, 302 Furthermore, animal protein was also found to be lower in 
the black group which is consistent with the lower incidence of CaOx urolithiasis in the black 
group as animal protein is associated with an increase in the risk of this disease.295, 297, 298, 302 
Interestingly, dietary oxalate was found to be higher in the black group.297, 298, 302 This is 
counterintuitive as an increase in dietary oxalate is a risk factor for CaOx urolithiasis. 
Similarly, dietary magnesium297, 298, 302 and vitamin B6295, 297 were found to be lower in the 
black group even though these two dietary factors may reduce the risk of CaOx urolithiasis.  
Extensive research on the renal response to dietary and supplemental challenges has also 
been conducted. These studies included the investigation of a high dietary oxalate/low 
calcium challenge295, low calcium296, high oxalate296, lacto vegetarian296, vitamin C 
supplementation296 and vitamin E supplementation298 amongst others. The results of these 
studies demonstrated that a different renal response to the respective challenges were 
evident between the two groups. Some of these studies will be described in the paragraphs 
below.  
A study investigating the effect of a diet rich in oxalate (510 mg) and poor in calcium (318 – 
334 mg) was conducted.295 Healthy South African black and white males (11 per group) were 
enrolled in the study. This study showed that urinary oxalate increased significantly in the 
white group (by 57 %) whereas no change was observed in the black group. The researchers 
proposed that lower oxalate absorption rates in the black group may be present. 
Interestingly, when a low calcium (400 mg) diet was administered in another study, urinary 
oxalate increased significantly in the black group whereas no difference was observed in the 
white group.296 The researchers speculated that the black individuals may be more sensitive 
to the proposed mechanism whereby a diet low in calcium leads to an increase in the urinary 
excretion of oxalate107 and a consequent increase in the risk of CaOx stone formation. In the 
same study, a high oxalate diet (510 mg) was administered.296 Surprisingly, the urinary 
oxalate did not increase in either group relative to their baseline excretions. In the white 
group, urinary potassium, pH and the RS of brushite increased whereas urinary citrate 
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increased in the black group. The researches acknowledged that the increase in both pH and 
citrate are favourable as it decreases the risk of stone formation.96, 241, 313 The increase in 
urinary potassium in the white group was also seen as a protective mechanism for the 
inhibition of CaOx crystallisation in response to the oxalate challenge.314 However, the 
researchers postulated that since the black group are relatively immune to stone formation, 
the citrate response in this group to the high oxalate protocol may be a more effective 
protective mechanism than the increased urinary pH and potassium in the white group.  
The investigation of high dietary calcium (915 mg) and a calcium supplement (915mg) was 
also investigated.299 This study showed that both dietary calcium and a calcium supplement 
did not significantly alter any urinary biochemical or physicochemical risk factors in the black 
group. However, in the white group, urinary potassium increased significantly and the RS of 
brushite decreased significantly after a high calcium diet was administered. The (Tiselius 
Risk Index) TRI and the RS of CaOx decreased and the CaOx MSL increased after ingestion 
of the calcium supplement. These changes were regarded as favourable and in agreement 
with the hypothesis that a diet rich in calcium decreases the risk of CaOx stone formation.49, 
115  
The effect of vitamin C (1000 mg), high dietary sodium chloride (15 -18 g) and a lacto-
vegetarian diet on the urinary risk factors associated with CaOx urolithiasis in the respective 
groups was also investigated.296 After the vitamin C challenge, the TRI increased in the black 
group whereas no changes were observed in the white group. Urinary chloride increased in 
both groups whereas sodium increased in the black group only after the ingestion of high 
dietary sodium; surprisingly, the urinary calcium excretion did not increase in either group. 
Urinary pH increased significantly in the black group only after a lacto-vegetarian diet was 
followed.  
Another study investigated the effect of the following supplements: vitamin B6 (100mg), L-
glutamine (2000mg) and L-cysteine (500mg) on the urinary risk factors for CaOx 
urolithiasis.299 In the white group, the vitamin B6 challenge significantly decreased urinary 
calcium, urinary phosphate and the RS of brushite; L-glutamine significantly decreased the 
RS of CaOx; and L-cysteine decreased urinary calcium. No significant changes were 
observed in the black group.  
Other supplements such as vitamin E have also been investigated. A study showed that the 
ingestion of this supplement by the respective groups significantly increased plasma vitamin 
E in the white group as well as urinary citrate in both groups.298 The increase in urinary 
citrate was however greater in the white group. The researchers speculated that the increase 
in plasma vitamin E in the white group only, may be indicative of different absorption rates of 
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the vitamin between the respective groups or that the mechanism whereby it is packaged 
into chylomicrons315, which are secreted into the systematic circulation, may be suppressed 
in the black group. The greater increase in urinary citrate in the white group was speculated 
to be as a result of the inhibition of lipogenesis of AA by vitamin E316, 317, leading to an 
increase in urinary citrate, which may occur to a lesser extent in the black group.  
Finally, a dietary survey conducted at Groote Schuur Hospital (South Africa) during 1971 -
1979 revealed that the most important difference between the black and white population 
groups seemed to be the type of phosphorus (P) ingested.318 The main source of P in the 
white group was inorganic P derived from animal sources. In the black group, inorganic P 
was comparable to that of the white group. However, in addition to inorganic P, the black 
group ingested a considerable amount of organic P derived from maize, beans and brown 
bread in the form of IP6. Modlin hypothesised that the significantly higher intake of IP6 in the 
black group compared to the white group may manifest itself in a higher urinary excretion 
which may contribute to the relative rarity of renal lithiasis in the former group. 
 More recently, a pilot study investigating the effect of dietary IP6 on urinary risk factors 
associated with CaOx urolithiasis was conducted in healthy black and white South African 
subjects in the Kidney Stone Research Laboratory (KSRL) at the University of Cape Town.319 
However, this study revealed counterintuitive findings whereby the black group excreted a 
significantly lower amount of urinary IP6 than the white group while on their unrestricted 
diets. In addition, the renal response to an IP6 dietary challenge was investigated in the 
aforementioned study. This dietary intervention revealed that IP6 excretion increased 
significantly in the black group after IP6 administration, whereas no change was observed in 
the white group. The researchers suggested that the renal handling of dietary IP6 may be 
different in the two groups.  
The hypotheses by Modlin as well as the findings of the latter study are of interest in the 
present PhD project. 
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Hypotheses and objectives 
In the aforementioned study, quantification of urinary phytate was determined using an 
indirect colorimetric assay in which the amount of phosphate per IP6 molecule was 
detected.319 The reliability of the method therefore depends on adequate separation of 
inorganic phosphate and IP6 during sample preparation. However, the sample preparation 
used in this study did not adequately separate inorganic phosphate. As such the results and 
conclusions presented in that study remain questionable. Before any firm conclusions can be 
drawn, urinary IP6 needs to be determined by a much more reliable and robust method. 
Indeed, this constitutes one of the objectives of the present study. Furthermore, the notion of 
urinary phytate being an inhibitor of calcium stone formation deserves interrogation. This 
aspect constitutes a second objective. Finally, the observation of a much higher dietary 
intake of IP6 in South African black individuals compared to their white counterparts, and the 
relative rarity of stone disease in the former group, warrant investigation.  
The hypotheses of the present thesis are as follows: 
1. Exogenously derived urinary IP6 is a powerful inhibitor of calcium renal stone 
formation by virtue of its ability to form calcium- phytate complexes.    
2. The relative rarity of renal stone formation in South Africa’s black population 
compared to the white population can be partly attributed to the much higher dietary 
intake of IP6 in this group. 
The overall aim of the work described in this thesis is to test the rigour of the above two 
hypotheses. 
In order to achieve this overall aim, the following objectives were defined: 
 
1. Determine the calcium-phytate thermodynamic formation constants using 
potentiometry. 
2. Use the aforementioned constants to model the effect of urinary IP6 on the 
concentrations of ionized calcium and the supersaturation of calcium salts in urine. 
3. Test the practical application of a new method for the determination of urinary IP6 in 
an animal model with a view of applying the method in human urine. 
4. Test the predictions of the modelling performed in objective 2 by investigating the in 
vitro effect of IP6 on CaOx crystallisation mechanisms in artificial urine and real 
urine from healthy black and white South African subjects. 
5. Assess the dietary intake of IP6 and other nutrients in healthy black and white 
subjects using semi-quantitative food frequency questionnaires. 
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6. Determine the baseline concentration of urinary IP6 in the groups identified in 
objective 5 above. 
7. Determine the concentration of IP6 and other lithogenic and anti-lithogenic urinary 
components in each group after the administration of an IP6- deficient and IP6- rich 
diets.  
8. Determine the urinary physicochemical and biochemical risk factors associated with 
CaOx crystallisation following the dietary protocols described in objective 7 above.  
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Chapter 2 : Potentiometric determination of calcium-phytate equilibrium 
constants 
Introduction 
Since previous studies demonstrated that phytate inhibits the crystallisation of calcium salts 
in vitro at concentrations similar to those which occur in urine284, 285, 320, theoretical modelling 
of its effects on CaOx crystallisation processes could provide insight on the mechanisms by 
which this occurs. Modelling can be achieved by using the speciation program JESS (Joint 
Expert Speciation System).321, 322 The latter has previously been used by the Kidney Stone 
Research Lab (KSRL) at the University of Cape Town, South Africa, in several studies to 
investigate the urinary speciation of calcium and other complexes in the context of 
urolithiasis.323-327 One of these studies revealed that a calcium-citrate-phosphate species, 
previously unreported in urolithiasis research, accounted for a significant percentage of the 
complexation of calcium in urine.323 More recently, the potential of malate (a polycarboxylic 
anion) as a chelator of free calcium was investigated.324 Modelling of this urinary component 
showed that it had no effect on the supersaturation of CaOx and CaP salts in urine at 
physiological concentrations.324 In another recent study the supersaturation of urinary salts 
were determined in urine of enteric hyperoxaluric patients, healthy subjects and stone 
formers.325 This study revealed that the supersaturation of CaOx was substantially higher in 
patients with enteric hyperoxaluria than in healthy individuals and stone formers despite their 
lower calcium excretions. The JESS modelling performed in this study suggested that 
calcium supplementation can help to reduce stone risk in patients with enteric 
hyperoxaluria.325 Other modelling studies by the KSRL have also shown that urinary sulfate 
could theoretically reduce the risk of CaOx and CaP stone formation326 and that precursors of 
CaOx and CaP should be taken into account when investigating stone forming 
mechanisms.327 
JESS contains a database of thermodynamic constants for over 12 000 chemical complexes 
which can be used for modelling chemical speciation at different pH values, temperatures 
and ionic strengths (IS). However, the database does not contain formation constants for 
phytate complexes. Moreover, a review of the literature reveals that only three quantitative 
studies on the formation constants of soluble alkaline earth metal complexes with phytate 
have been conducted and that large discrepancies in the magnitudes of these constants 
exist.328-330 Two of these studies used ISE-H+ potentiometry to investigate the binding of Ca2+ 
to phytate.328, 329 One of these identified only 3 mononuclear species328 whereas the other 
identified 3 binuclear species and 4 trinuclear species in addition to 3 mononuclear 
species.329 The magnitude of the formation constants in the former study was several orders 
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higher than the latter study. The third study used ISE-Ca2+ potentiometry to investigate the 
binding of Ca2+ to phytate.330 This study reported conditional formation constants of two 
soluble Ca-phytate complexes, one of which was mononuclear and one of which was 
binuclear.330 The author of JESS, Peter M May (Murdoch University, Murdoch Western 
Australia), also indicated (in private correspondence) that the inclusion of literature phytate-
complex equilibrium constants in the JESS database resulted in unsatisfactory results due to 
poorly defined thermodynamic constants of these complexes. Furthermore, the IS 
dependence of all formation constants in the JESS data base seemed to be acute when 
phytate was included in the data base, possibly due to the highly negative charge of the latter 
molecule. Thus, in light of all of the above, the determination of reliable formation constants 
(at an IS similar to that of the urine model) was necessary in the present project so that 
modelling of phytate-calcium complexes could be undertaken. 
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Theory: equilibrium reactions 
Stability constants, also referred to as formation constants, are equilibrium constants and are 
a measure of the strength of interaction between two or more components in solution 
equilibria.331 A formation constant, denoted by “K”, is associated with all equilibrium 
reactions.331 For example, consider the protonation of a ligand described by the following 
equation:  
                                                                    L + H ↔ LH                                                   (1) 
where L is the ligand and H is the proton. The thermodynamic protonation constant may be 
expressed as:  
                                                                                                        TKH =     __{LH}____                                        (2) 
                                                                                    {L} {H} 
 
where {LH}, {L} and {H} are the respective activities of a single protonated ligand, ligand and 
proton; respectively. The activity is related to the concentration by the following equation: 
 
                                                           {X} = ϒx[X]                                                             (3) 
 
where {X}  is the activity of the species X (a ligand, proton or metal ion), ϒx is the activity 
coefficient of species X and [X] is the concentration of X. Equation (2) can therefore be 
written as follows: 
                                                               TKH = __ (ϒLH [LH]) __                                                       (4) 
                                                         (ϒL [L])(ϒH [H]) 
 
Equation (4) may be re-arranged as: 
                                                                                    TKH =     ϒLH__         [LH]__                                        (5) 
ϒLϒH               [L] [H] 
 
When measuring the equilibrium constant, a medium containing a background electrolyte at 
a constant IS is used. At a constant IS: 
 
                                                                                              _ϒLH                                                                                                           (6) 
                                                              ϒLϒH       = constant 
 
 
  Equation (5) may therefore be expressed as:  
                                                                                                           KH =     __[LH]____                                   (7) 
                                                                                     [L] [H] 
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where TKH is now the concentration equilibrium constant. For a ligand with 2 protonation 
constants, K1 and K2, the protonation constants may be expressed in a stepwise manner: 
 
                                                        L + H ↔ LH                      K1 =     [LH]_            (8) 
                                                                                [L] [H] 
 
                                                        LH + H ↔ LH2                 
 K2 =     [LH2]_            (9) 
                                                                                [LH] [H] 
 
 
Thus, for a ligand with n protonation constants the formation constant may be written as: 
 
                                                        Kn =      [LHn]_                                                 (10) 
                                                                   [LHn-1] [H] 
 
The formation constant for the interaction between a metal (M) and a ligand may be 
expressed in a similar series of equations: 
                                                           M + L ↔ ML     KML = __[ML]__                      (11) 
                                                                                                  [M] [L] 
 
                                                          ML + L ↔ ML2     KML2 = __[ML2]__                 (12) 
                                                                                                      [ML] [L] 
 
Therefore,  
 
                                                 KMLn =      [MLn]_                                              (13) 
                                                                   [ML] [L] 
 
The cumulative formation constant (β) for protonation of a ligand with n protons may be 
calculated as follows: 
 
                                                      β1n = 
TK11 x 
TK12 x 
TK13….. K1n = __[LHn]__            (14) 
                                                                                                               [L] [H]n 
 
Similarly, the cumulative β for a reaction between M and L may be expressed as: 
 
                                            β MLn = 
TKML1 x 
TKML2 x 
TKML3….. KMLn = __[MLn]__        (15) 
                                                                                                                  [ML] [L]n 
 
In the present study, the ligand of interest is phytate which consists of a 6-membered ring 
with 6 phosphates and 12 dissociable protons over a wide pH range.332-335 The equilibrium 
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equation for the protonation of the ligand (phytate) in the present study is therefore 
expressed as follows: 
 
                           H+1 + Hn-1Phy-(12-n+1) ↔ HnPhy-(12-n)           K1n =       [PhyHn]__        (16) 
                                                                                                              [PhyHn-1] [H] 
 
Since phytate is cyclic and contains 6 phosphate moieties, more than one M is able is able to 
bind per ligand. Thus equation (13) cannot be applied for the complexation between Ca2+ 
and phytate in the present study. The equilibrium equation used for complexation between 
Ca2+ and phytate in the present study is therefore written as: 
 
                       mCa
2+ + HnPhy
-(12-n) = CamPhyHn
-(12-2m-n)    Kmn = __[CamPhyHn]          (17) 
                                                                                                         [Cam] [HnPhy] 
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Methods 
Experimental techniques used for the determination of formation constants include 
isothermal titration calorimetry (ITC) and potentiometric titrations. Briefly, the former 
technique measures the heat that is released or absorbed when binding occurs between two 
substances.336-338 Heat is measured by a calorimeter during the gradual titration of one 
substance to another. Analysis of the reaction heat as a function of concentration provides 
the formation constants as well as the reaction stoichiometry, enthalpy and entropy. 336-338 
This technique is generally used for the study of macromolecules.336, 339, 340 A potentiometric 
titration on the other hand is the measurement of the change in potential (EMF) as a titration 
progresses at a fixed temperature and IS.331, 341 This technique is commonly used to study 
acid-base reactions, redox reactions and complex formation reactions. 331, 341 Potentiometric 
measurements are performed using ion-selective electrodes (ISE) including the hydronium 
selective electrode (ISE-H+, also referred to as a glass electrode) and the calcium selective 
electrode (ISE-Ca2+, made of a polymeric substance). These electrodes are by definition 
sensitive to the change in concentration of a certain analyte i.e. H+ and Ca2+; respectively. 
The resulting potential as well as the volume at each titration point is used to determine the 
binding constants using a mathematical algorithm. This technique is recommended for the 
study of low-molecular weight (LMW) compounds.341 Since phytate is regarded as a LMW 
compound, potentiometry was selected for the determination of calcium-phytate formation 
constants in the present study.       
When using glass electrode potentiometry, several systematic errors need to be minimized. 
These include temperature, electrode calibration, control of CO2 contamination, water quality 
and preparation and standardization of acid, base, ligand and metal solutions. The methods 
used in the present study to minimize these systematic errors are described below. 
Experimental details on the titrations conducted to determine protonation constants of the 
ligand (phytate) as well as the metal-ligand (Ca-phytate) formation constants are also 
described.  
Instrumentation 
A Ω Metrohm potentiometer (848 Titrino plus) fitted with a glass electrode with an internal 
Ag/ AgCl reference electrode, automatic titrator (burette; Ω Metrohm) and titration vessel with 
a magnetic stirrer (Ω Metrohm 801) was used in the present study for potentiometric 
titrations. The estimated accuracy of the EMF and titrant volume was ± 0.1 mV and 0.003 ml; 
respectively. Temperature was kept constant at 25 ± 0.1 °C by means of a circulating “water 
jacket” around the titration vessel in an air-conditioned laboratory. 
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Calibration of glass electrode 
As mentioned earlier, changes in potential, also known as the electromotive force (EMF) are 
measured in potentiometry. This technique is used when an end-point in an acid-base 
titration is difficult to determine; for example in a very dilute solution or when a suitable 
indicator is not available.  
 
In potentiometry, ion selective electrodes are used as the “indicator” together with a 
reference electrode and a sensitive potentiometer (a device that measures the EMF). These 
electrodes include that of ISE-H+ and ISE-Ca2+ as mentioned earlier. Electrodes are 
immersed in a solution containing an analyte. This experimental setup is referred to as an 
“electrochemical cell” (Ecell). Ecell for ISE-H
+ (glass electrode) potentiometry may be depicted 
as follows342:  
 
Reference electrode | salt bridge | analyte solution | glass electrode 
                                       Eref                        Ej                                                                                             Eg   
 
where each electrode possesses a half-reaction. The reference electrode has a half-reaction 
with an accurately known potential and is not affected by the concentration of the analyte or 
any other ions in the solution whereas Eg depends on the activity of H
+ in the solution. Ej is 
the electrode junction potential that develops at liquid junctions at each end of the salt bridge 
and should remain constant at constant IS and temperature. The measured/ observed EMF, 
Ecell, is therefore as follows: 
 
                                                     Ecell = Eref + Ej + Eg                                                                 (18) 
 
Since Eg is dependent on the activity of H
+, Ecell  may be written in terms of the Nernst 
equation (an equation which shows how potential varies with the activity of an analyte) as 
follows at constant IS: 
 
                                             Ecell = E° + 2.30 RT log [H+]                                              (19)  
                                                                   z F 
 
where E° is the standard electrode potential, R is the universal molar gas constant 
(8.314 J.K-1mol-1), T is the temperature in Kelvin, z is the number of electrons and F is 
Faraday’s constant (96 485 C mol-1). A plot of Ecell vs log [H
+] yields a graph with an intercept 
corresponding to E° and a slope (s) of 2.303RT/zF. For the glass electrode, z =1. The slope 
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of such an electrode should therefore be equal to 59.14 mV at 298 K. Equation (19) may be 
simplified as follows: 
                                                Ecell = E° + s log [H+]                                                       (20)  
                                                                                       
 
In order to minimize systematic errors when carrying out potentiometric titrations the 
electrode should be calibrated regularly as described below. 
Electrode calibration was performed in the present study by titrating a strong base (0.1 M 
NaOH) against a strong acid (0.01 M HCl) at 25 ± 0.1 °C. A typical acid-base titration plot as 
obtained in the present study is shown in Figure 2.1 for the titration of a strong base against 
a strong acid. This titration curve may be divided into three regions as indicated. The acid 
region indicates the amount of unreacted acid in the flask at the beginning of the titration at 
which the measured EMF is positive. The end point region indicates the region at which one 
drop of base causes a drastic change in the measured EMF. The equivalence point (point at 
which the number of moles of base is equal to the number of moles of acid) is found within 
the end point region. Lastly, the alkaline region indicates the region at which an excess 
amount of base is present and the measured EMF is negative.  
 
 
Figure 2.1 A typical EMF vs volume of NaOH plot depicting an acid-base titration as 
obtained in the present study. 
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The electrode was then calibrated using the above data in a computer program called GLEE 
(glass electrode evaluation) which was designed for the calibration of a glass electrode.343 
This computer program provides the pseudo-Nernstian standard electrode potential (E°) and 
slope (s) of the electrode which is obtained from a plot of EMF vs pH as shown in Figure 2.2. 
Data points used for the calibration of the electrode is between pH values of 2.5- 4.0 and 
10.7- 11.3. These ranges are chosen for the following reasons:  
1. The measured pH deviates from linearity at very low pH of an acid-base titration. 
2.  Calculation of the hydrogen ion concentration is subject to large error in the end-
point region since the pH rises very sharply from pH 3.5 to 10 for the addition of one 
drop of base. Furthermore, the presence of carbonate impurity can affect the data up 
to pH ≈ 10.7. Data within the region of 4.0 to 10.7 is therefore omitted. 
3.  At high pH values, errors due to the liquid junction potential exist therefore data 
above pH 11.3 is omitted.  
 
Figure 2.2 A typical EMF vs pH plot for the calibration of glass electrode using GLEE343 as 
obtained in the present study. Pink points indicate data points which are omitted in the 
calibration. 
 
 CO2 contamination 
Titrations were conducted under a stream of purified nitrogen gas (an inert gas) to prevent 
CO2 contamination. The level of carbonic acid contamination also referred to as the level of 
protolytic impurity was checked by using the aforementioned acid-base potentiometric data in 
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GLEE343 to obtain a “Gran” plot as shown in Figure 2.3. A Gran plot is constructed by plotting 
the data obtained from the acid region and alkaline region; these results in two slopes which 
should meet at a point corresponding the end point of a titration. An indication of CO2 
contamination is when the two slopes do not have the same end point. GLEE343 calculates 
the percentage difference in the two end points and is reported as the “protolytic impurity 
level” as shown in Figure 2.3. A percentage difference of ≤ 1 % is regarded as favourable.  
 
 
Figure 2.3 A typical Gran plot constructed in GLEE343 as obtained in the present study for 
the determination of CO2 contamination. Pink points indicate data points which were 
excluded from the calculation. 
 
Preparation of solutions 
Millipore water was boiled and cooled to room temperature for the removal of CO2. This 
water was used for the preparation of all solutions in the present study. NaOH and HCl 
solutions were prepared from ampoules of NaOH (1.09959-Trisol, Merck) and HCl 
(1.09970-Trisol, Merck). NaOH (0.1 M) was standardized using potassium hydrogen 
phthalate (KHP, a “primary standard”). HCl (0.01 M and 5 mM) was standardized using the 
standardized NaOH.344 Phytic acid stock solution (10 mM) was prepared by weighing the 
dipotassium salt (Sigma Aldrich) and dissolving it in H2O followed by the removal of the 
potassium by a strong cationic exchange resin (Dowex 50 x 8- 200 mesh, H+ form, Sigma). 
The absence of potassium was checked by flame atomic absorption spectroscopy (AAS). 
Chapter 2                                                                        Calcium-phytate formation constants 
 
33 
 
Calcium (5 mM) solution was prepared in 5 mM HCl and standardized using EDTA in a 
complexometric titration.345, 346 Eriochrome blackT was used as an indicator in this titration in 
which the end point is signalled by a colour change from red to blue. All standard solutions 
were prepared in A-grade glassware (volumetric flasks) and the IS was kept constant at 
0.15 M by the addition of NaCl (Sigma Aldrich). This IS was chosen as it mimics the 
physiological concentration of urine.347, 348 
Ligand protonation and metal-ligand titrations 
Potentiometric data for the protonation of phytate was conducted by titrating 0.1 M NaOH 
against a volume of 15 ml phytate at concentrations between 1.003- 1.019 mM. For metal-
ligand titrations, 0.1 M NaOH was titrated against 25 ml of a solution containing both phytate 
and Ca at metal: ligand concentration ratios of 1:1, 2:1, 3:1 and 4:1; titrations were stopped 
when precipitation occurred. All titrations were carried out with gentle stirring under inert 
conditions to avoid CO2 contamination. 
Calculations 
The program HyperQuad349 was used to refine potentiometric data obtained for phytate 
protonation and complexation between Ca and phytate. This program uses least-squares 
refinement. A comprehensive account of the mathematical equations used in the refinement 
algorithm can be found in Gans 1985.350 Briefly, the method of refinement is based on 5 
assumptions as follows: 
1.  Each chemical species in the solution equilibria has a formation constant associated 
with it and is expressed as a concentration quotient as shown in the equations 
presented earlier under “Theory”.   
2. The electrodes used obey a pseudo-Nernstian equation as shown in equation (20). 
3. Systematic errors such as electrode calibration, sample weighings and dilutions, 
standardization of reagents, temperature variance and water quality have been 
minimized. 
4. The “independent” variable is not subject to error and error in the “dependent” 
variable assumes a Guassian distribution. The “independent” and “dependent” 
variables are defined below.  
5. A model of the equilibrium system has been hypothesized and is representative of the 
experimental observations. 
The dependent variable in the refinement algorithm is the measured EMF. The independent 
variable is the titre volume. Since the independent variable is the titre volume, the EMF in the 
region of the end point is subject to large error and is significantly affected by any error in the 
titre volume; a standard propagation formula is used to calculate the error in the measured 
EMF and is as follows: 
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                                                σ2 = σE
2 + (δE/δV)2 σV
2                                          (22) 
 
where σ2 is the calculated variance of the measurement, σE
2 is the error of the electrode, σV
2 
is the error in the titre volume and δE/δV is the slope of the titration curve. Weights are 
assigned at each titration point and are inversely proportional to the variance in equation 
(19). Thereby accommodating for the error in measurement near the end point where δE/δV 
is large. Weights are calculated by estimating δE/δV at each point using a method of unit 
weights which is essential for batch titration data. These weights are then used to estimate 
the agreement between the theoretical model and experimental data and are calculated from 
the following equation: 
 
                                                              σ = ∑ __Wir
2__  1/2                                       (23) 
   i     m-n 
 
Where m is the number of data points and n is the number of parameters. σ is the calculated 
agreement between the theoretical model and experimental data and should in principle 
approach a value of 1 if the assumptions in 1 -5 are fulfilled and σE and σV were assigned 
correctly.  
 
The general strategy used in the present study for the refinement of formation constants is 
as follows: 
1. Measured potentiometric data including the titre volume and measured EMF, the 
measured standard electrode potential and Nernstian- slope, are inserted into 
HyperQuad. 
2. A theoretical model of the equilibrium system is hypothesized, including the estimated 
formation constants (based on literature values) for each predicted species. 
3. Formation constants may be refined by selecting the “refinement” option. Formation 
constants may also be kept “constant” or “ignored” in a model before starting the 
refinement iteration. 
4. If the refinement is successful i.e. “convergence” is obtained between the 
experimental and theoretical model then the calculated formation constants for each 
species are accepted. However, if refinement is not successful, a new model is 
hypothesized. This process is known as “model selection”. 
5. The model with the lowest σ value and no ill-defined formation constants is chosen as 
the best model. Formation constants are ill-defined if its standard deviation is greater 
than 33 % of its value or is negative. Standard deviations of ill-defined constants are 
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flagged as “excessive” or “negative” in HyperQuad349 and the refinement iteration is 
then stopped (at this point a new model is selected). 
6. The species distribution is then plotted in HySS351 (a computer program) using the 
formation constants obtained in 5.  
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Results and discussion 
Calibration of glass electrode 
The glass electrode was calibrated by titrating 0.1 M NaOH against 10 mM HCl at a constant 
IS of 0.15 M (NaCl) and temperature of 25 °C. The resulting potentiometric data was used in 
GLEE343 for the determination of the Nernstian slope, standard electrode potential (E°), pKw 
as well as the protolytic impurity. The results of n = 8 titrations are reported in Table 2.1. A 
range together with the median is reported for each parameter. Plots of the raw data are 
included in Appendix 2. An acid-base titration was conducted on each day before 
commencing titrations with the ligand to ensure that a Nernstian slope within the range below 
was obtained. 
Table 2.1 Calibration of glass electrode at t= 25 °C. The range and median of n= 8 titrations 
are reported.  
Nernstian-slope 
 
E° 
 
pKw Protolytic 
impurity level (%) 
58.6 - 59.4  
(59.0) 
393.5 - 403.2  
(397.9) 
13.67 - 13.72  
(13.67) 
0.22- 1.45  
(0.68) 
 
The accurate determination of formation constants using potentiometry is dependent on 
reducing systematic errors as mentioned on page 33. These include the calibration of the 
electrode and the removal of CO2 contamination. In the present study the calibration of the 
glass electrode was successful, giving a median value of 59.0 for the Nernstian- slope. This 
indicates that the electrode’s functionality was excellent. As the glass electrode is sensitive to 
the presence of H+ ions, the control of CO2 contamination is important to prevent the 
formation of carbonate which affects the concentration of H+ in solution. The prevention of 
CO2 contamination in the present study was successful as indicated by the level of protolytic 
impurity (median value = 0.68%). These systematic errors were therefore minimized in the 
present study.  
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Protonation of phytic acid 
The protonation of phytate was studied within the pH range of 2 -11 using a glass electrode. 
This pH range was chosen as the protonation of phytate occurs over a wide pH range as 
reported in previous studies. 332-335 
A replicate of 5 titrations (total of 609 data points) were conducted to study the protonation of 
phytate. The resulting data was used in HyperQuad349 to determine the formation constants 
of HnPhy(12-n)-. A hypothetical model with 1≤ n ≤ 8 was proposed for the protonation of the 
former species and log β’s were estimated from a previous study by Stefano et al.  
Results are reported in Table 2.2 which summarises values for log β, the mean experimental 
log K’s and literature log K’s. log β of the first two protonation constants was kept constant in 
the model during refinement in the present study and will be justified below. The agreement 
between the hypothesized model and the experimental data is indicated by the parameter “σ” 
which was equal to 14 as shown in Table 2.2. This result will be discussed later. In the 
present study, the magnitude of the first three protonation constants were close to one 
another followed by a decrease in log K for protonation constants 4- 8.  
 
Table 2.2 Experimental and literature protonation constants of Phytate. IS = 0.15 M, 
t = 25 °C. 
Species 
(model) 
 
logβ 
 
σ 
 
log Kexp 
 
log Klit335 
H1Phy-11 9.41  
 
 
14 
9.41 9.41 
H2Phy-10 19.08 9.67 9.67 
H3Phy-9 28.49  9.41 ± 0.05 9.33 
H4Phy-8 36.44  7.95 ± 0.09 7.97 
H5Phy-7 42.75  6.31 ± 0.13 6.35 
H6Phy-6 48.06  5.31 ± 0.14 5.10 
H7Phy-5 51.28 3.22 ± 0.15 2.75 
H8Phy-4 53.73 2.4 ± 0.14 n.o 
log β is the logarithm of the sum of the overall protonation constants, σ is an estimate of the 
fit between the theoretical and experimental data. log K refers to the following reaction:  
H+ + Hn-1Phy
(12-n)- = HnPhy
(12-n)-. n.o = not observed.  
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The agreement of the theoretical model and the experimental data is shown in Figure 2.4 for 
the protonation of phytate. Plots of all other titrations conducted for the determination of 
phytate protonation constants are included in Appendix 2. The speciation distribution of 
HnPhy
(12-n)- is shown in Figure 2.5.  
 
Figure 2.4 A typical plot of EMF vs volume of NaOH added for the titration of NaOH (0.1 M) 
against phytate (0.001 M). Experimental curve is shown in blue and theoretical in red. 
IS = 0.15 M (NaCl); t = 25 °C 
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Figure 2.5 Species distribution of HnPhy
(12-i)- (0.001 M) in the pH range of 2-11 using 
HySS351. t = 25 °C; IS = 0.15 M (NaCl) 
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Comment 
In order to determine stability constants of any metal-ligand complex, protonation constants 
are required as a first step as the acid-base equilibria of a ligand affects its interactions with 
other ions and ligands. Extensive research has been conducted on the acid-base properties 
of phytate.332-335, 352-354 However, the stability constants for phytate protonation differ amongst 
laboratories. This is mainly due to different experimental conditions which have been used in 
which both the medium (containing a background electrolyte) and IS significantly affect the 
value of the determined stability constants.352-354 Most quantitative studies on the protonation 
of phytate in alkali media have reported only 7 protonation constants (over a pH range of 2 – 
11) as the first 5 occurs at a pH less than 2.335, 352-354 However, others have reported up to 8 
and 12 protonation constants.333, 334 Eight protonation constants were identified in the present 
study over a pH range of 2- 11 as mentioned above.  
During the “model selection” process in the present study, difficulty in obtaining convergence 
between the experimental data and the theoretical model was encountered. It was found that 
this difficulty occurred due to the unique acid-base properties of phytate in which previous 
studies have reported that the first 3 protonation constants are of similar magnitude and 
shows a peculiar trend in alkali media.334, 335, 352, 355 These studies have demonstrated that in 
a KCl medium the following trend in log K occurs for the first 3 protonation constants: 
log K1 > log K3 > log K2 and in a NaCl medium: log K2 > log K1> log K3.335, 352 This peculiar 
trend is due to strong interactions between phytate and alkali metals. When NaCl is the 
background electrolyte, the inversion in strength of the first two protonation constants at an 
IS < 0.6 M is mainly due to the formation of Na5H2Phy which has two hydrogen bridges.334, 355 
In light of the aforementioned, the first two protonation constants were kept constant during 
refinement in the present study. Of the remaining constants which were refined in the present 
study, H3Phy – H7Phy were comparable to the study by Stefano et al in which calculated 
protonation constants at an IS of 0.15 M were reported (as shown in Table 2.2).335 The eighth 
protonation constant in the present study is comparable to a previous study in which NaClO4 
(IS = 0.15 M) was used as the background electrolyte (log K8 = 1.98).334  
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Calcium-phytate complexation 
The formation of Ca-phytate complexes was investigated over a pH range of 3-7. No 
significant complexation occurred at pH < 3 and precipitation occurred at pH > 7. The 
following number of titrations were conducted at each metal:ligand molar ratio: 1:1 
(5 titrations), 2:1 (3 titrations), 3:1 (3 titrations) and 4:1 (2 titrations). A total number of 515 
experimental data points were used in HyperQuad349 for the determination of formation 
constants of CamPhyHn
-(12-2m-n)
. A model with 1≤ m ≤3 and 1≤ n ≤6 was hypothesized for the 
former species and log β was estimated from literature values reported by Crea et al329 and 
Torres et al.328  
Seven Ca-phytate species (4 mononuclear and 3 binuclear) were identified using 
HyperQuad349 as shown in Table 2.3. The hypothetical model used in the present study 
differed to the literature. Furthermore, a comparison of the formation constants identified in 
the present study to those in the literature is not in agreement. These findings will be 
discussed below. 
Table 2.3 Experimental and literature formation constants of CamPhyHn
-(12-2m-n) 
Species 
(model) 
 
logβ 
 
σ 
log Kexp 
(NaCl, IS = 0.15 
M; t = 25 °C) 
log Klit329 
(NaCl, IS = 0.25 M; t 
= 25 °C) 
log Klit328 
(NaClO4, IS = 0.15 M t 
= 37 °C) 
CaPhyH3
-7 36.22  
 
 
12 
7.73 ± 0.05 3.42 - 
CaPhyH4
-6 42.69 6.25 ± 0.05 2.06 8.3 
CaPhyH5
-5 48.23 5.48 ± 0.05 2.11 8.4 
CaPhyH6
-4 52.31 4.25 ± 0.05  - 7.4 
Ca2PhyH
-7 26.01 16.6 ± 0.25 - - 
Ca2PhyH2
-6 32.59 13.51 ± 0.21 - - 
Ca2PhyH3
-5 39.27 10.78 ± 0.09 6.47 - 
Ca2PhyH4
-4 n.o.  - 5.24 - 
Ca2PhyH5
-3 n.o - 4.09 - 
Ca3PhyH2
-4 n.o - 11.23 - 
Ca3PhyH3
-3 n.o - 9.41 - 
Ca3PhyH4
-2 n.o - 7.35 - 
Ca3PhyH5
-1 n.o - 6.31 - 
log β is the sum of the overall formation constants. n.o. (not observed), σ is the estimate of 
agreement between the theoretical model and experimental data. log K refers to the following 
reaction:  Mm
2+ + HnPhy-(12-n) = MmPhyHn-(12-2m-n) 
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The agreement between the theoretical model used in the present study and the 
experimental data is shown in Figure 2.6 for a titration conducted at a Ca:Phytate molar ratio 
of 1:1. Plots of all other titrations are shown in Appendix 2. 
 
 
Figure 2.6 A typical EMF vs volume of NaOH added for the titration of NaOH (0.1 M) against 
a solution containing Ca: 2 mmol.L-1 and phytate: 2 mmol.L-1. IS = 0.15 M, t = 25 °C. 
Experimental curve is shown in blue and theoretical in red. 
The percentage distribution of each species relative to phytate at a Ca:Phy molar ratio of 1:1 
is shown in Figure 2.7. Only mononuclear species were present at this ratio with maximum 
percentages of 65. CaPhyH5
-5 was present over the entire pH range investigated with a 
maximum at pH = 4.8.  
 
 
Figure 2.7 Species distribution of CamPhyHn
-(12-2m-n) at a Ca:Phy molar ration of 1:1. 
Ca: 2 mmol.L-1, phytate: 2 mmol.L-1, IS = 0.15 M (NaCl), t =25 °C 
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The percentage distribution of species at a Ca:Phytate molar ratio of 2:1 is shown in Figure 
2.8. The formation of binuclear species was present at this metal: ligand ratio, however 
mononuclear species were still predominant.  
 
 
 
---- CaPhyH6
-4 
---- CaPhyH5
-5 
---- CaPhyH4
-6 
---- CaPhyH3
-7 
---- Ca2PhyH3
-5 
---- Ca2PhyH2
-6 
---- Ca2PhyH
-7 
 
Figure 2.8 Species distribution of CamPhyHn
-(12-2m-n) at a Ca:Phy molar ration of 2:1. 
Ca: 4 mmol.L-1, phytate: 2mmol.L-1, IS = 0.15 M (NaCl), t =25 °C 
 
Species distribution plots at Ca:Phytate molar ratios of 3:1 and 4:1 are also shown in Figure 
2.9 and Figure 2.10. The formation of trinuclear species was not found at the conditions used 
in the present study.  
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Figure 2.9 Species distribution of CamPhyHn
-(12-2m-n) at a molar ration of 3:1. 
Ca: 3 mmol.L 1, phytate: 1 mmol.L-1, IS = 0.15 M (NaCl), t =25 °C 
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Figure 2.10 Species distribution of CamPhyHn
-(12-2m-n) at a molar ration of 4:1. 
Ca: 4 mmol.L-1, phytate: 1 mmol.L-1, IS = 0.15 M (NaCl), t =25 °C 
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Comment 
As stated earlier, only a few studies have been conducted for the determination of the 
stability constants of CamPhyHn
-(12-2m-n). A comprehensive study by Crea et al investigated 
the formation constants of complexes formed between calcium and phytate at molar ratios of 
1:1, 3:1 and 4:1 at IS between 0.1 and 0.75 M (NaCl) using glass electrode potentiometry.329 
These conditions are comparable to the conditions used in the present study. The study by 
Crea et al329 reported formation constants for 10 CamPhyHn
-(12-2m-n) complexes of which 3 
were mononuclear (CaPhyH5
-5, CaPhyH4
-6, CaPhyH3
-7), 3 were binuclear (Ca2PhyH5
-3, 
Ca2PhyH4
-4, Ca2PhyH3
-5) and 4 were trinuclear (Ca3PhyH2
-4, Ca3PhyH3
-3, Ca3PhyH4
-2, 
Ca3PhyH5
-1).329 In the present study, formation constants of only 7 species were identified, 4 
of which were in common with the former study as shown above (Table 2.3). The constants 
of the present study were however several orders of magnitude higher than those of Crea et 
al.329 The reason for the discrepancy between results of the present study and those of Crea 
et al329 is due to differences in the hypothesized model for the Ca-phytate equilibrium system. 
The model of Crea et al329 consisted of trinuclear species in addition to mono- and binuclear 
species whereas trinuclear species were not included in the model of the present study. This 
would undoubtedly affect the stability constants of other species.  
As a check of the credibility of the results obtained in the present study, the model of the 
equilibrium system and the stability constants of Crea et al329 was used in HyperQuad349 as a 
hypothetical model for the experimental data obtained in the present study. No convergence 
was obtained between the model of Crea et al329 and the experimental data obtained in the 
present study as shown below in Figure 2.11. This can be compared to the excellent 
agreement between the theoretical model used in the present study and the experimental 
data. The hypothesized model for the equilibrium system in the present study is therefore 
accurate. 
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Figure 2.11 A comparison of the equilibrium model used in the present study to those of 
Crea et al.329 Ca: 2 mmol.L-1, Phy: 2 mmol.L1; IS = 0.15 M, t = 25 °C 
 
In another study by Torres et al, formation constants of CamPhyHn
-(12-2m-n) complexes were 
investigated in NaClO4 at Ca:Phy ratios of 1:1 and 1:5 and a temperature of 37 °C.328 Of 
course in this study only mononuclear species were identified (CaPhyH6
-4, CaPhyH5
-5, 
CaPhyH4
-6) due to the presence of an excess of ligand as opposed to an excess of metal. 
The magnitude of these stability constants is comparable to those of the present study.  
Conclusion 
Comparison of the formation constants for CamPhyHn
-(12-2m-n)  complexes obtained in the 
present study to those of Crea et al329 and Torres et al328 highlights the challenge in obtaining 
accurate stability constants of alkaline-earth metal- phytate complexes as well as the 
necessity to experimentally determine these constants under conditions similar to those in 
urine.  
It should be borne in mind that the use of accurately determined formation constants in JESS 
is essential for the reliable determination of chemical speciation in urine or any other system. 
As mentioned earlier, an indication of the reliability of formation constants obtained using 
HyperQuad349 is based on the σ value (an estimation of the fit between the theoretical model 
and experimental data) as well as the standard deviation of the respective log K values. In 
the present study a σ value of 14 and 12 was obtained for the respective models used in the 
present study. In an ideal case σ would be equal to 1 if assumptions 1-5 have been fulfilled 
as mentioned on page 33. The values obtained in the present study, although > 1, were the 
smallest values obtained for this parameter during the “model selection” process. 
Furthermore, no ill-defined formation constants were obtained as the standard deviations of 
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the log K values obtained in the present study for HnPhy
(12-n)- and CamPhyHn
-(12-2m-n) 
complexes were within acceptable limits i.e. less than 33 % of its corresponding log K and no 
negative log K values were obtained. Both of these parameters are of course affected by the 
accuracy of instrumentation used as well as the control of CO2 contamination. These factors 
were minimized as stated above. In addition to this, the protonation constants of phytate 
obtained in the present study were comparable to literature values in which the experimental 
conditions were similar. All of the above lends confidence to the results obtained in the 
present study.  
 The formation constants of both HnPhy
(12-n)- and CamPhyHn
-(12-2m-n) complexes obtained in 
the present study were therefore used in the JESS program to model Ca-phytate speciation 
in urine. This is reported in the next chapter.  
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Chapter 3 : Effect of phytate on chemical speciation and supersaturation of 
stone-forming salts in urine of South African black and white subjects: 
theoretical modelling 
  
Introduction 
“Chemical speciation of an element” refers to its distribution amongst defined chemical 
species in a particular system.341 The term “chemical species” is defined as a specific form of 
an element: isotopic composition, electronic or oxidation state, or complex or molecular 
structure.341 Chemical speciation is of importance in a wide range of applications in analytical 
chemistry, geochemistry, toxicology and environmental chemistry.356, 357 In environmental 
studies chemical speciation is essential for determining the biological availability and toxicity 
of trace constituents as well as the geochemical behaviour of chemical species.356 As 
mentioned in the previous chapter chemical speciation has also provided insight in the field 
of urolithiasis.  In this context chemical speciation is useful for the determination of the 
speciation of calcium and other elements which in turn contribute to the supersaturation of 
stone-forming salts. For example, the distribution of total calcium in urine can be at different 
concentrations of aqueous or solid CaOx, CaP, calcium- citrate and other calcium-containing 
complexes. If most of the calcium is complexed to citrate (or some other anionic ligand in 
urine), then less of it will be available for binding to free oxalate (or phosphate). As a 
consequence, the supersaturation (SS) of CaOx and CaP would be lower, thereby 
decreasing the risk of crystallisation of these substances in urine.  
 Both chemical speciation and the concomitant RS of urine can be assessed using the 
software program JESS.321, 322 As mentioned in the previous chapter JESS contains a 
substantial database of thermodynamic constants for multiple binary, tertiary and quaternary 
complexes which may form at equilibrium in urine. This data base has now been expanded 
by inclusion of the thermodynamic binding constants for phytate protonation and calcium- 
phytate complexes, which were determined experimentally as part of the present PhD project 
and which were described in the previous chapter.  
As mentioned in Chapter 1 of this thesis, the molecular structure of phytate contains 6 
phosphate groups and has a high negative charge at physiological pH.  Therefore, in 
principle, phytate is able to complex calcium in urine thereby contributing to the modulation of 
CaOx crystallisation.  The extent to which this occurs depends on the chemical composition 
of each individual urine sample. Since the incidence of stone formation is different in South 
Africa’s black and white population groups, the influence of phytate may differ in the two 
groups.       
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The hypotheses that phytate is able to exert thermodynamic effects on CaOx and CaP 
crystallisation in urine and that such effects may be different in black and white South 
Africans were tested in the present project. The study is described in this chapter.   
Methods 
Urine data and the theoretical model 
Individual baseline urine compositions of healthy South African black (n = 18) and white 
(n =16) males were used as input data for the JESS theoretical model. The urinary 
parameters which were used for each sample are listed in Table 3.1. Values of each urine 
parameter for each urine sample are included in Appendix 3.1. These urine parameters were 
determined as described in Chapter 6. Equilibrium constants and hence species formation 
are dependent on temperature and ionic strength (IS).327, 358 Accordingly, the temperature for 
the model was set at 37°C (physiological temperature). IS was calculated by JESS for each 
urine sample. 
Table 3.1 Urinary parameters used in the JESS theoretical model.  
Urinary parameters 
pH Citrate (mol/L) 
Calcium (mol/L) Phosphate (mol/L) 
Magnesium (mol/L) Chloride (mol/L) 
Sodium (mol/L) Urate (mol/L) 
Potassium (mol/L) Phytate (mol/L) 
Oxalate (mol/L)  
 
Modelling urinary saturation and speciation 
The physiological concentration of phytate in urine is between 0.5- 3 mg/l corresponding to 
0.76 – 4.45 µM.259 The effect of three physiological concentrations of phytate within in this 
range, on the SS of stone-forming salts was modelled in each urine sample. These 
concentrations were as follows: 0.76 µM, 2.27 µM and 4.45 µM. In addition, the effect of two 
non-physiological concentrations of phytate i.e. 30 µM and 1.50 mM phytate was also 
studied. These concentrations were chosen as they had been used in an in vitro study by 
Saw et al which will be discussed later. 285   
The RS of the following stone-forming salts were calculated for each urine sample at each 
modelled concentration of phytate: COM, COD, COT, CaOx, brushite, hydroxylapatite (HAP), 
octacalcium phosphate (OCP), tribasic calcium phosphate (tCaP), uric acid and sodium urate 
(Na-urate). The supersaturation of the latter two urinary salts were determined because of 
potential effects due to possible changes in IS (this will be discussed later). This was 
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followed by determining the speciation of calcium, phytate, oxalate, magnesium, phosphate 
and citrate in each urine sample. JESS has a maximum output of 30 species per element. 
However, only the 15 most predominant species per element were determined in the present 
thesis. 
Statistical analysis 
Statistical analyses were performed using GraphPad InStat3 for intra- and inter-group 
comparisons of urinary saturation and speciation of elements. Mean values were compared 
using paired t-tests for intra-group comparisons and unpaired t-tests for inter-group 
comparisons. Repeated measures analysis of variance (ANOVA) followed by a post-hoc 
Dunnett test was performed for multiple comparisons (3 or more groups) where applicable. A 
p-value < 0.05 was considered as statistically significant.  
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Speciation 
Ionized calcium (Ca2+) 
Since the hypothesis being tested here is that phytate binds with calcium to reduce the 
concentration of Ca2+, the concentration of this species at each concentration of phytate was 
compared. Results are shown in Figure 3.1 and Figure 3.2 for black and white subjects, 
respectively. In both groups, no significant differences in the concentration of Ca2+ were 
observed at physiological phytate concentrations or at the hypothetically elevated 
concentration of 30 µM. However, the concentration of Ca2+ was significantly lower at a 
concentration of 1.50 mM phytate relative to all other concentrations of phytate (p< 0.01).  
 
Figure 3.1 Calculated concentration of ionized calcium in urine of black subjects at different 
concentrations of phytate. Error bars indicate standard error of the mean. Significantly 
different to all other concentrations (p< 0.01).  
 
 
Figure 3.2 Calculated concentration of ionized calcium in urine of white subjects at different 
concentrations of phytate. Error bars indicated standard error of the mean. Significantly 
different to all other concentrations. (p< 0.01) 
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In order to gain insight into the effects of phytate on urinary speciation at a phytate 
concentration of 1.50 mM, comparisons were made with the speciation at the lowest 
physiological concentration of phytate (0.76 µM). Mean values and the standard error of the 
mean (SE) are shown in bar-graphs, while actual values are given in tables. All raw data are 
reported in Appendix 3.2.  
It should be noted that in the speciation bar graph representations of speciation (as well as in 
corresponding tables with actual values) in the paragraphs that follow, the concentrations 
which are indicated are those of the element (calcium and magnesium) or ligand (oxalate, 
citrate, phosphate and phytate) in each species. 
Calcium speciation 
The mean concentration of calcium in each of the calcium species at a concentration of 
0.76 µM and 1.50 mM phytate is shown in Figure 3.3 and Figure 3.4 for the black and white 
group, respectively, while actual values for each species for both groups are given in Table 
3.4. Individual values of each species for each urine sample are reported in Appendix 3.2.  
As has been demonstrated above, the concentration of Ca2+ is significantly decreased when 
the concentration of phytate is raised to 1.50 mM  in urine of both black and white subjects. 
This effect is accounted for by the highly significant increase in the formation of Ca2HPHy
-7 
(species number 16 in Figure 3.3 and Figure 3.4) which utilizes a larger percentage of the 
available Ca2+. The significant decrease in the concentration of Ca2+ is accompanied by a 
concomitantly significant decrease in the formation of all other calcium complexes in  both 
groups except for that of CaCitPO4
-4 (species number 2 in Figure 3.3 and Figure 3.4) which 
increased significantly in both groups. This latter observation is surprising and will be 
discussed later in the discussion.  
Intergroup comparisons of the calcium speciation was also determined. No statistical 
difference was observed. p values are reported in Appendix 3.3.  
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Figure 3.3 Calcium speciation in urine of black subjects (n= 18) in the presence of 0.76 µM 
and 1.50 mM phytate.  
 
 
Figure 3.4 Calcium speciation in urine of white subjects (n= 16) in the presence of 0.76 µM 
and 1.50 mM phytate. 
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Phytate speciation 
The mean concentration of phytate in each phytate-species is shown in Figure 3.5 and 
Figure 3.6 for the black and white group, respectively, while actual values for each species 
for both groups are given in Table 3.5. Individual values of each species for each urine 
sample are reported in Appendix 3.2. These results confirm a significant increase in the 
formation of Ca2HPhy
-7 at a concentration of 1.50 mM phytate in both groups. However, not 
all of the phytate binds with calcium to form Ca2HPhy
-7 at the latter concentration of phytate; 
instead a larger amount of phytate exists as the mono-protonated HPhy-11. The percentage 
distribution of phytate in urine in the presence of 0.76 µM and 1.50 mM phytate is shown in 
Figure 3.7 and Figure 3.8 for both groups. Interestingly, it is seen that at the lower 
concentration of phytate the species Ca2HPhy
-7 dominates while at the higher concentration 
of phytate, HPhy-11 is the major species. This will be discussed later. 
Inter-group comparisons of phytate speciation showed no statistical significance between the 
two groups. p values are reported in Appendix 3.3. 
 
 
Figure 3.5 Phytate speciation in urine of black subjects (n= 18) in the presence of 0.76 µM 
and 1.50 mM phytate. 
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Figure 3.6 Phytate speciation in urine of white subjects (n= 16) in the presence of 0.76 µM 
and 1.50 mM phytate.
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Figure 3.7 Percentage distribution of phytate in urine of black subjects (n = 18) in the 
presence of 0.76 µM and 1.50 mM phytate. 
 
 
Figure 3.8 Percentage distribution of phytate in urine of white subjects (n= 16) in the 
presence of 0.76 µM and 1.50 mM phytate. 
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Oxalate speciation 
The mean concentration of oxalate in each oxalate-species is shown in Figure 3.9 and Figure 
3.10 for the black and white groups, respectively, while actual values for each species are 
reported in Table 3.6. Individual values of each species for each urine sample are reported in 
Appendix 3.2. Interestingly, the concentration of ionized oxalate (Ox-2) increased significantly 
at the elevated phytate concentration in both groups. This effect can be attributed to 
concomitant decreases in the formation of the complexes MgOx and CaOx (species number 
3 and 4 in Figure 3.9 and Figure 3.10) in both groups of subjects which thereby release 
unbound Ox-2 and raise its concentration. The decrease in the concentration of CaOx is due 
to the decrease in the concentration of Ca2+ caused by complexation of phytate (Figure 3.3 
and Figure 3.4) while the decrease in the formation of MgOx is surprising and will be 
discussed later.   
Inter-group comparisons of the distribution of oxalate showed no statistical significant 
difference between the two groups. p values are reported in Appendix 3.3.  
 
 
 Figure 3.9 Oxalate speciation in urine of black subjects (n = 18) in the presence of 0.76 µM 
and 1.5mM phytate.  
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Figure 3.10 Oxalate speciation in urine of white subjects (n = 16) in the presence of 0.76 µM 
and 1.50 mM phyatate. 
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Magnesium speciation 
Magnesium speciation is shown in Figure 3.11 and Figure 3.12 for the respective groups 
while actual values for each species are reported in Table 3.7 for both groups. Individual 
values for each species for each urine sample are reported in Appendix 3.2. The formation of 
several magnesium species changed significantly in the presence of 1.50 mM phytate. A 
significant increase in Mg2+ is observed with a significant decrease in MgOx in both groups. 
This is counterintuitive since an increase in the former species (as well as the increase in 
Ox2- as shown above) should result in an increase in MgOx. This will be discussed later. 
Inter-group comparisons of magnesium speciation showed that the formation of MgCit2
-4 was 
significantly lower in the black than the white group in the presence of both 0.76 µM (p= 0.03) 
and 1.50 mM (p= 0.02) phytate. This result is due to a lower citrate concentration in the black 
than the white group (1.47 ± 0.14 vs 1.77 ± 0.12 mmol/L; p = 0.13) albeit not statistically 
significant.  
 
 
Figure 3.11 Magnesium speciation in urine of black subjects (n= 18) in the presence of 
0.76 µM and 1.50 mM phytate.  
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Figure 3.12 Magnesium speciation in urine of white subjects (n =16) in the presence of 
0.76 µM and 1.50 mM phytate. 
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Phosphate speciation 
The mean concentration of phosphate in each phosphate-species is shown in Figure 3.13 
and Figure 3.14 for the black and white groups, respectively, while actual values for each 
species are reported in Table 3.8 for both groups. Individual values for each species of each 
urine sample are reported in Appendix 3.2. Of interest is the significant decrease in the 
formation of H2PO4
-1 (species number 1 in Figure 3.13 and Figure 3.14) in the presence of 
1.50 mM phytate in both groups. This is accompanied by a significant increase in HPO4
-2 
(species number 2 in Figure 3.13 and Figure 3.14) which forms upon the deprotonation of the 
former species. HPO4
-2 is a precursor for the formation of CaP salts. Thus, its significant 
increase may lead to an increase in the SS of CaP salts. However, the converse occurred 
(Table 3.2 and Table 3.3) because the increase in HPO4
-2 is exceeded by a greater decrease 
in Ca2+ (Table 3.4 and Table 3.5), culminating in a decrease in the SS of CaP salts.  
No statistical difference in the speciation of phosphate was observed between the groups 
(p values are reported in Appendix 3.3).  
 
 
Figure 3.13 Phosphate speciation in urine of black subjects (n= 18) in the presence of 
0.76 µM and 1.50 mM phytate.   
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Figure 3.14 Phosphate speciation in urine of white subjects (n= 16) in the presence of 
0.76 µM and 1.50 mM phytate. 
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Citrate speciation 
The mean concentration of citrate in each citrate-species is shown in Figure 3.15 and Figure 
3.16 for the black and white groups, respectively, while actual values for each species are 
reported in Table 3.9 for both groups. Individual values for each species of each urine 
sample are reported in Appendix 3.2. Of interest is the significant increase in unbound citrate 
(Cit-3, species number 4 in Figure 3.15 and Figure 3.16) in both groups. This increase is 
accounted for by a significant decrease in the formation of CaCit-1 (species number 2 in 
Figure 3.15 and Figure 3.16). The latter is due to a significant increase in the formation of 
Ca2HPhy
-7 which utilizes a large amount of Ca2+.  
Inter-group comparisons showed that the concentration of Cit-3 was lower in the black group 
than the white group in the presence of 0.76 µM phytate, tending toward statistical 
significance (p= 0.05) and was significantly lower in the presence of 1.50 mM phytate 
(p =0.01). This result is due to a lower urinary citrate concentration in the black than the white 
group as mentioned previously. These comparisons are reported in Appendix 3.1 and 
Appendix 3.3. 
 
 
Figure 3.15 Citrate speciation in urine of black subjects (n = 18) in the presence of 0.76 µM 
and 1.50 mM phytate. 
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Figure 3.16 Citrate speciation in urine of white subjects (n= 16) in the presence of 0.76 µM 
and 1.50 mM phytate. 
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Discussion 
The hypothesis under investigation in the study described in this chapter was that urinary 
phytate modulates both CaOx and CaP crystallisation in a thermodynamic manner by virtue 
of the ability of its 6 phosphate groups to bind calcium, thus decreasing the SS of CaOx and 
CaP salts. Since the results of this theoretical study showed that the concentration of urinary 
Ca2+ and the concomitant RS values of Ca-containing salts were unaffected at physiological 
concentrations of phytate the aforementioned hypothesis is rebutted. 
The failure of phytate to significantly decrease the concentration of Ca2+ at physiological 
concentrations of this ligand in the urine models used in the present study can be explained 
as follows. Firstly, although phytate contains 6 phosphate moieties with a highly negative 
charge at physiological pH, making it a favourable candidate for the binding of Ca2+, a 
maximum of only two Ca2+ ions can bind per mole of phytate as reported in the preceding 
chapter. As such, the notion of phytate being a strong chelator of Ca2+ in urine because of its 
6 potential binding sites is exaggerated. Secondly, the question of whether the formation of 
the solitary Ca2HPhy
-7 (as observed in the present study in urine of both groups) is able to 
significantly reduce the concentration of Ca2+, clearly depends on the physiological urinary 
concentration of PhyH-11 and how it compares with the concentration of calcium. The 
physiological concentration of urinary phytate and hence PhyH-11 is 1000 times smaller than 
that of calcium (micro-molar vs milli-molar). It is therefore not surprising that the physiological 
concentrations of phytate as well as the much higher non-physiological concentration of 
30 µM had no effect on the concentration of Ca2+ and the concomitant SS values of CaOx 
and CaP salts in the present study. This argument is supported by the observed significant 
decrease in Ca2+ and the SS of CaOx and CaP salts at a phytate concentration of 1.50 mM 
(due to the formation of Ca2HPhy
-7) in the present study. This occurred since the magnitude 
of this phytate concentration is comparable to that of urinary calcium.  
Three surprising findings have been highlighted in the present study at the hypothetically 
elevated concentration of phytate (1.50 mM) relative to the lower physiological concentration 
of this ligand (0.76 uM). These were the significant increase in CaCitPO4
-4, the significant 
decrease in MgOx and the significant decrease in the SS of Na-Urate and uric acid. The first 
can be explained in terms of the concentrations of Ca2+, Cit-3 and HPO4
-2 as these are 
precursors for the formation of the complex species CaCitPO4
-4. Since a large amount of 
Ca2+ is utilized by PhyH-11 in the present study culminating in a significant increase in both 
Cit-3 and HPO4
-3 it is speculated that the increase in the concentration of the latter two 
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species compensated for the decrease in Ca2+ and contributed to the increase in 
CaCitPO4
-4.  
On the other hand, the decrease in MgOx with an increase in Mg2+ and Ox2- is 
counterintuitive and suggests that a decrease in its formation constant has occurred. 
Similarly the decrease in the SS of uric acid and Na-urate indicates that its solubility 
increased. As mentioned earlier, factors which affect both the magnitude of formation 
constants and the SS include pH, temperature and IS. Since the first two were fixed in the 
present study it is speculated that a significant change in the latter may have occurred due to 
the large negative charge of phytate. Indeed, statistical comparisons of the IS at a 
concentration of 1.50 mM phytate relative to 0.76 µM phytate showed a significant increase 
in the IS as shown in below in Table 3.10. 
Table 3.10 Effect of 0.76 µM and 1.50 mM phytate on the IS of urine from black and white 
subjects. Mean ± SE. 
Black subjects (n= 18) White subjects (n= 16) 
0.76 µM 1.50 mM P- value 0.76 µM 1.50 mM p value 
0.13 ± 0.05 0.22 ± 0.05 <0.0001 0.15 ± 0.01 0.23 ± 0.01 <0.0001 
Indicates statistical significance. 
In general, an increase in IS results in a decrease in the magnitude of stability constants and 
an increase in solubility.359-361 Thus, the significant decrease in MgOx (with a concomitant 
increase in Mg2+ and Ox2-) is explained by the significant increase in IS in the present study. 
Similarly the decrease in the SS of uric acid and Na-urate is due to the increase in the IS.  
It should be noted that other monovalent and divalent cations such as Na+, K+ and Mg2+ may 
also bind to phytate to form a wide variety of binary, ternary and quaternary complexes such 
as Na2H5Phy
-5, Na3H4Phy
-5, Na4H6Phy
-2, K2H10Phy, Mg2H2Phy
-6, Mg3H5Phy
-5 and 
MgH3Phy
-7.332 The determination of stability constants for such species was however not 
undertaken in the present thesis and was therefore not included in the JESS model. Thus, a 
significant percentage of the mono-protonated species HPhy-11 is observed at a 
concentration of 1.50 mM phytate which may otherwise have been complexed to other metal 
ions. In any case, the inclusion of these formation constants would have had a negligible 
effect on the RS of CaOx and CaP salts under physiological conditions as the concentrations 
of these species would be negligible due to the low physiological concentration of phytate as 
mentioned above. 
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In this study, it was also hypothesized that urinary phytate may have different effects in the 
urine of black subjects compared to their white counterparts due to differences in their 
urinary composition. However, the modelled effects of phytate in the present study were 
similar between the respective groups. This indicates that it is unlikely that dietary (and 
hence urinary) phytate can account for the differences in stone modulation in the two groups. 
It is clear that urinary phytate does not modulate CaOx and CaP crystallization in a 
thermodynamic manner due to the low concentration of this ligand relative to calcium and 
other urinary components. Thus, if it is indeed an inhibitor of urinary calcium crystallization as 
has been suggested by some authors, it must do so via a kinetic process. Indeed, previous in 
vitro studies showed that phytate concentrations between 0.75 µM and 2 µM reduced the 
rate of CaOx crystal nucleation and growth in artificial urine. 320, 362 More recently, a study by 
Saw et al showed that the growth rate of artificial stones decreased significantly in artificial 
urine containing urinary macromolecules (UMM) in the presence of 2.5 µM phytate and that 
the concentration of Ca2+ was not affected at this concentration of phytate.285  
The study by Saw et al285 also demonstrated that a phytate concentration of 30 µM 
decreased the crystallization rate in artificial urine (without the addition of UMM) and that mill-
molar (as opposed to micro-molar) concentrations of phytate were required to decrease the 
concentration Ca2+. This result led the authors to conclude that the inhibitory effect of phytate 
is not via a decrease in the supersaturation of CaOx.285 Interestingly, a concentration of 
30 µM phytate also decreased the crystallization rate in human urine (although not to the 
same extent as in the former medium). However, the effect of milli-molar concentrations of 
phytate on the concentration of Ca2+ was negligible. This is in contrast to the theoretically 
predicted result for 1.50 mM phytate in the present study. This may be due to thermodynamic 
effects of urinary macromolecules in real urine which cannot be modelled without stability 
constants involving the formation of Ca-UMM complexes. 
Recognizing that theoretical modelling of thermodynamic factors cannot include or address 
every possible condition which prevails in solution, and that the modelling of kinetic factors is 
difficult (and beyond the scope of the present study), the next phase of the overall project 
shifted to an in vitro model in which the effects of phytate on both of these factors were 
investigated in artificial urine and in the urine of black and white subjects. These studies are 
described in Chapter 5.  
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Chapter 4 : Method for the determination of phytate in urine 
 
Introduction 
The determination of IP6 in biological samples such as urine is challenging since its 
concentration is extremely low (micromolar) and the sample matrix is complexed.266, 363 
Methods developed for the determination of this substance in urine require sophisticated 
instrumentation such as HPLC364 and ICP365, 366 as well as laborious sample preparation 
including hydrolysis, evaporation and digestion.363 These methods can therefore not be 
routinely applied in all analytical laboratories.   
As mentioned in Chapter 1, IP6 is composed of an inositol and 6 phosphate moieties. Most 
methods for the quantification of IP6 in urine are therefore based on properties of the   
inositol364, 367 or phosphate moiety365, 366, 368. Both approaches require hydrolysis of the IP6 
molecule. On the other hand, determination of IP6 in foods without the hydrolysis of the 
molecule has been successfully carried out.259 The latter methods are based on the indirect 
colorimetric detection of IP6 since the molecule has no absorption bands in the UV-visible 
light range and no reagent interacts directly with it to form a coloured compound.259 These 
methods exploit the high binding affinity of the phosphate groups to polyvalent cations such 
as Fe3+, Y3+ and Cu2+.259 A metal- dye system is used containing one of these metals. IP6 
binds to the metal resulting in a decrease in the concentration of the metal-dye compound 
and a subsequent decrease in the absorbance. An example of a metal-dye system is Wade’s 
reagent in which the coloured compound is Fe(III)-sulfosalicylic acid.369 In the presence of 
IP6, its characteristic pink colour decreases upon complexation of the metal to IP6. Methods 
applied in food analysis are however not sensitive enough to detect IP6 in biological samples 
in the absence of significant preconcentration. 
These challenges have recently been addressed by Costa-Bauza and Grases et al363 who 
developed a method that can be used for routine analysis without the use of sophisticated 
instrumentation and hydrolysis of the molecule. This method (“Method 1”) involved the 
purification and preconcentration of IP6 using solid phase extraction (SPE) prior to 
colorimetric detection. The colorimetric assay used Fe(III)-thiocyanate as the metal-dye 
system with a detection limit of 0.055 µM. Subsequent to this method, another was 
developed (“Method 2”) for the detection of IP6 in urine of rats using an alternative metal-dye 
system.370 This metal-dye system consisted of Al(III)- xylenol orange. Method 2 was slightly 
modified for the detection of IP6 in human urine371 and will be discussed later in the present 
chapter. 
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During the validation process and assessment of the practical application of Method 2, a 
dietary intervention was conducted by the present researcher in a rat study in the Laboratory 
of Renal Lithiasis at the University of Balearic Islands, Spain, as part of a student exchange 
program. The aim was for the present researcher to receive expert training in all aspects of 
this method (as well as Method 1) in the laboratory in which it was developed, and to 
ultimately apply it in a project for a PhD thesis, involving urine from human subjects in the 
Kidney Stone Research Laboratory (KSRL) at the University of Cape Town. However, 
because of the very high cost of the resin (AG 1-x8 chloride form, 200 – 400 mesh; BIO 
RAD) used in both methods, an alternative resin had to be sourced and used. The efficacy of 
the alternative resin in both methods therefore had to be tested prior to its use in the KSRL.   
The objectives of this chapter were therefore to: 
1. Test the practical application of Method 2 by investigating whether it is able to detect 
a change in IP6 concentration in the urine of rats in relation to the dietary intake of 
this substance. 
2. Determine the efficacy of an alternative resin for possible use in both methods by 
testing its capacity for removing interfering substances, its reproducibility and the 
percentage recovery it achieves. 
3. Selection of the “best” method for IP6 analysis in the KSRL by comparison of the two 
methods with respect to removal of interfering substances, reproducibility and 
percentage recovery.    
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Methods 
Experiments described in the present chapter were conducted at the University of Cape 
Town in the KSRL and at the University of Balearic Islands, Spain in the Renal Lithiasis 
Laboratory. Experiments conducted in the latter laboratory are denoted by the following 
symbol “‡”.  
The protocols for both methods of urinary IP6 pre-concentration and quantification in each 
method are first described. This is followed by a description of the testing of the practical 
application of Method 2. Finally the investigation of the efficacy of an alternative resin for use 
in Method 1 and Method 2 is described.   
Preconcentration of phytate (method 1) 
The method described by Costa-Bauza et al363 was used for sample preparation and 
preconcentration of IP6. Briefly, 20 ml of urine was set to a pH of 3 (using 1 M HCl) and was 
diluted with 20 ml of distilled water. This was transferred to a 150 ml beaker containing 0.5 g 
of an anion exchange resin without previous conditioning and mechanically shaken for 
15 mins at a speed of 160 rpm (Labcon; Johannesburg). The resin mixture was then 
transferred to an empty 20 ml SPE tube (Sigma Aldrich), fitted with a frit, to separate the 
urine mixture from the resin. Care was taken not to let the resin run dry. The resin was then 
washed with 120 ml HCl (50 mM) in a stepwise manner by adding approximately 20 ml 
aliquots of HCl with manual stirring using a glass rod. The resin was then washed with 5 ml 
distilled water. Finally, IP6 was eluted with 4 ml of 2 M NaCl. This was also done in a 
stepwise manner by adding 1 ml aliquots of NaCl and mechanically shaken for 5 mins at 
180 rpm. The final eluate (4 ml) was homogenized by vortex-mixing and used for 
quantification as described in the following paragraph.  
Quantification of phytate (method 1) 
IP6 was quantified using a colorimetric assay.363 A reagent containing Fe-SCN was prepared 
daily by mixing equal volumes of two solutions (S1 and S2). S1 was a mixture of 8 ml KSCN 
(5 M) and 2 ml glycine/HCl buffer (0.5 M, pH 2). S2 was a mixture of 5 ml Fe(NO3)3 (5 mM) in 
HNO3 (5 mM), 2.5 ml NaClO3 (0.4 M) and 5 ml sodium persulfate (75 mM). 
IP6 standards in the range of 0 – 25 µM were prepared from dipotassium phytic acid (Sigma 
Aldrich) in NaCl (2 M). The assay was conducted by adding 0.5 ml of reagent to 3 ml of the 
eluate or standard. Absorbance was measured at 460 nm (Spectronic Unicam; Helios 
gamma) 5 min after mixing. IP6 was determined from the calibration curve. A typical 
calibration curve obtained in the present study is shown Figure 4.1. A schematic diagram 
which summarises Method 1 is shown in Figure 4.2. 
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Figure 4.1 A typical plot of absorbance vs IP6 concentration depicting a calibration curve 
for the determination of IP6 (Method 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Schematic diagram (adapted from Grases et al370) for the detection of urinary 
IP6 using Method 1. 
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Preconcentration of phytate (method 2) 
This method was originally developed for the determination of IP6 in the urine of rats.370 A 
10 ml aliquot of urine was mixed with an equal volume of 10 mM EDTA 
(ehtylenediaminetetraacetic acid) and diluted with 20 ml of distilled water. The pH of the 
resulting mixture was adjusted to 6 (using 1 M HCl or 1 M NaOH depending on the initial pH) 
and this was then transferred to a 50 ml corning tube and centrifuged at 3000 rpm for 
15 mins. The supernatant was then acidified to a pH of 3 (1 M HCl) and was quantitatively 
transferred to a 150 ml beaker containing 0.25 g of an anion exchange resin without previous 
conditioning. Each mixture was stirred at 160 rpm for 15 mins using an orbital stirrer to 
facilitate adsorption of phytate to the resin. These mixtures were then carefully transferred to 
an empty SPE tube fitted with a frit to separate the urine mixture from the resin. The resin 
was washed with 300 ml HCl (100 mM) followed by washing it twice with 5 ml aliquots of 
distilled water. During washing, the resin was stirred manually with a glass rod. IP6 was then 
eluted with 2 M NaCl in 5 steps using 0.5 ml of NaCl each time. The total volume (2.5 ml) 
was then homogenized by vortex mixing prior to phytate quantification.  
This method was slightly modified for the determination of IP6 in human urine.371 The same 
procedure was followed except dilution of the urine with distilled water was not necessary (as 
human urine is not as concentrated as the urine of rats) and a volume of 100 ml HCl (50 mM) 
was used for washing of the resin. 
Quantification of phytate (method 2) 
Phytate was determined colorimetrically using aluminium and xylenol orange. The following 
solutions (S1 and S2) were freshly prepared. S1 consisted of 4mM Al(NO3)3.9H2O in an 
acetic acid/acetate buffer (1.5 M, pH= 5.2) and S2 contained 4mM Xylenol Orange (XO) in 
distilled water. IP6 standards with a concentration of 0 – 14 µM were prepared using phytic 
acid dipotassium salt (Sigma, Aldrich) in NaCl (2 M).    
The assay was conducted by adding 0.5 ml of S1 to 2.5 ml of the eluate or standard and 
vortex-mixed. After 30 seconds, 0.5 ml of S2 was added. The mixture was then allowed to 
stand for 45 mins after which absorbance readings were taken at 560 nm. The concentration 
of IP6 in each eluate was determined from a calibration curve. An example of a typical 
calibration curve obtained in the present study is shown in Figure 4.3. A schematic diagram 
which summarises Method 2 is shown in Figure 4.4. 
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Figure 4.3 A typical plot of the logarithm of absorbance vs IP6 concentration depicting a 
calibration curve for IP6 determination (Method 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 schematic diagram (adapted from Grases et al370) for the determination of IP6 in 
urine of rats and humans using Method 2. 
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Assessment of the practical application of Method 2: Animal study ‡ 
All aspects involved in the development of Method 2 had been previously performed by 
members of the Renal Lithiasis Laboratory in Spain prior to the present researcher’s 
studentship. The practical application of the method on the other hand was tested by the 
present researcher. As mentioned in Chapter 1, previous studies in both animals and rats 
have demonstrated that urinary IP6 decreased when its dietary intake was restricted and 
increased when it was administered. Testing the practical application of Method 2 was 
therefore undertaken by conducting a dietary intervention in a rat study as described below. 
Three male Wistar rats (28- 30 months old) and 2 female Wistar rats (11 months old) from 
Harlan Ibérica S.A (Barcelona, Spain) were used in this study. Rats were housed (1 or 2 rats) 
per cage at a temperature of 18 – 23 °C and a relative humidity of 50 % with a 12 h light-dark 
cycle. They were fed a purified diet containing undetectable amounts of IP6 (AIN-76A 
Harland Tekland, Madison, WI, USA) for a duration of 15 days. This was followed by the 
administration of a standard non-purified diet containing 1 % IP6 (UAR A03; Panlab S. L.; 
Barcelona, Spain) for another 17 days. Diets and tap water were fed ad libitum. The 
composition of each diet is shown in Table 4.1. 
Table 4.1 Composition of AIN-76A purified diet and UAR-A03 standard non-purified diet. 
 AIN-76A 
(g. kg-1 dry mass) 
UAR-A03 
(g. kg-1 dry mass) 
Protein 203 267 
Carbohydrate 650 565 
Lipid 50 57 
Cellulose 50 45 
Ash 47 66 
Calcium 3.91 9.90 
Magnesium 0.47 1.85 
Zinc 0.028 0.045 
Phosphorusa 7.20 5.30 
IP6 undetectable 9.0 
                                     aExcludes phosphorus from IP6. 
24 hr urine samples were collected by housing the rats in metabolic cages (Tecniplast; 
Gazzada; S. A. R. L.; Buggagiate, Italy). Urine was collected on day 0 which served as the 
baseline sample and periodically over the course of the study to determine urinary IP6 in 
relation to its dietary intake.  
The procedures used in this experiment were applied according to the Directive 86/609/EEC 
regarding the protection of animals used for experimental and other scientific purposes. 
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Efficacy of an alternative resin 
The efficacy of an alternative, more affordable, resin (Dowex 1 x 8 chloride form, 200- 400 
mesh; Sigma Aldrich) for use in both Method 1 and Method 2 was tested in the KSRL. Since 
the purification of IP6 (in both methods) is based on its adsorption to an anionic exchange 
resin, a study involving the removal of interfering anions such as oxalate, sulfate and 
phosphate which occur in urine was undertaken in the present project. Artificial urine (AU) 
was used for this purpose. The reproducibility of both methods using the alternative resin 
was determined by calculating the co-efficient of variation (CV) of intra-day replicates (n= 5). 
The percentage recovery was determined by the addition of 1 and 2 µM IP6 to the AU. 
Finally, both methods were used for the determination of IP6 and its percentage recovery in 
human urine.   
Artificial urine 
A stock solution of AU was prepared from 320 mM NaCl, 50 mM NaH2PO4, 6.52 mM MgCl2, 
164.2 mM KCl, 4.34 mM K3Citrate, 43.8 mM (NH4)2SO4 and 7.0 mM NH4Cl and adjusted to a 
pH of 6 (using HCl 1M).372 Standard solutions of calcium (CaCl2 120 mM) and oxalate 
(Na2Ox 50 mM) were prepared separately. 16.7 ml CaCl2 and 3 ml Na2Ox was added to 
480.3 ml of the AU stock solution and diluted to a volume of 1000 ml using milliQ water. The 
final concentration of calcium and oxalate was therefore 2.0 mM and 0.15 mM; these 
concentrations are within the range of urinary concentrations routinely determined in the 
KSRL during the past 5 years. The composition of AU is shown Table 4.2.  
AU was kept at 4°C for up to 1 week and was discarded upon precipitation of salts and/or 
bacterial growth. All solutions were prepared in Millipore water with a resistivity of 18 mΩ.  
        Table 4.2 The composition of artificial urine. 
Species Concentration (mM) 
Na+ 185.15 
Cl- 252.86 
K+ 88.61 
PO42- 25 
NH4+ 47.3 
SO42- 21.9 
Mg2+ 3.26 
Cit 2.17 
Ca2+ 2.0 
Ox2- 0.15 
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Real urine 
24 hr urine samples were provided by 7 healthy males (while on their free diets) between the 
age of 18 – 25 years from the student cohort at the University of Cape Town. Each male 
provided a minimum of 1 x 24 hr sample; a total of 14 urine samples was analysed in the 
present study. Samples were collected in sterilised plastic bottles without any preservative. 
These were tested for bacteria and blood and were discarded if tested positive. All IP6 
analysis was performed on the day that urine samples were received. 
Calculations and statistical analysis 
The reproducibility of both methods was determined by calculating the CV (expressed as a 
percentage). This was calculated using the following equation:  
CV= (standard deviation/ average) x 100 
Paired t-tests were performed for the comparison of urinary IP6 detected in the same urine 
sample using Method 1 vs Method 2. The software program GraphPad Instat 3 was used for 
this purpose. 
  
Chapter 4                                                                          Method for urinary IP6 determination 
 
84 
 
Results 
Assessment of the practical application of Method 2: animal study ‡ 
The mean urinary excretion profile of IP6 in rats in relation to its dietary intake is shown in 
Figure 4.5. All raw data are reported in Appendix 4.1. A noticeable decrease in urinary IP6 
was observed after 6 days of consuming the phytate-deficient AIN- 76A diet and reached 
values that were close to zero within 15 days. When a standard diet containing 1 % IP6 was 
administered, urinary IP6 started to increase after 4 days and reached maximum values 
within 15 days.  The same trend was observed in both male and female rats, irrespective of 
age. The reason for the decrease in urinary IP6 in male rats after day 30 is not obvious. 
 
 
Figure 4.5 Urinary IP6 excretion in relation to its dietary intake over a period of 37 days in 
male (A) and female (B) Wistar rats. 
 
  
0.000
0.200
0.400
0.600
0.800
1.000
1.200
1.400
1.600
1.800
0 3 6 9 12 15 18 21 24 27 30 33 36
[IP
6]
 µ
M
 
time (days) 
AIN- 76A UAR A03 
0.000
0.500
1.000
1.500
2.000
2.500
3.000
3.500
4.000
4.500
0 3 6 9 12 15 18 21 24 27 30 33 36
[IP
6]
 µ
M
 
time (days) 
AIN- 76A UAR A03 
A 
B 
Chapter 4                                                                          Method for urinary IP6 determination 
 
85 
 
Efficacy of an alternative resin 
The mean results obtained for the removal of interfering ions as well as the reproducibility 
and percentage recovery of IP6 in AU is shown in Table 4.3 for both methods. All raw data 
are reported in Appendix 4.2. Consideration of the mean value and its SE for the assay of 
IP6 in AU without the addition of IP6 indicates that it’s close to zero for both Method 1 and 
Method 2 (0.11 ± 0.02 µM and 0.30 ± 0.18 µM, respectively). This indicates that the removal 
of interfering ions was efficient. The CV was small indicating that reproducibility of both 
methods is good. However, the percentage recovery for Method 2 was found to be lower 
than for Method 1. 
 
Table 4.3 Study of interferences, reproducibility and percentage recovery of IP6 in artificial 
urine. 
     IP6 added  
       (µM) 
IP6 detected ± SD (µM)       
        CV (%) 
 
     % recovery 
Method 1 
AU (n =5) 0 0.11 ± 0.02 baseline 
AU (n= 5) 1 1.17 ± 0.09 7 106 
AU (n = 5) 2 1.84 ± 0.13 7 87 
Method 2 
AU (n =5) 0 0.30 ± 0.18 baseline 
AU (n= 5) 1 0.81 ± 0.11 14 51 
AU (n = 5) 2 1.42 ± 0.09 7 56 
 
The determination of IP6 as well as its percentage recovery in real urine samples, using both 
methods, is shown in Table 4.4. Each determination was performed in duplicate per urine 
sample; mean values are reported in Table 4.4 . For simplicity the standard error of the mean 
has been omitted in this table but is included in Appendix 4.2 (raw data). 
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Table 4.4 Detection and percentage recovery of IP6 in real urine. 
 IP6 detected (µM) 
Method 1 Method 2 
Addition of IP6 (µM) 0 1 % recovery 0 1 % recovery 
Urine 1 1.79 2.71 92 0.62 1.36 73 
Urine 2 1.61 2.64 103 0.90 1.52 63 
Urine 3 1.41 2.22 81 0.77 1.30 53 
Urine 4 0.40 1.27 87 0.36 1.25 88 
Urine 5 1.31 2.12 82 0.66 1.37 72 
Urine 6 0.84 1.58 75 0.79 1.32 53 
Urine 7 0.24 1.09 85 0.48 1.06 59 
Urine 8 1.37 2.13 76 1.08 1.55 46 
Urine 9 1.38 2.13 74 0.80 1.30 50 
Urine 10 0.65 1.64 99 0.67 1.24 58 
Urine 11 1.23 2.06 83 0.71 1.28 57 
Urine 12 0.81 1.68 87 0.43 0.99 56 
Urine 13 0.98 2.14 116 0.66 1.27 61 
Urine 14 0.89 1.96 106 0.40 1.04 64 
 
Statistical comparisons of the above data are shown in Figure 4.6. Mean values, the 
standard error, p values as well as the percentage recovery is shown. These comparisons 
indicated that the baseline IP6 detected in urine using Method 2 was significantly lower 
compared to Method 1 (p = 0.0013). Furthermore, the concentration of IP6 detected in urine 
after the addition of 1 µM IP6 was also significantly lower for Method 2 (p < 0.0001), 
culminating in a lower % recovery. 
 
 
Figure 4.6 Statistical comparison of IP6 detected in urine using Method 1 and Method 2. 
Error bars indicate the standard error of the mean. Indicates statistical significance. 
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Comment 
The colorimetric assay used in Method 1 is based on a decrease in the concentration of 
Fe(III)-SCN upon the complexation of Fe to IP6. This assay is however compromised by 
traces of reducing substances which remain after purification of samples which reduce Fe(III) 
to Fe(II) and results in a false positive for the detection of IP6. To overcome this limitation, 
Method 2 was developed by Costa-Bauza370 and colleagues (as mentioned earlier in this 
Chapter) in which Al(III)-xylenol orange was used as an alternative metal-dye system. 
Aluminium has 3 oxidation states i.e +1, +2 and +3. However, the latter oxidation state is 
most common. This metal is therefore not susceptible to reduction by traces of reducing 
substances in the purified sample hence overcoming the aforementioned limitation when 
using Fe. In addition to this modification, the purification and preconcentration of IP6 via SPE 
has also been modified by Costa-Bauza370 and colleagues by using EDTA in the sample 
preparation. This was done to complex metals such as calcium and magnesium, 
subsequently preventing the loss of IP6 during an intermediate step of the purification 
process as the latter is able to bind to these metals. The lower percentage recovery in 
Method 2 (using the alternative resin, Dowex 1x 8) was therefore surprising as EDTA was 
used to increase the recovery of IP6. However, EDTA has four carboxylic acid groups with 
pKa’s between 0 – 2.66. It is therefore possible that some of the un-chelated EDTA adsorbed 
to the resin (Dowex 1x 8) due to its high negative charge. This has been shown for other 
anion exchange resins in which the purification of proteins was studied.373 The adsorption of 
EDTA therefore resulted in the reduction of the resin capacity in the present study and the 
subsequent loss of IP6 during the washing step which led to low percentage recoveries. 
Conclusions 
Proof of the practical application of Method 2 (using the AG 1x8 resin) was demonstrated in 
this study since it was able to detect a decrease in urinary IP6 concentrations when its 
dietary intake was restricted as well as a gradual increase thereof when dietary IP6 was 
administered to rats. However, assessment of the more affordable, alternative resin (Dowex 
1x8) for utilization in both Method 1 and Method 2 showed that this resin was unsuitable for 
the latter method due to a reduction in the resin’s capacity as described above. Method 1 
was therefore chosen for IP6 urine analysis in subsequent studies undertaken in the present 
thesis in the KSRL. 
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Chapter 5 : In vitro study of the effect of phytate on calcium oxalate 
crystallisation 
Introduction 
The crystallisation propensity of urine may be used as an evaluation of the risk to form 
kidney stones.374 Thus, in vitro crystallisation experiments in both inorganic media and real 
urine remain of fundamental importance in urolithiasis research.50, 374, 375 Different methods 
have been developed to mimic physiological aspects of the renal system as well as to 
differentiate between processes of crystallisation such as nucleation, aggregation and 
growth.50 These methods may be classified by the type of process used, the analytical 
technique or by the supersaturation profile.50 The crystallisation experiments may be either 
batch (discontinuous), continuous, seeded or unseeded.50 Many of these experiments may 
be conducted using sophisticated instrumentation or by using simple and affordable methods 
(depending on the equipment that’s available). However, inter-procedural comparisons may 
not necessarily be the same.376 It is therefore important to use caution when making inter-
procedural comparisons and the same method should be used for quantitative 
comparisons.377  
In vitro experiments do however have certain limitations regarding the imitation of 
physiological conditions e.g. simple experiments in inorganic media in which the urine flow 
dynamics are not modelled.374, 378 It should also be noted that results obtained in inorganic 
media do not necessarily reflect those of real urine as the latter is a complex medium 
containing many components which may act as inhibitors and/ or promoters of 
crystallisation375, 379 Nevertheless, experiments in inorganic media provide useful insight into 
the effect of individual urinary components in isolation on crystallisation mechanisms.374 
In the present thesis, theoretical modelling showed that phytate (IP6) does not affect the 
concentration of ionized calcium (Ca2+) nor the supersaturation of urine with respect to CaOx 
and CaP under physiological conditions. The objectives of the present chapter were 
therefore as follows: 
1. To test experimentally the theoretical predictions described earlier in this thesis 
(Chapter 4), using in vitro experiments in which the concentration of Ca2+ in artificial 
and real urine is determined in the presence of physiological and non-physiological 
concentrations of IP6.  
2.  To determine and compare the effects (if any) of IP6 on crystallisation propensity in 
artificial urine and in urine of South African black and white subjects by measuring 
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CaOx MSLs, CaOx crystallisation rates, CaOx crystal size distributions and CaOx 
crystal morphologies. 
3. To investigate the effect of IP6 on specific CaOx kinetic crystallisation mechanisms 
(nucleation, growth and aggregation). 
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Methods 
Experimental approach 
Various experiments were conducted in AU and in pooled urine of black (BPU) and white 
(WPU) subjects. These are summarised in Table 5.1. These experiments were conducted to 
achieve the first two objectives of the present study as outlined in the introduction to this 
chapter.  
Experiments conducted to achieve the third objective of the present study as outlined in the 
introduction to this chapter, namely to determine the effect of IP6 on specific crystallisation 
mechanisms, were conducted in metastable CaOx solutions. These are summarised in Table 
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C
ha
pt
er
 5
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 in
 v
itr
o 
cr
ys
ta
lli
sa
tio
n 
st
ud
ie
s 
   
   
   
 
91
 
 Ta
bl
e 
5.
1 
S
um
m
ar
y 
of
 v
ar
io
us
 e
xp
er
im
en
ts
 c
on
du
ct
ed
 in
 a
rt
ifi
ci
al
 a
nd
 p
oo
le
d 
ur
in
e 
of
 b
la
ck
 a
nd
 w
hi
te
 s
ub
je
ct
s 
to
 a
ch
ie
ve
 o
bj
ec
tiv
es
 1
 a
nd
 2
.  
A
b
br
ev
ia
tio
ns
 s
ho
w
n 
in
 p
ar
en
th
es
es
 a
re
 u
se
d 
th
ro
ug
ho
ut
 t
he
 c
ha
pt
er
. 
C
on
ce
nt
ra
tio
ns
 o
f 
IP
6 
in
 B
P
U
2-
 5
 a
nd
 W
P
U
2-
 5
 a
re
 t
he
 t
ot
al
 
co
nc
en
tr
at
io
ns
. C
on
ce
nt
ra
tio
ns
 o
f 1
5 
µM
 a
nd
 3
0 
µM
 IP
6 
w
er
e 
ch
os
en
 b
as
ed
 o
n 
a 
pr
ev
io
us
 s
tu
dy
.2
85
 
n:
 n
um
be
r o
f e
xp
er
im
en
ts
 c
on
du
ct
ed
. n
‡ :
 n
um
be
r o
f S
E
M
 s
tu
bs
. 
*n
ot
 d
et
er
m
in
ed
; n
o 
at
te
m
pt
 m
ad
e.
 
**
no
t d
et
er
m
in
ed
; e
xc
es
si
ve
ly
 h
ig
h 
M
S
L 
th
us
 c
ry
st
al
lis
at
io
n 
co
ul
d 
no
t b
e 
in
du
ce
d.
 
**
*n
ot
 d
et
er
m
in
ed
; u
na
va
ila
bi
lit
y 
of
 a
 C
ou
lte
r 
C
ou
nt
er
 a
t t
he
 ti
m
e 
at
 w
hi
ch
 e
xp
er
im
en
ts
 w
er
e 
co
nd
uc
te
d.
 
 
[C
a2
+ ]
 
 n 
C
aO
x 
M
S
L 
 n 
C
ry
st
al
lis
at
io
n 
ki
ne
tic
s 
 n 
P
S
D
 
 n 
S
E
M
 
 n‡
 
A
U
 +
 0
 µ
M
 IP
6 
(A
U
0)
 
√ 
6 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
A
U
 +
 0
.7
57
 µ
M
 IP
6 
(A
U
1)
 
√ 
3 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
A
U
 +
 2
.2
7 
µM
 IP
6 
(A
U
2)
 
√ 
3 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
A
U
 +
 4
.4
5 
µM
 IP
6 
(A
U
3)
 
√ 
3 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
A
U
 +
 1
5 
µM
 IP
6 
(A
U
4)
 
n.
d*
 
_ 
√ 
3 
n.
d*
* 
_ 
n.
d*
* 
_ 
n.
d*
* 
_ 
B
P
U
 
√ 
3 
√ 
3 
√ 
3 
  
n.
d*
**
 
 
  _ 
√ 
2 
B
P
U
 +
 2
.2
7 
µM
 (
B
P
U
2)
 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
B
P
U
 +
 4
.4
5 
µM
 (
B
P
U
3)
 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
B
P
U
 +
 1
5 
µM
 (
B
P
U
4)
 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
B
P
U
 +
 3
0 
µM
 (
B
P
U
5)
 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
W
P
U
 
√ 
3 
√ 
3 
√ 
3 
   
   
   
   
  
 
n.
d*
**
 
 
  _ 
√ 
2 
W
P
U
 +
 2
.2
7 
µM
 (
W
P
U
2)
 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
W
P
U
 +
 4
.4
5 
µM
 (
W
P
U
3)
 
√ 
3 
√ 
3 
√ 
3 
√ 
2 
W
P
U
 +
 1
5 
µM
 (W
P
U
4)
 
√ 
3 
√ 
3 
n.
d*
* 
_ 
n.
d*
* 
_ 
W
P
U
 +
 3
0 
µM
 (W
P
U
5)
 
√ 
3 
√ 
3 
n.
d*
* 
_ 
n.
d*
* 
_ 
C
ha
pt
er
 5
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 in
 v
itr
o 
cr
ys
ta
lli
sa
tio
n 
st
ud
ie
s 
   
   
   
 
92
 
 Ta
bl
e 
5.
2 
S
um
m
ar
y 
of
 v
ar
io
us
 e
xp
er
im
en
ts
 c
on
du
ct
ed
 in
 u
ns
ee
de
d 
an
d 
se
ed
ed
 m
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
ns
 to
 a
ch
ie
ve
 o
bj
ec
tiv
e 
3.
 
m
et
as
ta
bl
e 
so
lu
ti
on
 o
f C
aO
x 
+ 
Te
st
 s
ub
st
an
ce
‡  
C
ry
st
al
 N
uc
le
at
io
n 
&
 
A
g
gr
eg
at
io
n 
as
sa
y 
n 
C
ry
st
al
 G
ro
w
th
 a
ss
ay
 
n 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
0 
µM
 IP
6 
(c
on
tr
ol
) 
√ 
18
 
√ 
15
 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
0.
75
7 
µM
 IP
6 
√ 
6 
√ 
6 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
2.
27
 µ
M
 IP
6 
√ 
6 
√ 
6 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
4.
45
 µ
M
 IP
6 
√ 
5 
√ 
6 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
(c
on
tr
ol
) 
√ 
6 
 
 
n.
d*
 
  _ 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
A
U
0 
√ 
7 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
A
U
1 
√ 
5 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
A
U
2 
√ 
4 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
A
U
3 
√ 
5 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
(c
on
tr
ol
) 
√ 
3 
√ 
6 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
P
U
 
√ 
6 
√ 
6 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
(P
U
 +
 2
.2
7 
µM
 IP
6;
 P
U
2)
 
√ 
6 
√ 
6 
M
et
as
ta
bl
e 
C
aO
x 
so
lu
tio
n 
+ 
(P
U
 +
 4
.4
5 
µM
 IP
6;
 P
U
3)
 
n.
d*
 
_ 
√ 
6 
A
b
br
ev
ia
tio
ns
 s
ho
w
n 
in
 p
ar
en
th
es
es
 w
ill
 b
e 
us
ed
 t
hr
ou
gh
ou
t 
th
e 
ch
ap
te
r.
 C
on
ce
nt
ra
tio
ns
 o
f 
IP
6 
in
 P
U
2 
an
d 
P
U
3 
in
di
ca
te
s 
th
e 
to
ta
l 
co
nc
en
tr
at
io
n.
 
‡ I
n 
ca
se
s 
w
he
re
 u
rin
e 
an
d 
ur
in
e 
do
se
d 
w
ith
 v
ar
io
us
 c
on
ce
nt
ra
tio
ns
 o
f 
IP
6 
w
er
e 
us
ed
 a
s 
th
e 
te
st
 s
ub
st
an
ce
, 
th
e 
fo
llo
w
in
g 
vo
lu
m
e 
ra
tio
s 
w
er
e 
us
ed
 in
 th
e 
re
sp
ec
tiv
e 
as
sa
ys
: 
nu
cl
ea
tio
n 
an
d 
ag
gr
eg
at
io
n 
as
sa
y-
 1
 m
l C
aC
l 2 
: 
20
0 
µl
 u
rin
e 
: 
1 
m
l 
K
2O
x 
an
d 
in
 th
e 
gr
ow
th
 a
ss
ay
- 
2 
m
l 
C
aO
x 
so
lu
tio
n 
: 
20
0 
µl
 u
rin
e.
 T
he
se
 r
at
io
s 
w
er
e 
us
ed
 t
o 
ob
ta
in
 a
 s
uf
fic
ie
nt
 d
iff
er
en
ce
 i
n 
th
e 
ra
te
 o
f 
ea
ch
 c
ry
st
al
lis
at
io
n 
m
ec
ha
ni
sm
 r
el
at
iv
e 
to
 t
he
 
co
nt
ro
l.2
10
 
*n
ot
 d
et
er
m
in
ed
; m
al
fu
nc
tio
n 
of
 in
st
ru
m
en
t a
t t
he
 ti
m
e 
at
 w
hi
ch
 e
xp
er
im
en
ts
 w
er
e 
co
nd
uc
te
d.
 
Chapter 5                                                                                      in vitro crystallisation studies                                                                                                                                                                          
 
93 
 
Phytic acid 
Stock solutions of phytate (1 mM and 10 mM) were prepared by dissolving phytic acid 
dipotassium salt (Sigma) in milliQ water. These were used for standard additions in 
experiments which will be described below. 
Preparation of artificial urine 
Artificial urine was prepared as described in Chapter 4. The composition of this medium is 
shown in Table 4.2. 
 
Real urine collection and treatment 
24 hr urine samples were collected by healthy black (n= 6) and white (n= 6) South African 
males from the University of Cape Town. The latter was used in objective 3 of the present 
study.  Each subject provided one 24 hr sample. These 24 hr samples were collected in 
plastic bottles without any preservative. Urine samples were tested for the presence of blood 
and infection (Combur 10 test strip, Boehringer Manheim, Manheim Germany) and were 
discarded if tests were positive. All samples were filtered through a 0.75 µm filter paper 
followed by a 0.45 µm nitrocellulose filter paper prior to all crystallisation experiments to 
remove cellular debris.  
For objective 1 and 2 of the present study, urine samples were pooled according to race to 
eliminate the effect of intra-racial urinary differences with respect to composition.304, 305 Each 
pool was constituted by mixing equal volumes (300 ml) of the 6 urine samples in accordance 
with a previous study on the optimum number of samples required for a statistically 
representative pool.380 The endogenous amount of IP6 in pooled urine of black subjects 
(BPU) and white subjects (WPU) was determined, using the method described in Chapter 4, 
prior to standard additions of IP6 (Appendix 5.5). The urine composition of each pool was 
determined (as described in Chapter 6) and is shown in Table 5.3 together with the SS of 
CaOx, brushite and urate (calculated using JESS321, 322).  
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Table 5.3 Urine composition and the relative supersaturation of salts in pooled urine 
samples of black and white subjects. 
Parameter BPU WPU 
pH 6.13 6.24 
Citrate (x 10-3 mol/L) 2.01 1.67 
Oxalate (x 10-4 mol/L) 1.95 1.56 
Calcium (x 10-3 mol/L) 1.93 1.68 
Magnesium (x 10-3 mol/L) 1.13 1.27 
Sodium (x 10-1 mol/L) 1.53 1.51 
Potassium (x 10-2 mol/L) 2.22 1.91 
Urate (x 10-3 mol/L) 3.92 3.40 
Phosphate (x 10-2 mol/L) 3.23 3.03 
Chloride (x 10-1 mol/L) 1.38 1.31 
Phytate (x 10-6 mol/L) 1.00 1.10 
RS CaOx 4.05 2.90 
RS Brushite 1.97 1.96 
RS Urate 1.49 1.04 
 
For objective 3 of the present study, an additional set of 24 hr urine samples was collected 
by healthy males (n =4), irrespective of race. These were pooled (to eliminate the effect of 
inter-urinary differences with regard to composition) and treated as described above. The 
urine composition and SS of salts in this pooled urine (PU) is shown in Table 5.4.  
Table 5.4 Urine composition and the  relative supersaturation of pooled urine used for 
objective 3 of the present study. 
Parameter PU 
pH 6.36 
Citrate (x 10-3 mol/L) 1.61 
Oxalate (x 10-4 mol/L) 1.40 
Calcium (x 10-3 mol/L) 1.84 
Magnesium (x 10-3 mol/L) 1.13 
Sodium (x 10-2 mol/L) 9.65 
Potassium (x 10-2 mol/L) 3.15 
Urate (x 10-3 mol/L) 2.36 
Phosphate (x 10-2 mol/L) 1.52 
Chloride (x 10-1 mol/L) 1.38 
Phytate (x 10-6 mol/L) 0.708 
RS CaOx 3.59 
RS Brushite 1.67 
RS Urate 0.56 
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Objectives 1 & 2: Ca2+ and crystallisation propensity 
Determination of ionized calcium 
Ca2+ was determined using a calcium ion selective electrode (Photometer, Metrohm, Swiss). 
The electrode was calibrated regularly, to ensure that the Nernstian equation was obeyed, 
using six calcium standards in the range of 0.1 – 50 mM. A typical calibration plot obtained in 
the present study is shown in Figure 5.1. Ca2+ was measured in samples at 37 °C. 
 
 
Figure 5.1 Calibration curve used to determine ionized calcium in urine samples. 
 
CaOx metastable limit  
The CaOx metastable limit (MSL) is a measure of the ability of a solution to resist 
spontaneous crystallisation.50 In whole urine this can be used as an indicator of the urine’s 
heterogeneous nucleation capacity.50 The protocol described by Ryall was used to determine 
the CaOx MSL of a particular solution233 but a spectrophotometer (Spectronic Unicam, Helios 
gamma) instead of a Coulter Counter was used to follow crystallization by measuring the 
change in turbidity at 620 nm. 
In this method, 10 ml aliquots (x 13) of each sample were incubated at 37°C. Each of these 
was then dosed with progressively increasing concentrations of sodium oxalate (Na2Ox) to 
obtain final concentrations of oxalate between 0.15 – 1.95 mM. Dosing was performed at 1 
minute intervals. After an incubation period of 30 minutes per aliquot, the absorbance was 
measured in a glass cuvette. The MSL was determined by plotting the absorbance versus 
Na2Ox concentration. The concentration at which a sudden increase in absorbance occurred 
was taken as the MSL. A typical plot as obtained in the present thesis is shown in  Figure 
5.2. 
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 Figure 5.2 A typical plot of absorbance vs concentration of Na2Ox from which the CaOx 
MSL of a solution is determined. 
 
CaOx Crystallisation kinetics 
Crystallisation kinetics were determined in samples by adding Na2Ox (500 µl per 50 ml 
sample) at a concentration of 0.15 mM  above the previously determined MSL (thus inducing 
crystallisation) and measuring the change in turbidity at 620 nm over a certain time period as 
described below. In cases where crystallisation failed to be initiated after dosing with 0.15mM 
Na2Ox, a higher dosing concentration was used. Samples (50 ml) were incubated in soda-
lime bottles in a shaking water bath (100 rpm; Labcon Johannesburg) at 37 °C. The 
absorbance at 620nm was measured at time zero and every 15 minutes over a period of 
2 hrs. A typical kinetics plot as obtained in the present thesis is shown in Figure 5.3. The rate 
of CaOx crystallisation was determined from the slope of the curve with increasing 
absorbance.  
 
Figure 5.3 A typical plot of absorbance vs time which depicts CaOx crystallisation kinetics. 
 
MSL 
Rate of crystallization 
determined from 
slope 
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Particle size distribution 
CaOx crystallisation was induced in samples as described above for the crystallisation 
kinetics experiments and were incubated at 37 °C in a shaking water bath (100 rpm; Labcon, 
Johannesburg) for a duration of 2 hrs. The mean particle size and total volume of the 
precipitated particles were measured using a Coulter Counter (Multisizer III, Coulter Electron, 
England). Graphs of particle volume vs particle size were plotted. A typical graph as obtained 
in the present thesis is shown in Figure 5.4. The mode of the curve was regarded as the 
average size of particles precipitated in a particular solution.    
 
Figure 5.4 A typical particle volume- size distribution plot as obtained in the present study. 
 
Scanning electron microscopy 
At the end of each kinetics experiment (i.e after 2 hrs) as described above, 2 ml of each 
sample was filtered through a 0.22 µm filter paper (Merck Millipore). Filter papers were dried 
at room temperature and glued onto aluminium stubs for the analysis of crystals. Each stub 
was coated with gold palladium and crystals were viewed using a Nova NanoSEM 230 
scanning electron microscope operating at a landing energy of 5.00 keV, spot size of 2 and 
working distance of 5.5 - 6.1 mm. Stubs were viewed at magnifications of x 1000 to obtain an 
overview of the entire surface and at x 5000 to record typical deposits.  
Objective 3: specific crystallisation mechanisms 
Nucleation and aggregation   
These crystallisation characteristics  were investigated as described in a spectroscopic assay 
which was developed by Hess et al.381 This crystallisation experiment is a simple batch/ 
discontinuous process in which the change in particle number in a metastable 
supersaturated solution of CaOx is followed continuously by measuring a change in turbidity 
Mode = average particle size 
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as a function of time. The assay was designed for the investigation of the effects of individual 
urinary components in isolation, on these crystallisation mechanisms. 
The metastable supersaturated solution of CaOx was prepared by mixing two solutions as 
described below. 
Stock solutions of calcium (8.5 mM CaCl2, 200 mm NaCl, 10 mM NaAc, pH 5.7) and oxalate 
(1.0 mM K2C2O4, 200 mM NaCl, 10mM NaAc, pH 5.7) were prepared in distilled water, 
filtered (0.22 µM) daily before use and incubated in a water bath at 37°C. 1 ml of the calcium 
solution was transferred to a glass cuvette followed by the addition of a test substance (IP6, 
artificial urine, artificial urine dosed with various concentrations of IP6, pooled urine, pooled 
urine dosed with various concentrations of IP6). The volume of the test substance was varied 
to achieve various desired concentrations as described on page 92. Oxalate (1 ml) was 
added last to induce crystallisation. Absorbance was measured at 620 nm using a UV-Vis 
spectrophotometer (AnalytiKJena, Germany) fitted with a thermostatted mantle (37°C) and 
magnetic stirrer (500 rpm) for up to 1800s.  
The rate of nucleation was measured from the slope of the linear part of the graph with 
increasing absorbance; aggregation was measured from the slope of the linear part of the 
graph with decreasing absorbance. The percentage inhibition of CaOx nucleation (% IN) and 
aggregation (% IA) was calculated from the following equation:  
% Inhibition = 100 – [100 x (ST/SC)] 
where ST and SC are the slope of the test mixture and the control; respectively. A typical plot 
as obtained in the present thesis is shown in Figure 5.5. 
 
Figure 5.5 A typical plot of absorbance vs time which depicts simultaneous nucleation 
and aggregation. 
  
Nucleation 
Aggregation 
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Growth 
Crystal growth was monitored using a modified seeded crystal growth method.382 Similar to 
the above experiment, this study was designed to investigate the effect of individual urinary 
components in isolation on this crystallisation process. In this method crystal growth is 
measured by the decay of supersaturation which is measured indirectly by the change in 
turbidity. A metastable CaOx solution (0. 5 mM CaCl2 and 0.5 mM Na2Ox) was prepared in a 
tris(hydroxyl-methyl)-aminomethane (Tris) buffer (10 mM Tris HCl, pH 7.2, 90 mM NaCl). 382 
The mixture was stirred at room temperature for the duration of the experiment. In addition, a 
crystal slurry (16 mg/ml) was prepared from COM crystals in the same tris buffer and was 
stirred overnight to allow for equilibration. These COM crystals were prepared using the 
method described by Pak et al383. Crystal type was confirmed by powder X-ray diffraction.384  
An aliquot of the metastable CaOx solution (2 ml) was transferred to a quartz cuvette in a 
UV-VIS spectrophotometer (AnalytiKJena, Germany) fitted to a thermostatted mantle (37°C) 
and magnetic stirrer (500 rpm). The test substance (IP6, artificial urine, artificial urine dosed 
with various concentrations of IP6, pooled urine, pooled urine dosed with various 
concentrations of IP6) was then added to achieve various desired concentrations as 
described on page 92. Finally, the COM slurry (50 µl) was added last to induce crystal 
growth. Absorbance was measured at 214 nm for 400-600 s.  
The percentage inhibition of CaOx growth (% IG) was calculated from the following equation: 
% Inhibition = [(SC-ST)/ SC] x 100 
where SC and ST represent the slope of the control and the test mixture; respectively. A 
typical plot obtained in the present thesis is shown in Figure 5.6. 
 
 
Figure 5.6 A typical plot of absorbance vs time from which the rate of CaOx crystal 
growth is determined. 
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Statistical analysis 
Data were statistically analysed using GraphPad Instat3. One-way analysis of variance 
(ANOVA) was performed for multiple comparisons (3 or more groups) followed by a post-hoc 
Tukey- Kramer test. Unpaired t-tests were performed for inter-group comparisons. A p value 
< 0.05 was regarded as statistically significant. 
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Results 
Ca2+ and crystallisation propensity 
Artificial urine  
Concentration of Ca2+ 
The effect of IP6 on the mean concentration of Ca2+ in AU is shown in Figure 5.7. Actual 
values are reported in Table 5.5. All raw data are in Appendix 5.1. No significant change in 
the concentration of Ca2+ was observed. 
 
 
Comparisons: 
AU0 vs AU1: p > 0.05 
AU0 vs AU2: p > 0.05 
AU0 vs AU3: p > 0.05 
 
  
Figure 5.7 Effect of IP6 on free calcium in AU. Error bars indicate standard error of the 
mean. 
 
Table 5.5 Concentration of Ca2+ in AU and in AU dosed with IP6. Mean ± SE. 
sample [Ca2+] mM 
AU0  (0 µM IP6) 1.80 ± 0.07 
AU1  (0.757 µM IP6) 2.01 ± 0.10 
AU2  (2.27 µM IP6) 1.90 ± 0.05 
AU3  (4.45 µM IP6) 2.24 ± 0.20 
 
CaOx MSL 
The mean CaOx MSL of AU and AU dosed with 4 different concentrations of IP6 are shown 
in Figure 5.8. The CaOx MSL of each replicate was identical and therefore had a standard 
deviation of zero; thus statistical analysis could not be performed. Instead, the percentage 
difference with respect to the control was calculated as follows:  
[MSLT - MSLc/ average] x 100 
0.00
0.50
1.00
1.50
2.00
2.50
AU0 (0 µM
IP6)
AU1 (0.757
µM IP6)
AU2 (2.27
µM IP6)
AU3 (4.45
µM IP6)
[C
a2
+ ]
 m
M
 
Chapter 5                                                                                      in vitro crystallisation studies                                                                                                                                                                          
 
102 
 
where MSLT and MSLC refer to the MSL of the test and the control urine; “average” refers to 
the average value of the two MSLs. In the present study a % difference in the MSL of more 
than 30 % was regarded as “substantial”. This arbitrary definition is based on five previously 
published studies in which percentage differences of 26, 37, 59, 80 and 86 were found to be 
statistically significant.249, 296, 302, 305, 306 
 These results showed that the CaOx MSL was not affected at the two lower physiological 
concentrations of IP6.  A substantial increase in the MSL was however observed at the 
higher physiological (4.45 µM) and non-physiological concentrations of IP6 (15 µM). Raw 
data are included in Appendix 5.2. 
 
 
Comparisons (% difference): 
AU0 vs AU1: 12 % 
AU0 vs AU2: 12 % 
AU0 vs AU3: 32 % 
AU0 vs AU4: > 48% 
Key : 
AU0 : 0 µM IP6 
AU1 : 0.757 µM IP6 
AU2 : 2.27 µM IP6 
AU3 : 4.45 µM IP6 
AU4 : 15 µM IP6 
Figure 5.8 Mean change in absorbance vs [Na2Ox] in AU indicating the CaOx MSL in the 
presence of IP6. The mean CaOx MSLs ± SE are shown in parentheses in the figure legend.  
 
CaOx Crystallization Kinetics 
As mentioned in the methods section, crystallisation kinetics were determined by the addition 
of Na2Ox. However, preliminary experiments in AU with the addition of Na2Ox at 0.15 mM 
higher than the MSL failed to cause any increase in crystallisation; thus a concentration of 
0.3 mM above the MSL was used. 
The kinetics plots in Figure 5.9 show the mean change in absorbance upon crystallisation 
with respect to time in AU and AU dosed with 3 different concentrations of IP6. Each 
experiment was performed in triplicate. All raw data are reported in Appendix 5.2. The 
decrease in the absorbance which occurs at 90 minutes in two of the plots (AU0 and AU2) is 
due to crystals settling below the path of the UV beam.  
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The mean rate of crystallisation was determined from the slope of each curve between 30 
and 75 mins, and is shown in Figure 5.10. Actual values are reported in Table 5.6.  
The rate of crystallisation decreased significantly in the presence of all concentrations of IP6 
relative to AU0 (p < 0.001). The decrease in the rate of crystallisation was concentration 
dependent and showed the following trend:  
AU0 > AU1 > AU2 = AU3 
 
 
Figure 5.9 Mean change in absorbance vs time in AU indicating CaOx crystallisation 
kinetics in AU in the presence of IP6. 
 
 
Comparisons: 
 
AU0 vs AU1 : P < 0.05 
AU0 vs AU2: P < 0.001 
AU0 vs AU3: P < 0.001 
AU1 vs AU2: P < 0.05 
AU1 vs AU3: P < 0.05 
AU2 vs AU3: P > 0.05 
 
Figure 5.10 Effect of IP6 on the rate of CaOx crystallisation in AU. Error bars indicate the 
standard error of the mean Indicates statistical significance. 
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Table 5.6 Rate of crystallisation in AU and AU dosed with IP6. Mean ± SE. 
Sample Rate of crystallisation 
(x 10-4 min-1) 
AU0 (0 µM IP6) 3.22 ± 0.11 
AU1 (0.757 µM IP6) 2.44 ± 0.11 
AU2 (2.27 µM IP6) 1.78 ± 0.15 
AU3 (4.45 µM IP6) 1.78 ± 0.14 
 
Particle Size Distributions 
The mean PSD of particles in AU in the presence of different concentrations of IP6 are 
shown in Figure 5.11. The mean particle size of crystals obtained from the mode of each plot 
is shown in Table 5.7. Each experiment was performed in triplicate. Plots of all raw data are 
shown in Appendix 5.3. The addition of 4.45 µM IP6 (AU3) decreased the particle size 
significantly relative to AU0 (p < 0.01).  
 
 
                                      Figure 5.11 Effect of IP6 on the particle size distribution in AU. 
 
Table 5.7 Effect of IP6 on the average particle size in AU. Mean ± SE. 
 Particle size 
(µm) 
P-value  
(comparison relative to AU0) 
AU0 (0 µM IP6) 7.15 ± 0.12 -- 
AU1 (0.757 µM IP6) 6.65 ± 0.40 > 0.05 
AU2 (2.27 µM IP6) 6.81 ± 0.23 > 0.05 
AU3 (4.45 µM IP6) 5.26 ± 0.16 < 0.01 
  Indicates statistical significance. 
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Scanning Electron Microscopy 
Electron micrographs of crystals deposited in AU and AU dosed with different concentrations 
of IP6 were recorded at the same magnification and are shown in Figure 5.12. The total 
surface-area of each stub was examined and electron micrographs of typical deposits with 
respect to morphology, size and aggregation were recorded. Several single, oval-shaped 
COM crystals (approximate size: 8 µm) were predominant in AU control (Figure 5.12 a). A 
few small aggregates of tiny COM crystals (approximate size: 4 µm) were observed in the 
presence of larger COM crystals (approximate size: 10 µm) in AU1 (Figure 5.12 b). Very few 
crystals were observed in AU2; these included a few small, bipyramidal COD crystals 
(approximate size: 4 µm) (Figure 5.12 c). Several small aggregated COD crystals in the 
presence of larger single COD crystals (approximate size: 8 µm) were observed in AU3 
(Figure 5.12 d) no COM crystals were observed.  
To summarise, the overall trend observed in AU is that the hydration of the CaOx crystal 
changed from COM to COD with increasing IP6 concentration.  
  
  
Figure 5.12 CaOx crystals deposited in AU before and after the addition of varying 
concentrations of IP6. 
a: AU0 (0 µM IP6) b: AU1 (0.757 µM IP6) 
c: AU2 (2.27 µM IP6) d: AU3 (4.45 µM IP6) 
bipyramidal
COD crystal 
Oval-shaped COM 
crystals 
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COD crystal 
aggregates 
Large 
COD 
crystals 
Chapter 5                                                                                      in vitro crystallisation studies                                                                                                                                                                          
 
106 
 
Real urine of black and white subjects 
Concentration of Ca2+ 
The effect of IP6 on the mean Ca2+ in pooled urine of black subjects is shown in Figure 5.13. 
Actual values are reported in Table 5.8. Each experiment was performed in triplicate. Raw 
data are reported in Appendix 5.4. No significant change in Ca2+ was observed. 
 
Comparisons: 
BPU vs BPU2: p > 0.05 
BPU vs BPU3: p > 0.05 
BPU vs BPU4: p > 0.05 
BPU vs BPU5: p > 0.05 
 
Figure 5.13 Effect of IP6 on the concentration of Ca2+ in pooled urine of black subjects. Error 
bars indicate standard error of the mean. 
 
Table 5.8 Concentration of Ca2+ in BPU and BPU dosed with IP6. Mean ± SE. 
sample [Ca2+] mM 
BPU (1.00 µM IP6) 0.93 ± 0.05 
BPU2 (2.27 µM IP6) 0.99 ± 0.06 
BPU3 (4.45 µM IP6) 0.88 ± 0.03 
BPU4 (15 µM IP6) 0.96 ± 0.06 
BPU5 (30 µM IP6) 1.08 ± 0.03 
 
Figure 5.14 shows the effect of IP6 on the mean concentration of Ca2+ in pooled urine of 
white subjects. Actual values are reported in Table 5.9. Each experiment was performed in 
triplicate and raw data are reported in Appendix 5.4. Similar to the experiments in urine of 
black subjects, no change in Ca2+ was observed.  
Intergroup comparisons are reported later on page 114. 
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Comparisons: 
WPU vs WPU2: p > 0.05 
WPU vs WPU3: p > 0.05 
WPU vs WPU4: p > 0.05 
WPU vs WPU5: p > 0.05 
 
Figure 5.14 Effect of IP6 on the concentration of Ca2+ in pooled urine of white subjects. Error 
bars indicate standard error of the mean. 
 
Table 5.9 Concentration of Ca2+ in WPU and WPU dosed with IP6. Mean ± SE. 
sample [Ca2+] mM 
WPU (1.10 µM IP6) 0.69 ± 0.02 
WPU2 (2.27 µM IP6) 0.72 ± 0.04 
WPU3 (4.45 µM IP6) 0.80 ± 0.02 
WPU4 (15 µM IP6) 0.88 ± 0.03 
WPU5 (30 µM IP6) 0.83 ± 0.02 
 
CaOx MSL 
The effect of IP6 on the mean CaOx MSL in BPU is shown in Figure 5.15. Each experiment 
was performed in triplicate. All raw data are reported in Appendix 5.5. The percentage 
difference, relative to the baseline sample, is also reported. It is seen that the physiological 
concentrations of IP6 had no affect the CaOx MSL. However, MSL values increased 
substantially at the non-physiological concentrations of 15 µM and 30 µM IP6. 
  
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
WPU
(1.10 µM
IP6)
WPU2
(2.27 µM
IP6)
WPU3
(4.45 µM
IP6)
WPU4
(15 µM
IP6)
WPU5
(30 µM
IP6)
[C
a2
+ ]
 m
M
 
Chapter 5                                                                                      in vitro crystallisation studies                                                                                                                                                                          
 
108 
 
 
 
Comparisons (% difference): 
 
BPU vs BPU2: 13 % 
BPU vs BPU3: 13 % 
BPU vs BPU4: 35 % 
BPU vs BPU5: 60 % 
Key : 
BPU : control 
BPU2 : 2.27 µM IP6 
BPU3 : 4.45 µM IP6 
BPU4 : 15 µM IP6 
BPU5 : 30 µM IP6 
 
Figure 5.15 Mean change in absorbance vs [Na2Ox] in BPU indicating the CaOx MSL in the 
presence of IP6. The mean CaOx MSLs ± SE are shown in parentheses in the figure legend. 
 
Figure 5.16 shows the effect of IP6 on the mean CaOx MSL in WPU. Each experiment was 
performed in triplicate. Similar to the black males, the physiological concentrations of IP6 did 
not affect the CaOx MSL whereas the higher concentrations increased it substantially. 
 
 
 
Comparisons (% difference): 
WPU vs WPU2: -29 % 
WPU vs WPU3: -29 % 
WPU vs WPU4: > 53 % 
WPU vs WPU5: > 53 % 
Key : 
WPU : control 
WPU2 : 2.27 µM IP6 
WPU3 : 4.45 µM IP6 
WPU4 : 15 µM IP6 
WPU5 : 30 µM IP6 
 
Figure 5.16 Mean change in absorbance vs [Na2Ox] in WPU indicating the CaOx MSL in 
the presence of IP6. The mean CaOx MSLs ± SE are shown in parentheses in the figure 
legend. 
 
Intergroup comparisons are reported later on page 114. 
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CaOx Crystallization Kinetics 
Figure 5.17 shows the effect of IP6 on the mean change in absorbance with respect to time 
upon CaOx crystallisation in BPU. Each experiment was performed in triplicate. Raw data 
are reported in Appendix 5.5.  
The rate of crystallisation was determined from the slope between 30 and 75 mins and is 
shown in Figure 5.18 together with statistical comparisons. Actual values are reported in 
Table 5.10. 
 These results indicate that IP6 decreased the rate of CaOx crystallisation significantly as 
follows: BPU = BPU2>> BPU3 > BPU4 > BPU5.  
 
Figure 5.17 Mean change in absorbance vs time in BPU indicating CaOx crystallisation 
kinetics in the presence of IP6. 
 
 
Comparisons: 
BPU vs BPU2: p > 0.05 
BPUvs BPU3: p < 0.001 
BPU vs BPU4: p < 0.001 
BPUvs BPU5: p < 0.001 
BPU2 vs BPU3: p < 0.001 
BPU2 vs BPU4: p < 0.001 
BPU2 vs BPU5: p < 0.001 
BPU3 vs BPU4: p < 0.001 
BPU3 vs BPU5: p < 0.001 
BPU4 vs BPU5: p < 0.001 
Figure 5.18 Effect of IP6 on the rate of CaOx crystallisation in BPU. Error bars indicate 
standard error of the mean.  Indicates statistical significance. 
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Table 5.10 Rate of CaOx crystallisation in BPU and BPU dosed with IP6. Mean ± SE. 
Sample Rate of crystallisation 
(x10-3 min-1) 
BPU (1.00 µM IP6) 3.64 ± 0.01 
BPU2 (2.27 µM IP6) 3.93 ± 0.04 
BPU3 (4.45 µM IP6) 1.47 ± 0.04 
BPU4 (15 µM IP6) 0.77 ± 0.08 
BPU5 (30 µM IP6) 0.35 ± 0.02 
 
The effect of IP6 on the mean change in absorbance with respect to time upon crystallisation 
in WPU is shown in Figure 5.19. Each experiment was performed in triplicate. All raw data 
are reported in Appendix 5.5.  
The mean rate of crystallisation was determined from the slope between 0 and 45 mins (an 
increase in absorbance) and is shown in Figure 5.20. Actual values are reported in Table 
5.11. These results indicate that IP6 increased the rate of crystallisation significantly in 
WPU3 relative to WPU and WPU2. The following trend in the rate of crystallisation was 
observed:  
WPU = WPU2 < WPU3 
 
 Figure 5.19 Mean change in absorbance vs time in WPU indicating CaOx crystallisation 
kinetics in the presence of IP6. 
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Comparisons: 
WPU vs WPU2: p > 0.05 
WPU vs WPU3: p < 0.001 
WPU2 vs WPU3: p < 0.01 
 
Figure 5.20 Effect of IP6 on the rate of CaOx crystallization in WPU. Error bars indicate 
standard error of the mean. Indicates statistical significance. 
 
Table 5.11 Rate of CaOx crystallisation in WPU and WPU dosed with IP6. Mean ± SE. 
Sample Rate of crystallisation 
(x 10-4 min-1) 
WPU (1.10 µM IP6) 2.31 ± 0.46 
WPU2 (2.27 µM IP6) 3.09 ± 0.37 
WPU3 (4.45 µM IP6) 6.33 ± 0.01 
 
Scanning Electron Microscopy 
Electron micrographs of crystals deposited in BPU and BPU dosed with different 
concentrations of IP6 are shown in Figure 5.21. 
Small COM crystals (approximate size 3 µm) together with a few large COD crystals 
(approximate size 8 µm) were observed in BPU (Figure 5.21 a). COM crystals remained 
predominant at the lower concentrations of IP6 (Figure 5.21 b and c). However, at the higher 
concentrations, the small COM crystals were replaced by large single COD crystals 
(approximate size 19 µm). There is little evidence of aggregation of COM or COD crystals at 
any concentration of IP6 including the control urine (BPU; Figure 5.21 a).  
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Figure 5.21 CaOx crystals deposited in BPU. All micrographs shown are at a magnification 
of x 5000. 
a: BPU (1.00 µM IP6) b: BPU2 (2.27 µM IP6) 
c: BPU3 (4.45 µM IP6) d: BPU4 (15 µM IP6) 
e: BPU5 (30 µM IP6) 
large COD 
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cry 
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small COM 
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Crystals deposited in WPU before and after the addition of IP6 are shown in Figure 5.22. 
COD crystals were observed at both of the concentrations of IP6 which were used. The 
approximate size of these crystals decreased with increasing concentration from 8 µm in the 
control urine (Figure 5.22 a) to 4 µm (Figure 5.22 c).  
  
 
 
Figure 5.22 CaOx crystals deposited in WPU. All micrographs shown are at a magnification 
of x 5000  
a: WPU (1.10 µM IP6) b: WPU2 (2.27 µM IP6) 
c: WPU3 (4.45 µM IP6) 
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Inter-group comparisons 
These comparisons are reported in Table 5.12. Attention is drawn to the following. The 
significantly higher concentration of Ca2+ in BPU relative to WPU, the substantially higher 
CaOx MSL in BPU relative to WPU and the significantly higher rate of CaOx crystallisation in 
BPU relative to WPU.  
The presence of mostly COM crystals in BPU (Figure 5.21a) relative to the predominance of 
COD in WPU (Figure 5.22a) is also noted. 
Table 5.12 Ca2+ concentrations and crystallisation propensity in pooled urine of black and 
white subjects: Inter-group comparisons 
experiment BPU vs 
WPU 
BPU2 vs 
WPU2 
BPU3 vs 
WPU3 
BPU4 vs 
WPU4 
BPU5 vs 
WPU5 
Ionized calcium 
(Ca2+) 
B > W 
p = 0.01 
B >  W 
p= 0.02 
B > W 
p =  0.09 
B > W 
p= 0.29 
B > W 
p=  0.006 
CaOx MSL 
% difference 
indicated 
B > W 
54 % 
B > W 
91 % 
B > W 
91 % 
B < W 
26 % 
B = W 
0 % 
Rate of 
crystallisation 
B > W 
p = 0.002 
B > W 
p < 0.0001 
B > W 
p = 0.002 
_ _ 
Indicates statistical significant difference. Indicates “substantial” difference as defined 
previously. 
 
Specific crystallisation kinetic mechanisms 
Nucleation and aggregation 
 
Test substance: IP6 
The mean rates of CaOx crystal nucleation and aggregation in the presence of physiological 
concentrations of IP6 is shown in Figure 5.23 and Figure 5.24; respectively. Actual values 
and the percentage inhibition of each mechanism are reported in Table 5.13. The metastable 
solution of CaOx without the addition of IP6 served as the control. Plots of all raw data are in 
Appendix 5.6. 
The results indicate that IP6 significantly decreased the rate of both CaOx crystal nucleation 
and aggregation in a concentration dependent manner with the following trend: 
control > 0.757 µM IP6 > 2.27 µM IP6 = 4.45 µM IP6. 
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Comparisons: 
control vs 0.757 µM IP6 : p <0.0001 
0.757 µM IP6 vs 2.27 µM IP6 : p < 0.001 
0.757 µM IP6 vs 4.45 µM IP6 : p < 0.001 
2.27 µM IP6 vs 4.45 µM IP6 : p > 0.05 
 
Figure 5.23 Effect of IP6 on the rate of CaOx crystal nucleation. Error bars indicate 
standard error of the mean. Indicates statistical significance. 
 
 
 
Comparisons: 
control vs 0.757 µM IP6: p < 0.0001 
0.757 µM IP6 vs 2.27 µM IP6 : p < 0.05 
0.757 µM IP6 vs 4.45 µM IP6: p < 0.05 
2.27 µM IP6 vs 4.45 µM IP6: p > 0.05 
 
 
Figure 5.24 Effect of IP6 on the rate of CaOx crystal aggregation. Error bars indicate 
standard error of the mean. Indicates statistical significance 
 
Table 5.13 Rates of CaOx crystal nucleation and aggregation and the inhibition of each 
mechanism in the presence of IP6. Mean ± SE. 
[IP6]  
µM 
Rate of nucleation 
(x 10-3 s-1) 
% IN Rate of aggregation  
(x 10-4 s-1) 
% IA 
control 13.50 ± 0.33 -- 10.26 ± 0.34 -- 
0.757 7.28 ± 0.45 46 ± 3 6.48 ± 0.42 37 ± 4 
2.27 3.52 ± 0.14 74 ± 1 4.25 ± 0.10 59 ± 1 
4.45 3.58 ± 0.07 73 ± 1 4.93 ± 0.30 52 ± 3 
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Test substance: AU and AU dosed with IP6 
The effect of these test substances on the mean rate of CaOx nucleation and aggregation is 
shown in Figure 5.25 and Figure 5.26. Actual values together with the percentage inhibition 
of each mechanism are reported in Table 5.14. The metastable solution without the addition 
of the AU test substances served as the control. It is noted that the control values are 
different in the experiments presented in Table 5.13 and Table 5.14. Fresh CaOx metastable 
solutions were prepared for these experiments on the days on which they were performed. 
Since the actual conditions under which the metastable solutions were prepared cannot be 
fully controlled it is likely that CaOx crystals of different sizes and degrees of aggregation 
would be present, giving rise to different rates in the control samples. Plots of all raw data are 
shown in Appendix 5.6.  
The rate of CaOx crystal nucleation and aggregation decreased significantly in the presence 
of AU and AU dosed with IP6 and showed the following trend: 
Control> AU0 = AU1 > AU2 = AU3 
 These results indicate that the addition of IP6 at concentrations of 2.27 µM and 4.45 µM 
increased the inhibitory activity of AU. 
 
 
Comparisons: 
 
Control vs AU0: p <0.0001 
AU0 vs AU1 : P > 0.05 
AU0 vs AU2: P < 0.001 
AU0 vs AU3: P < 0.001 
AU1 vs AU2: P < 0.001 
AU1 vs AU3: P < 0.001 
AU2 vs AU3: P > 0.05 
 
Figure 5.25 Effect of AU and AU dosed with IP6 on the rate of CaOx crystal nucleation. Error 
bars indicate standard error of the mean. Indicates statistical significance. 
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Comparisons: 
 
Control vs AU0: p <0.0001 
AU0 vs AU1: P= 0.073 
AU0 vs AU2: P < 0.05 
AU0 vs AU3: P= 0.01 
AU1 vs AU2: P < 0.05 
AU1 vs AU3: P < 0.05 
AU2 vs AU3: P > 0.05 
 
Figure 5.26 Effect of AU and AU dosed with IP6 on the rate of CaOx crystal aggregation. 
Error bars indicate standard error of the mean. Indicates statistical significance. 
 
Table 5.14 Rates of CaOx crystal nucleation and aggregation and the inhibition of each 
mechanism in the presence of AU and AU dosed with IP6. Mean ± SE. 
 
Test   substance: PU and PU dosed with IP6 
The effect of these test substances on the mean rate of CaOx crystal nucleation and 
aggregation is shown in Figure 5.27 and Figure 5.28; respectively. Actual values and the 
percentage inhibition of each mechanism are reported in Table 5.15. The metastable CaOx 
solution without the addition of the PU test substances served as the control. As noted 
above, the values of these controls differ to that of the controls presented in other 
experiments. The reason for this is stated above. Plots of all raw data are reported in 
Appendix 5.6.  
These results indicate that the rate of CaOx crystal nucleation decreased significantly in the 
presence of PU and PU dosed with IP6 and showed the following trend: 
Control > PU = PU2 
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 Rate of nucleation 
(x 10-4 s-1) 
 
% IN  
Rate of aggregation  
(x 10-5 s-1) 
 
% IA  
control 11.10 ± 0.29 -- 8.14 ± 0.35 -- 
AU0 (0 µM IP6) 6.91 ± 0.18 38 ± 2 4.51 ± 0.20 45 ± 2 
AU1 (0.757 µM IP6) 6.97 ± 0.12 37 ± 1 4.01 ± 0.11 51 ± 1 
AU2 (2.27 µM IP6) 3.93 ± 0.19 65 ± 2 3.39 ± 0.19 58 ± 2 
AU3 (4.45 µM IP6) 3.40 ± 0.17 69 ± 2 3.17 ± 0.11 61 ± 1 
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The above trend indicates that 2.27 µM IP6 did not increase the urine’s inhibitory activity with 
regard to nucleation. 
The results for the rate of CaOx crystal aggregation on the other hand showed the following 
trend: 
Control >> PU > PU2 
 
 
Comparisons: 
 
Control vs PU: p < 0.05 
Control vs PU2: p < 0.05 
PU vs PU2: p > 0.95 
Figure 5.27 Effect of PU on the rate of CaOx crystal nucleation. Error bars indicate standard 
error of the mean. Indicates statistical significance. 
 
 
Comparisons: 
 
Control vs PU: p< 0.001 
Control vs PU2: p< 0.001 
PU vs PU2: p < 0.05 
 
Figure 5.28 Effect of PU on the rate of CaOx crystal aggregation. Error bars indicate 
standard error of the mean. Indicates statistical significance. 
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Table 5.15 Rates of CaOx crystal nucleation and aggregation and the percentage inhibition 
of each mechanism in the presence of PU and PU dosed with IP6. Mean ± SE. 
 
 
Growth 
 
Test substance: IP6 
Figure 5.29 shows the effect of IP6 on the mean rate of CaOx crystal growth. Actual values 
and the percentage inhibition of growth are reported in Table 5.16. The metastable solution 
of CaOx without the addition of IP6 served as the control. Plots of all raw data are in 
Appendix 5.7. 
The results indicate that the rate of CaOx crystal growth decreased significantly in the 
presence of IP6 and is not concentration dependent:  
Control > 0.757 µM IP6 = 2.27 µM IP6 = 4.45 µM IP6 
 
 
Comparisons: 
control vs 0.757 µM IP6: p < 0.001 
control vs 2.27 µM IP6 : p < 0.001 
control vs 4.45 µM IP6: p < 0.001 
0.757 µM IP6 vs 2.27 µM IP6: p > 0.05 
0.757 µM IP6 vs 4.45 µM IP6: p >  0.05 
2.27 µM IP6 vs 4.45 µM IP6: p > 0.05 
 
 
Figure 5.29 Effect of IP6 on the rate of CaOx crystal growth. Error bars indicate standard 
error of the mean. Indicates statistical significance. 
  
 Rate of nucleation 
(x 10-4 s-1) 
 
% IN 
Rate of aggregation 
(x 10-5 s-1) 
 
 % IA 
control 8.30 ± 0.87 -- 7.90 ± 0.50 -- 
PU (0.708 µM IP6) 4.22 ± 0.83 49 ± 10 2.16 ± 0.14 73 ± 2 
PU2 (2.27 µM IP6) 4.14 ± 0.75 50 ± 9 1.52 ± 0.15 81 ± 2 
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Table 5.16 Rates of CaOx crystal growth and its percentage inhibition in the presence of IP6. 
Mean ± SE. 
[IP6] µM Rate of growth 
(x10-3 s-1) 
% IG 
control 8.64 ± 0.19 -- 
0.757 4.29 ± 0.22 50 ± 3 
2.27 4.11 ± 0.15 52 ± 2 
4.45 3.61 ± 0.25 58 ± 3 
 
Test substance: PU and PU dosed with IP6 
The effect of these test substances on the mean rate of CaOx crystal growth is shown in 
Figure 5.30. Actual values and the percentage inhibition of CaOx crystal growth are reported 
in Table 5.17. The metastable CaOx solution without the addition of the PU test substances 
served as the control. It is noted that the control value in Table 5.17 differs to the control 
presented in Table 5.16. The reason for this has already been stated. Plots of all raw data 
are reported in Appendix 5.7.  
The rate of CaOx crystal growth decreased significantly in the presence of PU and PU dosed 
with IP6 relative to the control and showed the following trend:  
Control > PU = PU2 = PU3 
 
 
Comparisons: 
Control vs PU: p < 0.001 
PU vs PU2: p > 0.05 
PU vs PU3: p > 0.05 
PU2 vs PU3: p > 0.05 
 
Figure 5.30 Effect of PU on the rate of CaOx crystal aggregation. Error bars indicate 
standard error of the mean. Indicates statistical significance. 
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Table 5.17 Rates of CaOx crystal growth and its percentage inhibition in the presence of PU 
and PU dosed with IP6. Mean ± SE. 
 Rate of growth 
(x 10-4 s-1) 
% IG 
control 3.66 ± 0.14 -- 
PU (0.708 µM IP6) 2.21 ± 0.07 40 ± 32 
PU2 (2.27 µM IP6) 2.10 ± 0.13 43 ± 3 
PU3 (4.45 µM IP6) 2.09 ± 0.07 43 ± 2 
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Discussion  
As mentioned in Chapter 1, crystallisation is governed by thermodynamic (supersaturation) 
and kinetic (nucleation, aggregation and growth) factors.35 Inhibitors of CaOx crystallisation 
may therefore either decrease the urinary supersaturation of CaOx, by decreasing the 
concentration of Ca2+ or Ox2-, and/ or modulate crystallisation kinetics by inhibiting the rates 
of CaOx crystal nucleation, aggregation and growth.15 The studies described in the present 
chapter were undertaken to test experimentally the prediction of the theoretical modelling 
that the concentration of Ca2+ is unaffected by IP6 under normal physiological conditions, 
and to investigate the notion that its inhibitory activity towards CaOx crystallization processes 
were of a kinetic nature.  
Physiological concentrations of IP6 had no effect on the empirically derived concentration of 
Ca2+ in both AU and pooled urine of black and white subjects in the present study. This is in 
agreement with the theoretical prediction of the modelling performed in the present thesis as 
well as with the results of a previous in vitro study285. 
Regarding crystallisation propensity, the CaOx MSL can be interpreted as the ability of a 
solution to resist spontaneous nucleation.50 Thus, in the present study, the substantial 
increase in the CaOx MSL in both AU and pooled urine of black and white subjects in the 
presence of IP6 suggests that it retards crystal nucleation. However, the effective IP6 
concentration at which this was achieved in human urine was non-physiological (15 µM). 
This finding is in agreement with that reported in a previous study in which the effective 
concentrations of IP6 were even higher than those in the present study (AU: 12 µM vs 
4.45 µM; human urine: 120 µM vs 15 µM). The latter difference is due to the higher baseline 
concentration of Ca2+ in the media of the previous study (≈ 4mM and ≈ 7 mM, respectively) 
relative to the concentrations of Ca2+ in the present study (AU: 1.80 mM, BPU: 0.93 mM and 
WPU: 0.69 mM). The results of these in vitro investigations (present and previous studies) 
indicate that IP6 at physiological concentrations is unlikely to affect the in vivo urinary 
concentration of Ca2+ or the CaOx MSL. Since both of these properties are 
thermodynamically related to the supersaturation (SS) of CaOx, it appears that other 
mechanisms (which are kinetic in nature) are more likely to be involved in any inhibitory 
activity of IP6. 
Regarding the effect of IP6 on crystallisation kinetics, a significant decrease in the rate of 
CaOx crystallisation may be regarded as favourable as it decreases the risk of stone 
formation.374 Thus, the decrease in the rate of CaOx crystallisation in both AU and pooled 
urine of black subjects in the presence of physiological concentrations of IP6 could be 
regarded as being favourable, thereby supporting the notion of IP6 playing a kinetic role in 
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inhibiting CaOx crystallisation. On the other hand, an increase in the rate of CaOx 
crystallisation was observed in the pooled urine of white subjects. This inter-group difference 
will be discussed later.  
The formation of COD crystals in both AU and pooled urine of black subjects in the presence 
of IP6 is in agreement with recent studies which were conducted in AU.385, 386 .The formation 
of COD is favourable as it has been demonstrated that it adheres to a lesser extent to renal 
tubule cells than COM.222, 387 Other LMW (low molecular weight) molecules such as citrate 
and pyrophosphate as well as HMW (high molecular weight) compounds such as proteins 
(e.g. osteopontin and albumin) have been reported to favour the formation of COD.222, 388, 389 
The mechanism by which this occurs is due to specific interactions between the respective 
molecules and the crystal surface of COM which inhibits the growth of COM (a process 
known as “step-pinning”) and favours the formation of COD, as cited in a review article by 
Ryall.17 It is therefore speculated that IP6 may favour the formation of COD by the same 
mechanism. In principle, this would support the notion of it being a protective agent in CaOx 
urolithiasis. However, in the present study the effective concentration of IP6 in pooled urine 
of black subjects was non-physiological, suggesting that this process might not occur in vivo.  
With regard to the experiments in which different test substances were added to a 
metastable solution of CaOx, the observation that IP6 alone has the capacity to inhibit CaOx 
crystal nucleation (Figure 5.23 and Table 5.13) at all the physiological concentrations 
investigated in the present study, is promising. However, when 0.757 µM and 2.27 µM IP6 in 
AU and in pooled human urine were tested in the same metastable solutions, negligible 
inhibitory effects were observed (Figure 5.25 and Figure 5.27). This suggests that other 
urinary components may affect the inhibitory capacity of IP6 in vivo. 
Similarly, the inhibition of CaOx crystal aggregation at all concentrations of IP6 in the present 
study is promising (Figure 5.24 and Table 5.13). However, 0.757 µM IP6 had a negligible 
effect on the inhibitory capacity of AU (Figure 5.26 and Table 5.14) indicating that the urine 
composition influences the inhibitory capacity of IP6 as suggested above. Interestingly the 
presence of 2.27 µM IP6 increased the inhibitory capacity of pooled human urine with regard 
to aggregation (Figure 5.28 and Table 5.15) whereas no effect was observed for nucleation, 
as stated above. This is noteworthy as aggregation is regarded as the most important 
stone-forming mechanism as it occurs at a faster rate than nucleation and may lead to the 
development of a relatively large concretion.6, 33 The decrease in the rate of CaOx crystal 
aggregation in urine is therefore encouraging and supports the notion that IP6 may influence 
the kinetics of CaOx crystallisation in vivo. These results are important as no study has been 
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previously reported on the effect of IP6 on crystal aggregation in in vitro or in vivo studies in 
the context of urolithiasis.   
The effect of IP6 alone on CaOx crystal growth in the present study is intriguing. The results 
demonstrated that its inhibitory capacity is not concentration dependent (Figure 5.29 and 
Table 5.16). This suggests that the endogenous IP6 concentration of 0.708 µM in the pooled 
human urine may have contributed towards the inhibition of growth of this particular urine. 
The result of the present study regarding the concentration required for growth inhibition is in 
agreement with a previous potentiometric study in which 0.75 µM IP6 inhibited CaOx crystal 
growth in an aqueous medium containing calcium and oxalate.390 Since the inhibition of 
CaOx crystal growth was not concentration dependent in the present study, it suggests that 
any deficiency of IP6 may increase the risk of kidney stone formation. Alternatively, an 
increase in the urinary concentration of IP6 may decrease the risk of kidney stone formation.   
The observation that a lower effective concentration of IP6 was required to inhibit CaOx 
crystal growth relative to that required for the inhibition of CaOx crystal nucleation and 
aggregation is also noteworthy. This indicates that IP6 has a stronger inhibitory capacity for 
the inhibition of CaOx crystal growth and that, as such, it may play a crucial role in vivo. 
Consideration of all the physicochemical properties (CaOx MSL, rate of CaOx crystal 
nucleation, CaOx hydration state, CaOx crystal nucleation and growth) shows that higher 
effective concentrations of IP6 were required in real urine than in AU in the present study to 
achieve some measure of inhibition. This indicates that caution should be taken when 
extrapolating results from in vitro experiments in aqueous media to in vivo conditions. 
Nevertheless, AU is a useful model for providing insight into protocols and conditions that 
might be applied in in vivo studies.50, 374  
Significant inter-group differences as reported in Table 5.12 are not likely due to the effect of 
IP6 but due to differences in inter-racial urinary compositions. Inter-group comparisons at 
baseline have been extensively discussed in several studies conducted in the KSRL at the 
University of Cape Town.302, 305, 306, 384 It is therefore not necessary to repeat these 
discussions here. Of importance in the present study is to consider different effects which 
occurred in the urines of the two groups in the presence of IP6. Only two such differences 
were observed. Firstly, the rate of CaOx crystallisation decreased significantly in pooled urine 
of black subjects in the presence of 4.45 µM IP6 whereas a significant increase was 
observed in pooled urine of white subjects, as stated earlier in this discussion. Secondly, a 
decrease in crystal size was observed in the white group only (SEM) in the presence of this 
concentration of IP6. Decreases and increases in the rate of crystallisation have been given 
different interpretations in the literature. On the one hand, a decrease has been regarded as 
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a favourable effect which reduces the risk of stone formation374 while on the other hand,  
some researchers regard an increase in the rate of crystallisation as favourable as it results 
in the formation of smaller crystals which can be excreted harmlessly and decreases the 
supersaturation.378, 388  Thus, the significant increase in the CaOx crystallisation rate with a 
concomitant decrease in crystal size in the white group may be regarded as favourable. 
Furthermore, since a decrease in crystal size was observed in pooled urine of white subjects 
(SEM) but not in the black group; the increase in the crystallisation rate in the former group 
might be the overriding factor in this anomaly. The two interpretations of crystallisation rates 
can be confusing unless some other independent physicochemical property supports one or 
the other, as has happened in this particular case. Irrespective of the interpretation of this 
kinetic factor, of interest is that IP6 had different effects in the urines of black and white 
subjects, raising the possibility of its physicochemical activity being dependent on its urine 
environment.  
It is recognized that the present study had certain limitations. These are as follows. 
Observations and conclusions were drawn from experiments which were conducted in single 
pooled urine samples from each respective group. This can be improved by using more than 
one pooled urine sample. Furthermore, urine flow dynamics were not modelled in the present 
experimental model. This can be improved by using an experimental model such as MSMPR 
(mixed suspension mixed product removal).50, 374 In addition, the measured rate of CaOx 
crystallisation in AU and real urine in the present study does not distinguish between the 
different crystallisation mechanisms which occur in urine. This aspect can be improved in 
future studies by employing a superior crystallisation experiment such as MSMPR374 which 
can be used to distinguish between crystal nucleation and growth. 
In conclusion, the results of the studies described in this chapter are important for several 
reasons. Firstly, while previous studies have focussed on investigating the effect of IP6 on 
individual crystallisation processes, none has undertaken the comprehensive approach 
adopted in the present project. Secondly, the influence of IP6 on CaOx crystal aggregation 
kinetics is described here for the first time. Thirdly, the results of the present study indicate 
that the inhibitory effects of urinary CaOx crystallisation are more likely to be of a kinetic 
nature rather than a thermodynamic one.  
Finally, it is recognised that the results of the present study were derived in in vitro models. 
The possibility remains that the ingestion of IP6 may demonstrate in vivo effects due to 
physiological processes arising from metabolic effects of IP6 itself or from its degradation 
products (phosphate and lower phosphorylated inositols). The following chapter describes 
Chapter 5                                                                                      in vitro crystallisation studies                                                                                                                                                                          
 
126 
 
the effect of IP6 ingestion on risk factors associated with CaOx urolithiasis in a human 
model.  
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Chapter 6 : The effect of dietary phytate ingestion on its urinary excretion 
and on the risk factors associated with calcium oxalate urolithiasis in South 
African stone free and stone prone population groups 
Introduction 
A previous dietary survey by Modlin showed that the mean dietary intake of phytate (IP6) in 
black South Africans was higher than that of their white compatriots 
(4290 mg/day vs 275 mg/day).318 This nutrient is of interest in the present study as it occurs 
in the staple diet of the black population and as such may contribute to the rarity of kidney 
stone disease in this group. A recent study in the KSRL at the University of Cape Town 
investigated the effects of this nutrient on the urine chemistry in South African black and 
white males319 and was discussed in Chapter 1 of the present thesis. Briefly, the results of 
that study indicated that despite the higher dietary intake of IP6 in the black group, the 
baseline urinary excretion was lower than in the white group. It was concluded that the renal 
handling of IP6 in the two ethnic groups may be different. However, as mentioned in Chapter 
1, the method used in the aforementioned study was limited whereby the separation of 
inorganic phosphate and IP6 during sample preparation was inadequate thus rendering the 
results and conclusions questionable.  As such a more rigorous investigation using a more 
reliable and robust method is warranted. 
Numerous studies by Grases et al, investigating the pharmacokinetic profile of IP6 in animals 
as well as in humans showed that urinary IP6 is correlated to dietary IP6.265, 268, 391, 392 
Interestingly, studies in both humans and rats have shown that the excretion of IP6 reaches 
a plateau which is not exceeded by an excess intake of dietary phytate.268, 392 As such, 
urinary IP6 can be used as an indicator to identify a deficiency in the intake of IP6 but not 
necessarily an excess.  
The objectives of the present study are to include the determination of the respective 
baseline levels of dietary IP6 intake in black and white subjects, investigation of its influence 
on urine chemistry and its effect on urinary crystallisation of CaOx in both groups. Such 
studies are described in the present chapter. 
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Methods 
Subjects 
Healthy black and white South African males between the ages of 18 -36, average weight of 
70 ± 2 kg and BMI of 23 ± 1 kg/m2, without any history of kidney stone disease, were 
recruited from the student and staff cohort at the University of Cape Town. Vegetarians and 
individuals with nut allergies were excluded. Eligible participants were selected after 
completing a general questionnaire assessing their health (Appendix 6.1). Race was self-
declared.  
Two groups of males per race group were recruited from the same cohort. The first group of 
males consisted of black (n= 16) and white (n= 16) males. These males completed food 
frequency questionnaires (FFQ) for the assessment of their typical nutrient intake 
(objective 1). The second group of males consisted of black (n= 12) and white (n = 11) 
males. These males participated in a 10 day dietary intervention described below 
(objective 2).  
It should be noted that an overlap between the groups exists in which some of the males who 
participated in the study for objective 1, also participated in the study for objective 2. These 
studies were carried out at different time periods of the current thesis. Thus when objective 2 
was undertaken, the same group of males who participated in objective 1 were not available 
to participate. However, the estimated intakes of nutrients obtained from the FFQs in 
objective 1 is assumed to be representative of subjects used in the present study since 
subjects were recruited from the same cohort. 
Study design 
FFQ’s were self-administered and checked upon completion by the present researcher in the 
presence of the subject. 
A 10- day cross-over study consisting of two phases (Phase 1 and Phase 2) was conducted. 
Phase 1 consisted of an IP6-deficient diet while Phase 2 was IP6-rich. These diets were 
administered at breakfast (Table 6.1). Subjects consumed their own meals for other meal 
times (lunch, supper and snacks) in which dietary IP6 intake was restricted for the duration of 
the study as follows. IP6 rich foods (wholegrains) indicated in Table 6.2 were excluded from 
meals while fruits and vegetables which contain IP6 to a lesser extent than that of 
wholegrains259 were permissible. In addition to the restriction of dietary IP6, the intake of 
oxalate-rich foods was also restricted as shown in Table 6.3.  
Prior to Phase 1, a baseline urine sample was provided (day 0) while subjects were on their 
free unrestricted diets. During Phase 1, the IP6-deficient breakfast was ingested for 3 
consecutive days (days 1 – 3). Other meals were consumed in accordance with the 
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restrictions described in Table 6.2 and Table 6.3. A 24 hr urine sample was collected on 
day 3. Participants continued to avoid IP6-rich foods on days 4-7 to maintain a low urinary 
excretion of IP6 prior to Phase 2. On days 8 -10 (Phase 2) an IP6- rich breakfast (Table 6.1) 
in the form of oats (Jungle Oats, Tiger brands, South Africa) was administered followed by 
the collection of a 24 hr urine sample on day 10. Other meals were consumed as per 
Phase 1.  
Urine aliquots were used for the determination of IP6 and other biochemical parameters as 
well as for crystallisation experiments. All participants were required to keep a dietary record 
for the duration of the study to check for compliance. This study was approved by the Human 
Research Ethics Committee of the University of Cape Town, HREC ref: 174/2011 
(Appendix 6.2).  
 Table 6.1 IP6 deficient and rich breakfasts administered in the present study. 
IP6 deficient IP6 rich 
70 g Kellogs Corn Flakes 70 g (dry weight) Oats 
200 ml full cream milk 200 ml full cream milk 
200 ml Coffee 200 ml Coffee 
2 slices brown bread 2 slices brown bread 
8 g butter 8 g butter 
15 g strawberry jam 15 g strawberry jam 
 IP6 analysis is described on page 131. 
  
Table 6.2 List of IP6 foods excluded and included in meals for the duration of the present 
study.259  
Excluded from meals Included in meals 
Barley All fruits and vegetables 
Brown rice & wild rice -- 
Legumes -- 
Maize -- 
Nuts (including peanut butter and nut derived 
products) 
-- 
Oats (except that which is provided) -- 
Soybeans/Tofu -- 
Whole-wheat bread -- 
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Table 6.3 List of Oxalate foods excluded and included in meals for the duration of the 
present study.83, 102 
Excluded from meals Included in meals 
Alcohol ≥ 200 ml black tea per day 
Beetroot ≥ 100 g chocolate per day 
Green beans ≥ 20 g cocoa powder per day 
Rhubarb -- 
Spinach -- 
Strawberries -- 
Waterblommetjies -- 
Wheat germ -- 
 
 
Nutrient intake 
The typical nutrient intake in each respective group was assessed using a FFQ.393 Briefly, 
the questionnaire contained different categories of foods as follows: breads, breakfast 
cereals, nuts & seeds, vegetables, legumes & legume products, cereals & wholegrains and 
pastas, eggs & dairy products, meat & meat products, beverages, fish & seafood, fruit as well 
as snacks, desserts & sugar. Each subject was required to indicate the relative frequency 
and usual portion size of a particular food type that they would typically consume in 30 days.  
Questionnaires were analysed using a software program (FoodFinder 2) developed by the 
South African Medical Research Council (MRC).394 This program contains a data-base of 
nutrient contents for foods that are typically consumed by South Africans. It allows for the 
calculation of macronutrients, minerals, vitamins, fatty acids and cholesterol, amino acids 
and other organic components. Lithogenic and antilithogenic components were analysed 
including total protein, calcium, oxalic acid, magnesium and in particular IP6. The 
concentration of the latter nutrient in food is variable and influenced by environmental factors 
including growing location, irrigation, soil type, plant variety and processing as well as the 
method used for IP6 determination.259 Unfortunately, FoodFinder 2 does not have a complete 
data set for the content of organic acids in food. As such IP6 content obtained from 
FoodFinder2 only includes that derived from fruit and vegetables. Accordingly, IP6 content in 
cereals, legumes, oilseeds and nuts was obtained from various publications. Mean values 
are given in Table 6.4. These values were then used to estimate the IP6 content of each item 
in the FFQ.  
The daily intake of each of the aforementioned nutrients was estimated by dividing by a 
factor of 30. 
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24 hr dietary records on day 3 and day 10 were also assessed using FoodFinder 2. The 
nutrient intake on these days was compared to the estimated daily intake obtained from the 
30 day FFQs.  
 
   Table 6.4 Estimated IP6 content of foods obtained from literature.  
Food type IP6 content (mg/ 100g) edible 
Cereals & bread 
Barley395-397 652 ± 206 
Brown/wild rice395, 396, 398 743 ± 164 
Maize259, 399, 400 1044 ± 414 
Oats391, 396, 397, 400-402 785 ± 203 
whole-wheat bread391, 398, 401 406 ± 116 
Legumes 
Beans391, 395, 396, 398, 401, 403  845 ± 167 
Chick peas401, 403 1030 ± 510 
Lentils369, 391, 401, 403, 404 626 ± 135 
Nuts & oil seeds 
Almonds398, 405 1527 ± 585 
Brazil nuts259 290 ± 0 
Cashews398, 405 864 ± 365 
Macadamia398, 405 605 ± 342 
Peacans398, 405 1180 ± 728 
Peanut butter398 443 ± 0 
Peanuts391, 395, 398, 405 1097 ± 328 
Soybeans259, 395, 401 1421 ± 282 
Walnuts391, 405 1135 ± 466 
 
IP6 content in oats 
The concentration of IP6 in oats (Jungle Oats, Tiger Brands, South Africa) was determined 
using anion exchange chromatography as described in previous studies406-409, followed by a 
colorimetric assay369. Extraction406-409: Briefly, 2 g of oats was weighed and shaken with 20 
ml of 0.8 M HCl for 2 h at room temperature.  The mixture was then centrifuged at 3000 rpm 
for 10 mins and the supernatant was decanted and filtered through filter paper (MN 615, 
Machery-Nagel, Germany). 10 ml of this extract was mixed with an equal volume of 0.11 M 
EDTA and set to a pH of 6 by the addition of NaOH (1 M). 1ml of this mixture was diluted 
with 30 ml milli-Q water and added to a 150 ml beaker containing 0.5 g of Dowex 1x8 anion 
exchange resin (Sigma Aldrich). The mixture was then shaken at 150 rpm for 20 mins to 
facilitate the adsorption of IP6 to the resin. The mixture containing the resin was then poured 
into an empty 20 ml SPE tube to separate the liquid from the resin. The resin was then 
washed twice with 5 ml of H2O followed by washing it twice with 5 ml portions of 0.3 M NaCl. 
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IP6 was then finally eluted with 4 ml of 0.8 M NaCl in a stepwise manner by employing 1 ml 
of the NaCl each time. Recovery was tested by the addition of 600 µM dipotassium phytic 
acid (Sigma Aldrich). Quantification369: The eluate was homogenised and a 1:20 dilution 
was prepared using milli-Q water. IP6 concentration was determined colorimetrically, using 
Wade’s reagent as described by Latta and Eskin.369 This assay is based on the reaction 
between iron (Fe3+) and sulfosalicylic acid which results in a pink colour with maximum 
absorbance at 500 nm. In the presence of IP6, Fe3+ becomes bound to the phosphate ester 
resulting in a decrease in absorbance. A calibration curve was prepared using a series of 
standards of concentration 5 – 40 µg/ml IP6. 1 ml of Wade’s reagent (0.03 % FeCl3.6H2O + 
0.3% sulfosalicylic acid in milli-Q water) was added to 3 ml of the standard and eluate and 
vortex mixed for 5 s followed by centrifugation at 3000rpm for 10 mins. The absorbance was 
then measured at 500 nm using water to blank the spectrophotometer (Heλ10s, Spectronic 
Unicam). The concentration of IP6 in each eluate was determined from the standard curve. 
Urine collection 
24 hr urine samples were collected in 2.5 L plastic containers without any preservative. 
Details of the procedure for a 24 hr collection were provided to each participant 
(Appendix 6.3). The collection of a complete 24 hr sample was monitored by measuring 
urinary creatinine; urine samples with an abnormal concentration (normal range: 
9.0-17.7 mmol / 24 hr)410 were excluded. Urine samples were tested for blood and bacteria 
upon receipt (Medi-Test Combi 10, Machery-Nagel, Germany) and were discarded if tested 
positive.  
Urine composition 
Urinary IP6 was measured in each sample as described in Chapter 4. Each measurement 
was performed in duplicate per sample. Measurements were performed on the same day 
that samples were received. Urinary pH was measured using a pH meter (Hanna 
instruments, pH 211 microprocessor instruments); chloride was measured by using an ion-
selective electrode; sodium, potassium, calcium and magnesium were measured using flame 
atomic absorption spectrophotometry;411-413 oxalate was measured by using oxalate 
decarboxylase;414 citrate was measured by using citrate lyase;415 creatinine was determined 
by using picric acid;416 urate was determined from uricase and phosphate from ammonium 
molybdate.417, 418  
Physicochemical properties 
The RS of urinary stone-forming salts were determined by using JESS.321, 322 Concentrations 
(mol/L) of all of the aforementioned urinary parameters were used (except urinary creatinine) 
as input data (primary species) for the calculations. The SS of CaOx and CaP salts were 
determined.  
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The Tiselius risk index (TRI) of each sample was also determined using the following 
mathematical equation:419 
          (Ca/Cr)0.71 x (Ox/Cr)_______ 
  (Mg/Cr)0.14 x (Cit/Cr)0.10 
 
This ratio is used to calculate the relative biochemical risk of CaOx crystallisation where Ca, 
Ox, Mg and Cit are the urinary concentrations of calcium, oxalate, magnesium and citrate in 
mmol/ 24 hr and Cr, the urinary creatinine in mol/ 24 hr.  
Crystallisation experiments 
The CaOx MSL was determined as described in Chapter 5. Examination of crystals 
deposited in urine on day 0, day 3 and day 10 was performed by SEM as described in 
Chapter 5. The effect of urine on the rate of CaOx crystal nucleation and aggregation on day 
0, day 3 and day 10 was determined using the crystallisation assay described in Chapter 5. 
In this crystallisation assay a metastable solution containing calcium and oxalate only, served 
as the control. These kinetic experiments were conducted on different days and as such the 
control values varied from day to day. Therefore, experimental values were compared to the 
control measured on each particular day. All crystallisation experiments were performed a 
day after the sample was received. 
Statistics 
Statistical analysis was performed using the software program GraphPad InStat 3. Repeated 
measures ANOVA were performed for multiple intra-group comparisons followed by a post-
hoc Tukey- Kramer test. Unpaired t-tests were performed for inter-group comparisons. A p 
value < 0.05 was considered statistically significant. 
  
Chapter 6                                                                                         in vivo study: IP6 ingestion          
 
134 
 
Results 
Phytate content in oats 
The concentration of IP6 in oats is presented in Table 6.5. Raw data are presented in 
Appendix 6.4. The mean concentration of IP6 in each 20 ml extract was 2.38 ± 0.02 mM 
(shown in row 1). Standard additions of 0.6 mM IP6 (row 2) allowed for the determination of 
percentage recovery which was calculated as 88 %. The mean amount of IP6 per 100 g of 
oats was 1.57 g. Thus, the administered amount of Oats (70 g) in the present study 
contained 1.10 g of IP6. It should be noted that this concentration was determined in 
uncooked oats. However, previous studies have shown that IP6 is heat stable up to 100 
°C.420, 421 Thus conventional cooking without pre-soaking of oats has minimal effect on IP6 
concentration.421  
 
Table 6.5 Concentration of IP6 in oats. Mean and SE are reported. 
 
sample 
 
IP6 in extract mM/ 20 ml 
% 
recovery 
 
IP6 g / 100g 
 
IP6 g / 70g 
2g Oats (n=5) 2.38 ± 0.02  
88 
 
1.57 ± 0.01 
 
1.10 ± 0.01 
2g Oats + 0.6 
mM IP6 (n=5) 
2.91 ± 0.07 
 
Nutrient intake 
The mean nutrient intakes at baseline (FFQ) and on days 3 and 10 (24 hr food records) for 
the black subjects are given in Table 6.6.  
Attention is drawn to the significant decrease in dietary oxalate and the total IP6 intake on 
day 3 relative to baseline. This indicates that participants were compliant with regard to 
decreasing their intake of both oxalate and IP6.  
It is noted that several significant differences were observed on day 10 relative to baseline. 
Among these, is a significant decrease in oxalate hence confirming the subjects’ compliance. 
No significant difference in the total IP6 intake is observed indicating that the administered 
amount of IP6 in the present study is similar to their estimated baseline intake. All other 
significant differences will be taken into account when urinary composition is interrogated.  
Significant differences on day 3 relative to day 10 will also be taken into account when 
interrogating urinary composition. 
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The mean nutrient intakes at baseline, day 3 and day 10 are reported in Table 6.7 for the 
white group. The food diaries of 3 subjects were excluded as one subject deviated from the 
prescribed diet and two subjects collected incomplete urine samples. The results obtained 
from these subjects were therefore excluded from all analyses.    
Both oxalate and the total IP6 intake decreased significantly on day 3 relative to baseline 
indicating the subjects’ compliance with regard to the protocol of the present study. Oxalate 
was also significantly lower on day 10 relative to baseline. Dietary IP6 was significantly 
higher on day 10 relative to baseline indicating that the administered amount of IP6 in the 
present study was significantly higher than their usual intake.  
The total dietary IP6 intake was significantly higher on day 10 relative to day 3 in accordance 
with the protocol of the present study.
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Inter-group comparisons of the nutrient intakes are shown in Table 6.8. Attention is drawn to 
the following significant differences: total dietary carbohydrate and IP6 were significantly 
higher in the black group than in the white group at baseline.  
  Table 6.8 Inter-group comparison of nutrient intake 
  p value 
Baselinea Day 3  Day 10  
Total protein (g/day) 0.15 0.62 0.27 
Total fat (g/day) 0.78 0.73 0.40 
Total carbohydrate (g/day) 0.029 (B > W) 0.62 0.87 
Fibre (g/day) 0.056 0.68 0.27 
Added sugar (g/day) 0.47 0.70 0.49 
Oxalate (mg/day) 0.84 >0.99 0.64 
Calcium (mg/day) 0.98 0.34 0.49 
Magnesium (mg/day) 0.021 (B > W) 0.67 0.86 
Phosphorous (mg/day) 0.14 0.93 0.35 
Potassium (mg/day) 0.11 0.55 0.17 
Sodium (mg/day) 0.22 0.71 0.84 
Vitamin A (RE/day) 0.32 0.52 0.54 
Vitamin B6 0.13 0.21 0.0085 (B < W) 
Vitamin C (mg/day) 0.36 0.20 0.42 
Vitamin D (ug/day) 0.11 0.012 (B > W) 0.005 (B < W) 
Vitamin E (mg/day) 0.23 0.64 0.17 
Citric acid (mg/24h) 0.70 0.34 0.72 
IP6 fruit & veg (mg/day) 0.42 0.72 0.50 
IP6 (wholegrains and 
legumes) (mg/day) 
0.0002 (B > W) > 0.99 > 0.99 
Total IP6 (mg/day) 0.0002 (B > W) 0.72 0.50 
      a Baseline intake assessed using FFQ,  Indicates statistical significance, “B”= black 
subjects, “W’= white subjects. 
 
The type of wholegrains and legumes consumed by each group at baseline, the estimated 
portion size as well as the percentage of subjects who consume each type of IP6 containing 
food is reported in Table 6.9. Portion sizes were variable amongst subjects and are therefore 
reported as medians together with ranges. A notable difference in the consumption of beans, 
whole-wheat bread and maize meal was observed between the respective groups. A higher 
percentage of the black subjects consumed these foods relative to their white compatriots. 
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Table 6.9 Type of wholegrains consumed by each group in the present study. The median 
and the range, indicated in parentheses, are reported for the portion size.   
Source of IP6 Black males (n =16) White males (n =16) 
% subjects portion size (g) % of subjects portion size (g) 
Beans 75 142.5 (30-410) 31 100 (50-400) 
Whole wheat bread 94 120 (50 - 300) 50 105 (55-210) 
Oats 31 250 (100 - 375) 19 70 (50 - 250) 
Maize meal/samp 88 225 (75 - 1125) 19 160 (125 - 250) 
Pecan nuts 6 100 0  0 
Peanut butter 38 16 (10 -50) 56 15 (10 - 50) 
Peanuts 44 125 (30 - 250) 6 60 
Brown/wild rice 6 70 12 100 (50 -150) 
Cashew nuts 0 0 31 50 (30 - 200) 
Lentils 0 0 12 90 (80 - 100) 
 
Urine analysis 
The urinary excretions of IP6 on day 0, day 3 and day 10 are reported in Table 6.10 and 
Table 6.11 for the black and white group, respectively. As mentioned above the results of 3 
white males were excluded thus n= 8. The mean, standard deviation (SD), standard error 
(SE), minimum & maximum, median and p values are reported for each intra-group 
comparison.  
In the black group, no significant difference in the urinary excretion of IP6 was observed for 
the respective inter-day comparisons. In the white group, urinary IP6 was significantly higher 
on day 10 relative to both day 0 and day 3 (p < 0.05). All raw data are reported in Appendix 
6.5. 
 
     Table 6.10 Urinary IP6 excretion in black subjects (n= 12). 
Parameter 
  
  
Urinary IP6 (µM) 
Black subjects (n= 12) p value 
Day 0 (A) Day 3 (B) Day 10 (C) A vs B A vs C B vs C 
mean 0.89 0.82 0.95 > 0.05 > 0.05 > 0.05 
SD 0.50 0.51 0.34 
SE 0.14 0.15 0.10 
min 0.31 0.44 0.46 
max 1.69 1.98 1.53 
median 0.76 0.61 0.96 
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     Table 6.11 Urinary IP6 excretion in white subjects (n= 8).  
Parameter 
  
  
Urinary IP6 (µM) 
white males (n= 8) p value 
Day 0 (A) Day 3 (B) Day 10 (C) A vs B A vs C B vs C 
mean 0.39 0.39 0.67 > 0.05 < 0.05 
 
< 0.05 
SD 0.16 0.24 0.2 
SE 0.06 0.08 0.07 
min 0.2 0.16 0.47 
max 0.68 0.75 1.04 
median 0.38 0.32 0.65 
   Indicates statistical significance. 
 
Inter-group comparisons on day 0, day 3 and day 10 are shown in Figure 6.1. On day 0 
urinary IP6 was significantly higher in the black group (0.89 ± 0.14 µM) than the white group 
(0.39 ± 0.06 µM)) (p = 0.02). On day 3, urinary IP6 remained significantly higher in the black 
group (0.82 ± 0.15 µM) than the white group (0.39 ± 0.16 µM) (p = 0.04). Urinary IP6 was 
also higher in the black group (0.95 ± 0.10 µM) than the white group (0.67 ± 0.07 µM) on day 
10 and approached statistical significance (p = 0.057).  
 
 
Figure 6.1 Inter-group comparison of urinary IP6 excretion on day 0, day 3 and day 10. The 
statistical difference between bars labelled with the same letter is significant. ap= 0.02. 
bp= 0.04. 
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The mean urine composition and physicochemical properties on day 0, day 3 and day 10 are 
summarised in Table 6.12 and Table 6.13 for the black and white group, respectively. All raw 
data are in Appendix 6.6.  
In the black group, attention is drawn to the significant increase in urinary oxalate, 
magnesium and sodium on day 3 relative to day 0 as well as the significant increase in 
urinary citrate on day 10 relative to day 3. Since dietary IP6 consumption was similar on 
day 0 and day 10, the inter-day significant changes in urinary parameters are not of interest 
and will not be discussed.   
In the white group the significant increase in urinary citrate on day 10 relative to day 0 as well 
as its increase on day 10 relative day 3 (tending toward statistical significance; p = 0.07) is of 
interest.
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Inter-group comparisons of urinary composition and physicochemical properties are shown in 
Table 6.14. Attention is drawn to the significantly lower concentration of urinary phosphate in 
the black group than the white group on day 10.     
 
Table 6.14 Inter-group comparisons of urinary composition and physicochemical properties. 
  
  
p value 
Day 0  Day 3  Day 10  
pH 0.14 0.080 0.52 
Volume (ml) 0.19 0.86 0.77 
Citrate (mmol/24hr) 0.32 0.063 0.59 
Oxalate (mmol/24hr) 0.66 0.35 0.75 
Calcium (mmol/24hr) 0.91 0.52 0.43 
Magnesium (mmol/24hr) 0.59 0.67 0.14 
Sodium (mmol/24hr) 0.79 0.097 0.098 
Potassium (mmol/24hr) 0.002  
(B > W) 
0.012 
(B > W) 0.11 
Urate (mmol/24hr) 
0.32 (B < W) 0.23 (B < W) 
0.005 
(B < W) 
Creatinine (mmol/24hr) 0.94 0.70 0.18 
Phosphate (mmol/24hr) 
0.12 0.32 
0.001 
(B < W) 
Chloride (mmol/24hr) 0.73 0.68 0.83 
Phytate (µM)    0.020 
 ( B > W) 
    0.039  
  (B > W) 
      0.057 
(B> W) 
TRI 0.92 0.26 0.73 
RS CaOx 0.12 0.88 0.99 
RS Brushite 0.12 0.77 0.49 
RS Urate 0.20 0.23 0.09 
CaOx MSL (mM)    0.21    0.058 0.16 
           Indicates statistical significance. “B”= black subjects. “W”= white subjects. 
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Crystallisation experiments 
CaOx MSL 
In the black group, baseline urinary samples of 4 subjects tested positive for bacteria on the 
day of which crystallisation experiments were conducted. These samples were therefore 
excluded from crystallisation experiments. Comparisons of the CaOx MSL of these subjects 
on day 0 relative to day 3 and day 10 could therefore not be made. Thus, statistical 
comparisons of the CaOx MSL of n= 8 black subjects were calculated. 
The mean CaOx MSL for each group on the respective days is reported in Table 6.12 and 
Table 6.13. Raw data are reported in Appendix 6.7. No statistically significant differences 
were observed in either group for the respective inter-day comparisons.  
Inter-group comparisons of the mean CaOx MSL are reported in Table 6.14. No statistically 
significant differences were observed on each respective day.  
CaOx nucleation and aggregation 
The mean percentage inhibition of CaOx crystal nucleation and aggregation rates relative to 
the control was calculated and is reported in Table 6.15 and Table 6.16, respectively. A 
negative percentage indicates promotion of CaOx crystal nucleation and aggregation, 
respectively.  
Intra-group comparisons showed no statistically significant differences. Attention is drawn to 
the significantly higher percentage inhibition of CaOx crystal nucleation in the black group 
relative to their white counterparts on day 3 and day 10. (It is also noted that the percentage 
inhibition of CaOx crystal nucleation was higher in the black group on day 0 albeit not 
statistically significant). Plots of the raw data are shown in Appendix 6.8. 
 
Table 6.15 Intra- and inter-group comparisons of the percentage inhibition of CaOx crystal 
nucleation. Mean ± SE. 
 % inhibition of the rate of CaOx crystal 
nucleation 
p value (intra-group) 
Day 0  
(A) 
Day 3  
(B) 
Day 10  
(C) 
A vs B A vs C B vs C 
Black subjects 
(n=8) 
22 ± 5 43 ± 10 43 ± 6 
> 0.05 > 0.05 > 0.05 
White subjects 
(n=8) 
13 ± 13 11 ± 8 -10 ± 15 
> 0.05 > 0.05 > 0.05 
p value  
(inter-group) 
0.15 0.031 0.0003 
Negative percentage indicates promotion of CaOx crystal nucleation. Indicates significant 
difference. 
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Table 6.16 Intra- and inter-group comparison of the percentage inhibition of CaOx crystal 
aggregation. Mean ± SE. 
 % inhibition of the rate of CaOx 
crystal aggregation 
p value (intra-group) 
Day 0  
(A) 
Day 3  
(B) 
Day 10  
(C) 
A vs B A vs C B vs C 
Black subjects 
(n =8) 
23 ± 11 4.7 ± 16 29 ± 13 
> 0.05 > 0.05 > 0.05 
White subjects 
(n=8) 
33 ± 6 41 ± 5 33 ± 8 
> 0.05 > 0.05 > 0.05 
p value  
(inter-group) 
0.46 0.23 0.51 
 
Scanning electron microscopy 
Crystals deposited in the urines of 3 randomly chosen black and 3 randomly chosen white 
subjects were viewed on day 0, day 3 and day 10. The total surface-area of each stub was 
examined and micrographs of typical deposits with respect to morphology, size and 
aggregation were recorded as described in Chapter 5.  
Figure 6.2 shows electron micrographs of crystals deposited in urine of 3 black subjects on 
day 0 (BM1a - BM3a), day 3 (BM1b - BM3b) and day 10 (BM1c - BM3c). At baseline (day 0) 
the presence of single, bipyramidal COD crystals (mean cross section of 6 µm) was 
observed for all subjects.  
On day 3 the presence of single, oval-shaped COM crystals (mean cross section of 4 µm) 
was found in 2 out of 3 subjects (BM1b & BM2b) whereas single COD crystals (mean cross 
section of 8 µm) were present in all.   
On day 10, different observations were recorded for the three subjects. Single oval-shaped 
COM crystals (mean cross section 6 µm) occurred in one subject (BM1c) while single COD 
crystals (mean cross section 8 µm) occurred in another (BM3c). Mixed COM and COD 
occurred in the final subject (mean cross sections of 4 µm and 6 µm; respectively). In 
addition, a few small aggregated COM crystals were observed in two of the subjects (BM1c 
and BM2c). 
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Day 0 Day 3 Day 10 
   
   
   
 
Figure 6.2 Electron micrographs of CaOx crystals deposited in urine of black subjects on 
day 0 (BM1a – BM3a), day 3 (BM1b – BM3b) and day 10 (BM1c – BM3c). Micrographs are 
at a magnification of x 5000. 
  
Figure 6.3 shows electron micrographs of crystals deposited in urine of 3 white subjects on 
day 0 (WM1a – WM3a), day 3 (WM1b – WM3b) and day 10 (WM1c – WM3c). At baseline 
(day 0) a mixture of both COM and COD crystals ( mean cross sections of 6 µm and 9 µm; 
respectively) were observed in 2 out of 3 subjects (WM2a & WM3a) whereas single COD 
crystals alone (mean cross section of 9 um) were observed in the other (WM1a). A few large 
COD crystals with an altered morphology were observed in one sample (WM2a).  
On day 3, COM crystals (mean cross section of 5 µm) were predominant in all samples. On 
day 10 mostly single bipyramidal COD crystals were observed in all samples (mean cross 
section of 9 µm). 
BM1b BM1c BM1a 
Bipyramidal COD crystal Oval-shaped COM crystal 
BM2b BM2c BM2a 
Aggregated COM crystals 
BM3b BM3c BM3a 
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Figure 6.3 Electron micrographs of CaOx crystals deposited in urine of white subjects on 
day 0 (WM1a – WM3a), day 3 (WM1b – WM3b) and day 10 (WM1c – WM3c). Micrographs 
are at a magnification of x 5000. 
  
Day 0 Day 3 
 
Day 10 
   
   
   
WM1b WM1c 
WM2b WM2c 
WM3b WM3c 
WM1a 
WM2a 
WM3a 
COD crystal with altered 
morphology. 
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Discussion 
Based on a previous study by Modlin318, the hypothesis under investigation in the present 
study was that a significantly higher intake of dietary IP6 in South African black subjects 
relative to their white compatriots leads to a higher urinary excretion level of this substance 
which, in turn, contributes to the relative rarity of kidney stone disease in this group. Since 
the study by Modlin was conducted 35 years ago, the first objective of the study described 
here was to assess whether black subjects still have a relatively high intake of this nutrient 
compared to their white compatriots. Results of the present study showed that dietary IP6 
was indeed significantly higher in black subjects compared to white subjects.  
The estimated total dietary intake of IP6 in both groups of the present study differed to those 
of Modlin’s318 study as follows. The intake of this nutrient in the black group was lower in the 
present study relative to Modlin’s study (1650 ± 202 mg/ day vs 4290 mg/ day); and higher in 
the white group of the present study relative to Modlin’s study (640 ± 134 mg/ day vs 
275 mg/ day).While the former might be indicative of a change in lifestyle associated with a 
transition from rural to urban areas422, 423, the reason for the latter is not obvious. Irrespective 
of these differences, the major contributors of the total IP6 intake in the black group which 
were identified in the present study, namely maize, beans and wholewheat bread are in 
agreement with those reported by Modlin318. Furthermore, a study in a large cohort of 96 245 
females demonstrated a correlation between a high dietary intake of IP6 and the decreased 
risk of kidney stone formation.424 Thus, the higher dietary intake of IP6 in the black subjects 
of the present study relative to their white compatriots might contribute to the relative rarity of 
kidney stone disease in this group.  
Of importance to the present hypothesis is to establish whether the higher intake of dietary 
IP6 in black subjects manifests itself in a higher urinary excretion of this substance. The 
results of the present study showed that the mean urinary IP6 was indeed significantly higher 
in the black group than in the white group while following their free unrestricted diets 
(Figure 6.1). These results are however not in agreement with the only other study in which 
IP6 was measured in the urine of the respective groups. This latter study was conducted in 
the KSRL at the University of Cape Town, as stated earlier in the introduction of the present 
chapter.319 Not only was the concentrations of IP6 in both groups higher than those of the 
present study, the urinary excretion of this substance in the black group was lower than in 
the white group in the previous study. This discrepancy can be attributed to a difference in 
the analytical methods used in the two studies, possibly linked to the insufficient separation 
of inorganic phosphate in the previous study during sample preparation (as mentioned in 
Chapter 1) which yields a false positive for the quantification of IP6. This explains the higher 
IP6 values in the previous study relative to the present study. Furthermore, previous studies 
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showed that urinary phosphate is higher in the white group relative to the black group.4, 5, 294, 
296, 302 Thus, it can be speculated that this might have resulted in a higher false positive 
detection of IP6 in the urine of white subjects in the previous study which, in turn, explains 
the reported lower urinary IP6 in black subjects relative to white subjects. The significantly 
higher urinary excretion of IP6 in South African black subjects relative to white subjects in the 
present study has therefore been reliably demonstrated for the first time. 
A previous study reported that the urinary excretion of IP6 was significantly lower in CaOx 
stone formers than in healthy European (Spanish) individuals.265 Furthermore, the urinary 
excretions of IP6 in the black subjects of the present study are within the normal urinary 
range reported for healthy European (Spanish) individuals (0.757- 4.54 µM)259. Therefore, the 
significantly higher urinary excretion of IP6 in the black subjects of the present study relative 
to their white compatriots may be consistent with the relative rarity of urolithiasis in this 
group. 
With regard to the urinary excretion of IP6 in relation to its ingestion, the results of the 
present study showed that no significant decrease was observed after 3 days of IP6 
restriction in either group. This suggests that 3 days of restriction is insufficient to observe a 
significant decrease. This is inconsistent with a previous study by Grases et al in which 
urinary IP6 decreased by 50 % after only 36 hrs of IP6 restriction.391 Nonetheless, other 
studies by the same researchers demonstrated that urinary IP6 reached minute levels when 
its ingestion was restricted for a period of 15 days.268, 392 When IP6 was administered in the 
present study no significant increase was observed in the black group on day 10 relative to 
day 0 (Table 6.10). This might be explained by the fact that the administered amount in the 
present study (1100 ± 10 mg) is similar to their mean estimated intake at baseline 
(1650 ± 202 mg). Accordingly, no significant increase in urinary IP6 was observed on day 10 
relative to day 3 in this group. On the other hand, urinary IP6 increased significantly in the 
white group on day 10 relative to day 0 and day 3. This is consistent with the significant 
increase in the ingestion of IP6 in accordance with the protocol of the present study thereby 
demonstrating that an increase in urinary IP6 is correlated to its dietary intake.  
Inter-group comparisons of urinary IP6 on day 10 demonstrated that when the amount of IP6 
ingestion was the same between the two groups, the urinary excretion of IP6 in the black 
group was higher than in their white compatriots approaching statistical significance 
(p= 0.057). It is therefore tempting to speculate that the absorption of IP6 may be higher in 
the black group than the white group. However, studies have indicated that the rate of 
absorption of IP6 is low, requiring more than 10 days to reach normal levels when humans 
become deficient in this substance.268, 269, 392 Thus, since urinary IP6 was significantly lower in 
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the white group relative to the black group on day 0 and day 3 (and possibly immediately 
prior to Phase 2), it is possible that the urinary excretion of this substance may approach that 
of the black group after a more prolonged ingestion of a diet rich in IP6.    
With regard to possible metabolic effects of IP6 ingestion on the urine chemistry, the 
following should be borne in mind. As previously stated in Chapter 1, an excessive intake of 
IP6 in conjunction with a low intake of minerals such as calcium and magnesium may lead to 
a decrease in the bioavailability of these minerals and hence its urinary excretion.270-272 Thus, 
the converse may be true, namely that a significant decrease in IP6 consumption may lead to 
an increase in these urinary parameters. Furthermore, studies have demonstrated that the 
ingestion of 1- 2 g of IP6 with a balanced diet had a negligible effect on the bioavailability of 
calcium and magnesium.425, 426 Thus, in the present study, changes in the excretion of urinary 
calcium and magnesium were not anticipated since both the estimated baseline intakes of 
IP6 in the respective groups and the administered amount of IP6 were not in excess of the 
above mentioned range. However, it is speculated by the present researcher that changes in 
other biochemical urinary parameters associated with possible unknown metabolic effects of 
IP6 itself or its degradation products, namely phosphate and lower phosphorylated inositols, 
may occur.   
In light of the above, the significant increase in both urinary calcium and magnesium in the 
black group on day 3 relative to day 0 is unlikely to be attributed to the significant decrease in 
IP6 ingestion in the present study. This might have occurred due to fluctuations in the 
subjects’ dietary regime since meals were not standardized in the present study. This will not 
be discussed here as it digresses from the objectives of the present study.  
Regarding significant changes in other biochemical urinary parameters, the significant 
increase in urinary citrate in both groups on day 10 (after IP6 ingestion) relative to day 3 
(Table 6.12 and Table 6.13), is of interest. Citrate is well known for its inhibitory properties in 
CaOx urolithiasis as mentioned in Chapter 1. An increase in urinary citrate may be caused by 
an increase in plasma citrate (caused by an increase in citrate ingestion) or by metabolic 
alkalosis.427, 428 Both of the aforementioned processes result in an increase in urinary pH. 
However, in the present study no increase in urinary pH was observed in either group 
thereby ruling out the aforementioned mechanisms as a possible explanation for the increase 
in urinary citrate on day 10 relative to day 3. Other possible causes of increased urinary 
citrate include that of an increase in vitamin E intake298, dietary fat and dietary 
carbohydrate429. None of these increased in either group for the respective inter-day 
comparisons.  Furthermore, no correlation between dietary IP6 ingestion and the excretion of 
urinary citrate has been reported. However, a previous study demonstrated that the ingestion 
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of alkaline orthophosphate (K2HPO4) increased the urinary excretion of citrate.430 Another 
study also demonstrated that the ingestion of a potassium- phosphate preparation 
(Urophos-K) increased citraturia.228 Thus, since the hydrolysis of IP6 yields phosphate,431-433 
it is speculated by the present researcher that the latter might have influenced the urinary 
excretion of citrate in the present study. The mechanism by which orthophosphate caused an 
increase in urinary citrate was however not explained in the previous studies. Nonetheless, 
this observation is encouraging. No significant difference in the excretion of citrate was 
observed between the two groups, suggesting that the renal handling of IP6 in this regard is 
similar between the two groups. However, a significantly lower excretion of phosphate was 
observed in the black group relative to their white compatriots on day 10 (Table 6.14) 
indicating that the white subjects are more sensitive to the absorption of phosphate. This is 
consistent with previous studies as stated earlier in this discussion.     
The final objective of the present study was to determine whether a significant increase/ 
decrease in the urinary excretion of IP6 results in a significant effect on urinary CaOx 
crystallisation. This objective is based on the results presented in Chapter 5 of the present 
thesis is which certain crystallisation mechanisms were inhibited by IP6 in a concentration 
dependent manner in vitro. Furthermore, a previous in vivo study in CaOx stone formers 
demonstrated that an increase in urinary IP6 reduced the crystallisation propensity of the 
urine of these patients.292 However, in the present in vivo study, since no significant 
difference in urinary IP6 was observed in the black group for the respective inter-day 
comparisons, a conclusion cannot be made on phytate’s capacity to inhibit crystallisation in 
the urine of this group.  
On the other hand, a significant increase in urinary IP6 was observed in the white group on 
day 10 relative to both day 3 and day 0 (Table 6.11), but it was not sufficient to increase the 
CaOx MSL (Table 6.13). This is consistent with the observation reported in the preceding 
chapter in which physiological concentrations of IP6 did not increase the CaOx MSL in 
pooled urine of white subjects. Furthermore, the significant increase in urinary IP6 in the 
present study was not sufficient to increase the urine’s inhibitory capacity with regard to 
CaOx crystal nucleation and aggregation, nor was it sufficient to cause favourable changes 
in CaOx crystal size and/ hydration state (SEM). These results cast doubt on the purported 
inhibitory capacity of IP6 in CaOx urolithiasis. However, a recent in vitro study demonstrated 
that the effective concentration of IP6 required for the inhibition of artificially grown stones 
had no effect on the crystallisation of CaOx in suspension around the growing stone.285 
Therefore, although the significant increase in urinary IP6 failed to increase the CaOx MSL 
and inhibit CaOx crystal nucleation and aggregation in the present in vivo study, it may be 
crucial in the prevention of kidney stone growth at a macroscopic level.    
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The only noteworthy inter-group difference with regard to CaOx crystallisation was the higher 
percentage inhibition of CaOx crystal nucleation in the urine of black subjects relative to 
white subjects on each respective day (Table 6.15). This may not necessarily be due to the 
higher urinary excretion of IP6 in the black group per se as other urinary parameters such as 
the significantly higher urinary excretion of potassium and the lower urinary excretion of urate 
may have contributed towards this effect in this group (Table 6.14), although the 
mechanisms by which this may have been achieved are not obvious.  
It is recognized that the outcomes of the present study were influenced by its duration which 
may have been too short with respect to the period of IP6 restriction. This would account for 
no significant decrease in urinary IP6 being observed in either group when dietary IP6 was 
restricted. A second limitation in the study design was the absence of urinary IP6 
determinations immediately prior to initiating Phase 2 i.e. on day 7. As such it was not 
possible to demonstrate whether urinary IP6 was at a reduced level prior to the 
administration of the IP6 rich diet. At first glance it may appear that there are two further 
limitations to this study namely, that the dosage of IP6 might have been too small and that 
the period in which it was administered was too short. However, these limitations must be 
considered individually for the respective groups. Since urinary IP6 increased significantly in 
the white group after the ingestion of the administered amount of IP6 in the present study, it 
can be concluded that the dosage was satisfactory and that the duration during which it was 
administered was adequate. On the other hand, these variables (dosage and duration) might 
need further exploration in black subjects in future studies.  
Irrespective of the above, the results of the present study are important since the significantly 
higher urinary excretion of IP6 in South African black subjects was demonstrated for the first 
time in the present study. Furthermore, results of the present study suggest that IP6 
ingestion may increase the urinary excretion of citrate. This was also demonstrated for the 
first time.  
In order to address the limitation relating to the suspected short duration of IP6 restriction, a 
further study was undertaken. This is described in the next chapter.
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Chapter 7 : Investigation of the effect of an extended period of dietary 
restriction of IP6 followed by ingestion of an IP6 supplement  on the urinary 
risk factors for calcium oxalate urolithiasis in South African black and white 
subjects.  
 
Introduction 
The study described in this chapter is a follow up to that described in the previous chapter in 
which a decrease in the urinary excretion of IP6 was not observed after 3 days of dietary IP6 
restriction. The present study was conducted to address this limitation. 
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Methods 
Study design 
A similar design as described in Chapter 6, was used in the present study. However, instead 
of a 10- day cross-over study, an 18- day cross-over study (again consisting of two phases) 
was conducted.  
Prior to the first phase of the study, a 24 hr baseline urine sample was provided by subjects 
while following their free unrestricted diets. Phase 1 (IP6 restricted)  had a duration of 15 
days (compared to 7 days in the previous study), during which urinary IP6 excretion was 
determined in 24 hr urine samples on days 3, 7 and 15. This duration period was used as 
previous studies by Grases et al demonstrated that urinary IP6 approached values close to 
zero after 15 days of dietary IP6 restriction.268, 392  
During Phase 2 of the present study, an IP6 supplement (IP6 Gold, immune support formula, 
USA) containing 800 mg of IP6 was administered on days 16 -18. The switch from an IP6 
rich diet (preceding chapter) to an IP6 supplement was implemented due to its ease of 
administration and to reduce participant burden with respect to the dietary protocol.  Although 
no studies have been previously reported on the bioavailability of IP6 from the diet relative to 
its supplemental form, it can be reasonably speculated that its bioavailability from the latter 
may be greater as it is not part of a complex food matrix.  
Although the dosage of IP6 delivered by the supplement is lower than in the study presented 
in the previous chapter (1100 ± 10 mg), it is within the range reported in a previous study 
(400- 3200 mg).268 The latter study demonstrated that the ingestion of IP6 supplements at 
different dosages within this range resulted in the same urinary excretion of IP6. In the 
present study, subjects were required to ingest the IP6 supplement on an empty stomach, as 
directed on the supplement bottle, 1 hr before breakfast. Urinary IP6 was measured on 
day 18.  
Urine aliquots were kept for the determination of biochemical urine parameters as well as for 
crystallisation experiments. 
As in the preceding study (Chapter 6), dietary IP6 and oxalate were restricted for the duration 
of the study (Table 6.2 and Table 6.3). Each subject was required to keep a dietary record on 
days of urine collection. In an attempt to minimize confounding dietary factors, subjects were 
asked not to vary their dietary intakes on all days of urine collection (excluding day 0). This 
also ensured that each subject served as their own control.  
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This study was approved by the Human Research Ethics Committee of the University of 
Cape Town, HREC ref: 072/2014 (Appendix 7.1). 
Subjects  
Healthy black (n =7) and white (n =7) South African males between the ages of 18 -25, 
without any history of kidney stone disease were recruited from the student and staff cohort 
at the University of Cape Town. Vegetarians and individuals with nut allergies were excluded. 
Eligible participants were selected after completing a general questionnaire assessing their 
health. Race was self-declared. 
Dietary analysis 
24 hr dietary records were analysed using FoodFinder 2 as described in Chapter 6. 
Urine collection, treatment and composition 
24 hr urine samples were collected and treated as described in Chapter 6. Urinary 
composition, including IP6 analysis was determined as described in Chapter 6. Ionized 
calcium was determined as described in Chapter 5.   
Physicochemical properties 
The RS of CaOx, brushite and uric acid and the TRI was determined as described in 
Chapter 6. 
Crystallisation experiments  
The CaOx MSL was determined; this was then followed by determining the rate of CaOx 
crystallisation. Both methods are fully described in Chapter 5. These experiments were 
performed in urines collected on days 0, day 15 and day 18. The effect of urine samples on 
the rate of CaOx crystal nucleation and aggregation was not determined in the present study 
(as had been done in the study described in the previous chapter), as the required 
instrument malfunctioned at the time at which this study was undertaken. 
Statistics 
Statistical analyses of data on days 0, 15 and 18 were determined using GraphPad Instat 3. 
Repeated measures ANOVA were performed for multiple intra-group comparisons followed 
by a post-hoc Tukey- Kramer test. Unpaired t-tests for inter-group comparisons were 
performed. A p value < 0.05 was considered statistically significant. 
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Results 
Dietary   analysis 
Inter-day comparisons of the nutrient intake on days 0, 15 and 18 were determined and are 
shown in Table 7.1 and Table 7.2 for the black and white group, respectively.  
In the black group, the only significant difference was in the intake of vitamin B6 which was 
significantly higher on day 18 relative to day 0 (Table 7.1). Since vitamin B6 may influence 
oxaluria.434-436, its higher intake in the black group may be a confounding factor which needs 
to be taken into consideration when interrogating the urine chemistry (page 161). Attention is 
drawn to the decrease in the ingestion of total dietary IP6 on days 15 and 18 relative to day 0 
(albeit not statistically significant) in accordance with the protocol of the present study in 
which subjects were required to restrict their dietary intake of IP6. 
In the white group, no significant differences in the nutrient intake were observed for the 
respective inter-day comparisons thus eliminating the possibility of confounding dietary 
factors. (Table 7.2). A decrease in the ingestion of total dietary IP6 was observed on day 15 
and day 18 relative to day 0 (albeit not statistically significant) in accordance with the protocol 
of the present study in which subjects were required to restrict their dietary intake of IP6.  
Inter-group comparisons showed no significant differences in the nutrient intake as shown in 
Table 7.3.  
It should be noted that the dietary intake on day 0 (baseline) corresponds to the subjects’ 
nutrient intake on that particular day and is not necessarily representative of their typical 
dietary intake (unlike that obtained in Chapter 6 for the FFQs). The nutrient analyses of these 
single 24 hr dietary records were therefore not used as a means to compare the usual/ 
typical intakes in black versus white subjects but rather as a means to account for any intra- 
or inter-group differences in urine parameters which may have occurred due to differences in 
their nutrient intakes on days of urine collection. 
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Table 7.3 Inter-group comparisons (p values) of nutrient intake on day 0, day 15 and 
day 18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
p value 
Day 0 Day 15 Day 18 
Total protein (g/ day) 0.74 0.14 0.55 
Total fat (g/ day) 0.19 0.04 0.1 
Total carbohydrate (g/ day) 0.88 0.34 0.08 
Fibre (g/ day) 0.47 0.48 0.09 
Added sugar (g/ day) 0.48 0.24 0.06 
Oxalate (mg/ day) 0.67 0.83 0.49 
Calcium (mg/ day) 0.2 0.84 0.44 
Magnesium (mg/ day) 0.43 0.74 0.19 
Phosphorous (mg/ day) 0.53 0.51 0.89 
Potassium (mg/ day) 0.33 0.64 0.51 
Sodium (mg/ day) 0.19 0.43 0.95 
Vitamin A (RE/ day) 0.34 0.41 0.3 
Vitamin B6 0.62 0.69 0.14 
Vitamin C (mg/ day) 0.49 0.75 0.22 
Vitamin D (ug/ day) 0.56 0.07 0.2 
Vitamin E (mg/ day) 0.31 0.5 0.66 
Citric acid (mg/ day) 0.34 0.75 0.68 
IP6 (fruit & veg) (mg/ day) 0.16 0.2 0.48 
IP6(whole grains) (mg/ day) 0.31 >0.99 >0.99 
Total IP6 (mg/ day) 0.51 0.2 0.47 
Chapter 7                                                                             in vivo study: IP6 supplementation 
                                                                                                                      
161 
 
Urine analysis 
The mean urinary excretion of IP6 for the duration of the study is shown in Figure 7.1 while 
actual values are reported in Table 7.4. All raw data are reported in Appendix 7.2.  
In the black group, the mean urinary excretion of IP6 decreased within 3 days of the 
commencement of the study and remained constant up to day 15. Urinary excretion of IP6 
was significantly lower on day 15 relative to day 0 (p < 0.05). After 3 days of IP6 
supplementation (day 18), urinary IP6 increased (relative to day 15) albeit not statistically 
significant (p > 0.05).  
In the white group, urinary IP6 remained constant during Phase 1 of the study but increased 
significantly on day 18 relative to day 0 and day 15 (p < 0.05).  
Inter-group comparisons showed that urinary IP6 was higher in the black group than the 
white group on day 0, approaching statistical significance (p =0.06). No significant difference 
in the urinary excretion of IP6 was observed between the respective groups after 15 days of 
IP6 restriction (p = 0.59) and on day 18 after IP6 supplementation (p= 0.89). 
 
  
Figure 7.1 Mean urinary IP6 in black (red curve) and white (blue curve) subjects. Error bars 
indicate standard error of the mean. Phase 1: IP6 deficient diet. Phase 2: IP6 deficient diet + 
800 mg IP6 supplement. Pairwise comparisons of data points labelled with the same letter 
are significantly different; p < 0.05.
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Table 7.7 Inter-group comparisons of urinary composition and physicochemical risk factors. 
 
 
  
  
p value 
Day 0  Day 15  Day 18  
pH 0.8 0.38 0.46 
Volume (ml) 0.11 0.12 0.05 
Citrate (mmol/ 24 hr) 0.22 (B < W) 0.06 (B < W) 0.01* (B < W) 
Oxalate (mmol/ 24 hr) 0.48 0.28 0.71 
Calcium (mmol/ 24 hr) 0.38 > 0.99 0.38 
Magnesium (mmol/ 24 hr) 0.9 0.72 > 0.99 
Sodium (mmol/ 24 hr) 0.16 (B < W) 0.04 (B < W) 0.03 (B < W) 
Potassium (mmol/ 24 hr) 0.37 0.89 0.59 
Urate (mmol/ 24 hr) 0.16 (B < W) 0.11 (B < W) 0.004 (B < W) 
Creatinine (mmol/ 24 hr) 0.58 0.1 0.006 (B < W) 
Phosphate (mmol/ 24 hr) 0.34 0.6 0.002 (B < W) 
Chloride (mmol/ 24 hr) 0.26 0.15 0.34 
Phytate (µM) 0.06 (B > W) 0.89 0.59 
TRI 0.13 0.31 0.15 
RS CaOx 0.07 0.10 0.42 
RS Brush 0.31 0.04 (B > W) 0.40 
RS UA 0.40 0.37 0.64 
CaOx MSL (mM) 0.09 0.21 0.15 
Ionized calcium (mmol/ 24 hr) 0.74 0.33 0.52 
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Crystallisation experiments 
 
CaOx MSL 
The mean CaOx MSL of both groups is indicated in the aforementioned tables (Table 7.5 
and Table 7.6). Raw data are reported in Appendix 7.4. In both the black and the white 
groups, no significant difference in the CaOx MSL was observed for inter-day comparisons. 
Inter-group comparisons also showed no statistical difference as shown in Table 7.7. 
Rate of crystallisation 
Crystallisation was induced in urine samples by the addition of Na2Ox at a concentration of 
0.15 mM greater than the CaOx MSL. The urine of 1 black subject and 2 white subjects were 
supersaturated and had CaOx MSLs below 0.15 mM (the lowest concentration of Na2Ox 
used in the present study). The rate of crystallisation was therefore not determined in these 
samples. Accordingly, the mean rate of crystallisation in urine of 6 black and 5 white subjects 
on days 0, 15 and 18 are reported in Table 7.8. Both intra- and inter-group comparisons were 
made; no statistical differences were observed. All raw data are reported in Appendix 7.5. 
 
 Table 7.8 Mean rate of CaOx crystallisation in urine of black (n= 6) and white (n= 5) 
subjects.  
 
  
 Rate (change in OD620nm x 10
-3 min-1)  
mean ± SE 
p value (intra-group) 
Day 0 
(A) 
Day 15 
(B) 
Day 18 
(C) 
A vs B A vs C B vs C 
Black subjects 1.74 ± 0.78 0.82 ± 45 1.58 ± 0.36 > 0.05 > 0.05 > 0.05 
White subjects 0.50 ± 0.20 0.54 ± 0.33 1.53 ± 1.10 > 0.05 > 0.05 > 0.05 
p value 
Inter-group 
 
0.18 
 
0.64 
 
0.97 
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Discussion 
The objective of the present study was to establish whether a period of more than 3 days of 
dietary IP6 restriction would initiate a decrease in its urinary excretion. Surprisingly, urinary 
IP6 decreased in the black group after 3 days of IP6 restriction (Figure 7.1 and Table 7.4). 
This is inconsistent with the results presented in Chapter 6 in which no such decrease was 
observed in either group after IP6 restriction for this period of time. These conflicting results 
might not occur in bigger sample sizes drawing attention to a limitation of the present study. 
Nevertheless, an extended period of restriction as described in this chapter is of interest in 
terms of examining whether a further decrease in urinary IP6 is observed (as discussed in 
the next paragraph). On the other hand, a similar decrease was not observed in the white 
group of the present study which is consistent with the preceding chapter.  
After day 3, IP6 excretion remained constant up to day 15 in both groups despite the 
restriction of IP6 from whole-grains and legumes. This indicates that dietary IP6 derived from 
fruits and vegetables (which were not restricted in the present study and which contain IP6, 
although to a lesser extent than that of whole-grains259) must have contributed toward the 
total urinary excretion of IP6. Furthermore, foods containing refined wheat (such as pasta, 
white bread, pizza, biscuits, and cake), and refined white rice, all of which may contain 
IP6259, were also not excluded from meals. These factors should therefore be taken into 
consideration when planning future studies.  
In the present study, a period of 3 days of IP6 supplementation was sufficient to increase its 
urinary excretion (in both groups) to levels within the normal range. However, it must be 
noted that longer periods of IP6 ingestion may be required when urinary IP6 is extremely 
low.268, 392  
Regarding inter-group comparisons of the urinary excretion of IP6, the results of the present 
study demonstrated that the excretion levels of this substance are similar when their IP6 
intake is the same (Table 7.4, day 15 and day 18). This suggests that differences in the 
physiological handling of IP6 with respect to its absorption and subsequent urinary excretion 
may not exist between the respective groups.  
Based on the results presented in the previous chapter for both groups, it was speculated 
that a significant increase in IP6 consumption may influence the excretion of urinary citrate. 
However, no such effect was observed in the black group of the present study on day 18 
relative to day 15 (Table 7.5). This suggests that the conditions under which the supplement 
was ingested in the present study namely, on an empty stomach, might have affected the 
metabolism of this substance. Since it is speculated that the increase in urinary citrate might 
be due to an increase in phosphate (derived from IP6 hydrolysis) it might be possible that the 
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hydrolysis of IP6 has not occurred on an empty stomach. Indeed, studies in both ileostomy 
patients and in pigs demonstrated that the hydrolysis of IP6 in the stomach and the small 
intestine is dependent on phytases (an enzyme for IP6 hydrolysis) obtained from food such 
as wheat, barley and oats.431-433 On the other hand, a significant increase in urinary citrate 
was observed in the present study in the white group on day 18 relative to day 0  (p < 0.05; 
Table 7.6) with a concomitant increase in urinary phosphate (p > 0.05). This is puzzling since 
it suggests that IP6 hydrolysis has occurred in this group. This suggests that the transit time 
of the IP6 supplement in the stomach or the small intestine relative to the time at which a 
meal was ingested (which possibly contained wheat) might have influenced the hydrolysis of 
IP6 in this group. Nonetheless, the observation that urinary citrate increased in the white 
group only, in response to IP6 supplementation, demonstrates that the respective groups 
may have a different renal response to IP6 supplementation. This is not dissimilar to results 
of previous studies which were conducted in the KSRL at the University of Cape Town in 
which the renal response to five different supplemental challenges (calcium, vitamin B6, L-
glutamine and L-cystine supplement) were different in the respective groups.299 In these 
studies, no effect was observed in the black group whereas significant effects were observed 
in the white group.299 
Crystallisation properties (CaOx MSL and rate of CaOx crystallization) were not affected in 
either of the groups when urinary IP6 increased significantly (following ingestion of the IP6 
supplement). These results are consistent with the findings reported in the previous chapter 
thereby supporting the notion that if urinary IP6 inhibits the formation of kidney stones it does 
so by inhibiting stone growth at a macroscopic level as demonstrated in a previous in vitro 
study by Saw et al285.   
Direct comparison of the results of the present study to those presented in the preceding 
chapter cannot be made since the relative bioavailability of IP6 in the two forms (dietary and 
supplemental) is not known, nor was the net delivered dosage of IP6 standardized in the 
respective studies. Furthermore, identical crystallisation assays in the two studies were not 
possible due to various circumstances as stated in the methods of the present chapter 
(page 156), as such inter-study comparisons cannot be made.    
In conclusion, results of the present study demonstrated that increasing the period during 
which IP6 ingestion is restricted from 3 to 15 days may not be necessary to detect a 
significant decrease in urinary IP6 and conversely, that urinary IP6 can be increased with IP6 
supplementation. These findings are important because urinary IP6 is hypothesized to play a 
role in the inhibition of CaOx urolithiasis. The finding of an increase in citraturia following 
ingestion of the IP6 supplement is consistent with the finding reported for ingestion of dietary 
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IP6 and shows that this effect is independent of the form in which IP6 is administered. 
Results (with regard to citrate excretion) also showed evidence of different renal handling of 
the IP6 supplement in the two race groups. Since this phenomenon has been previously 
reported for different supplements, researchers should consider focusing on these 
physiological handling processes in their efforts to identify the cause of the different stone 
incidence rates in the two groups.  
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Chapter 8 : Concluding comments 
 
Studies on the ingestion of IP6 in the context of urolithiasis have hypothesized that this 
nutrient may provide protection against CaOx kidney stone formation via two mechanisms. 
Firstly, the administration of large quantities of IP6 can be undertaken with a view to 
increasing the formation of insoluble calcium-phytate complexes in the gastrointestinal tract 
thereby culminating in a decrease in the concentration of total urinary calcium. While this 
mechanism may be useful in treating patients with hypercalciuria it may not be helpful to treat 
patients with idiopathic CaOx urolithiasis. Secondly, the administration of moderate amounts 
of IP6 can be undertaken with a view to increasing urinary IP6 in order to inhibit CaOx 
crystallisation. This mechanism may be useful in treating patients with idiopathic CaOx 
urolithiasis. The work conducted in the present PhD project was undertaken on the basis of 
these mechanisms.  
Another aspect of the work undertaken in this project was based on a hypothesis published 
35 years ago that the relative rarity of CaOx renal lithiasis in the South African black 
population compared to the white population may be due to their higher intake of IP6. Testing 
this hypothesis in relation to whether the former group has a higher urinary excretion of IP6 
had been a challenge in a previous study which was conducted in the KSRL at the University 
of Cape Town since the methods which were available for urinary IP6 quantification required 
sophisticated instrumentation and in some cases relied upon the adequate separation of 
inorganic phosphate. This difficulty rendered the conclusions of that study questionable. 
Thus, the present project sought to test the aforementioned hypothesis after identifying and 
testing a more robust method for the quantification of urinary IP6.   
Regarding the first hypothesis of the present PhD project, the results have demonstrated that 
although soluble calcium-phytate complexes do form in urine, they do not influence the 
crystallisation of CaOx. Thus, the first hypothesis is rebutted. This led the researcher to 
speculate that the inhibitory effect of IP6 might be more of a kinetic nature than a 
thermodynamic one. This was confirmed in in vitro experiments in AU and pooled urine of 
South African black and white subjects. These in vitro experiments demonstrated two 
important kinetic properties of IP6, namely that physiological concentrations of IP6 have the 
capacity to inhibit CaOx crystal aggregation and that its effect on the inhibition of CaOx 
crystal growth may not be concentration dependent. These findings may be important for the 
inhibition of CaOx stone formation in vivo.  
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Regarding the second hypothesis under investigation in the present project, the results have 
demonstrated that a higher ingestion of IP6 in black subjects compared to white subjects 
manifests itself in a higher urinary excretion. This was demonstrated for the first time. Thus, 
the employment of a more robust method for the quantification of urinary IP6 was successful. 
Furthermore, since urinary IP6 may play an important role in the inhibition of CaOx crystal 
aggregation and growth in vivo as well as the notion of its inhibitory capacity at a 
macroscopic level, its higher concentration in the black group might be a contributory factor 
to the relative rarity of CaOx urolithiasis in this group. Therefore, the second hypothesis of 
the present PhD project has been validated. 
Regarding future studies, the present project demonstrated that an increase in IP6 ingestion 
resulted in an increase in urinary citrate. Although, it was speculated that an increase in 
phosphate (derived from IP6 hydrolysis) might have resulted in this effect, future studies can 
be undertaken to validate this.  
The work presented in this thesis contributes to the body of knowledge about kidney stone 
disease with regard to the role of urinary phytate. More importantly, the hypothesis that the 
relative rarity of renal stone formation in South Africa’s black population compared to the 
white population may be attributed to the much higher dietary intake of IP6 in this group has 
been validated. 
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Phytate protonation and calcium-phytate complexation_titration curves 
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3.8 4.3 4.8 5.3 5.8
EM
F 
(m
V
) 
volume of 0.1 M NaOH added (ml) 
CaPhy (2:1)_titration 2 
experimental data
theoretical model
0
50
100
150
200
250
3.8 4.3 4.8 5.3 5.8
EM
F 
(m
V
) 
volume of 0.1 M NaOH added (ml) 
CaPhy (2:1)_titration 3 
experimental data
theoretical model
0
50
100
150
200
250
2.65 2.85 3.05 3.25 3.45
EM
F 
(m
V
) 
volume of 0.1 M NaOH added (ml) 
CaPhy (3:1)_titration 1 
experimental data
theoretical model
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0
50
100
150
200
250
2.62 2.82 3.02 3.22 3.42
EM
F 
(m
V
) 
volume of 0.1 M NaOH 
CaPhy (3:1)_titration 2 
experimental data
theoretical model
0
50
100
150
200
250
2.62 3.12 3.62
EM
F 
(m
V
) 
volume of 0.1 M NaOH added (ml) 
CaPhy (3:1)_titration 3 
experimental data
theoretical model
0
50
100
150
200
250
2.64 2.84 3.04 3.24 3.44
EM
F 
(m
V
) 
volume of 0.1 M NaOH added (ml) 
CaPhy (4:1)_titration 1 
experimental data
theoretical model
0
50
100
150
200
250
2.66 2.86 3.06 3.26 3.46
EM
F 
(m
V
) 
volume of 0.1 M NaOH added (ml) 
CaPhy (4:1)_titration 2 
experimental data
theoretical model
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Appendix 3 
 
Appendix 3.1 
Urine data of black subjects used for theoretical modelling. All units in mol/L 
Lab no pH Cit Ox Ca Mg Na K Urate Phos Cl 
BU1a 5.58 1.69E-03 1.80E-04 3.44E-03 2.89E-03 1.69E-01 5.26E-02 4.43E-03 3.52E-02 1.57E-01 
BU2a 7.89 4.38E-04 1.23E-04 9.95E-04 1.00E-03 4.26E-02 2.14E-02 1.37E-03 9.09E-03 3.88E-02 
BU3a 6.05 1.08E-03 1.41E-04 1.63E-03 1.39E-03 5.74E-02 1.94E-02 1.76E-03 1.07E-02 5.35E-02 
BU4a 6.20 1.65E-03 2.29E-04 1.68E-03 1.41E-03 6.09E-02 2.85E-02 3.06E-03 1.44E-02 7.16E-02 
BU5a 6.70 5.79E-04 1.02E-04 7.62E-04 5.75E-04 4.90E-02 1.85E-02 1.28E-03 8.81E-03 5.28E-02 
BU6a 6.67 1.28E-03 2.22E-04 1.72E-03 2.36E-03 9.35E-02 3.17E-02 2.78E-03 1.65E-02 7.92E-02 
BU7a 8.36 6.49E-04 1.10E-04 1.02E-03 1.12E-03 6.13E-02 2.00E-02 8.77E-04 3.90E-03 6.49E-02 
BU8a 7.71 1.01E-03 2.60E-04 1.46E-03 1.21E-03 8.13E-02 3.72E-02 3.10E-03 1.55E-02 7.40E-02 
BU9a 7.06 1.84E-03 1.34E-04 1.20E-03 1.39E-03 8.35E-02 1.92E-02 1.95E-03 1.66E-02 1.01E-01 
BU10a 5.87 1.11E-03 1.68E-04 1.21E-03 1.00E-03 8.39E-02 3.94E-02 3.27E-03 2.36E-02 1.03E-01 
BU11a 6.68 1.89E-03 1.41E-04 1.54E-03 1.42E-03 9.26E-02 2.80E-02 3.45E-03 3.29E-02 1.10E-01 
BU12a 5.62 8.16E-04 1.46E-04 1.85E-03 1.69E-03 7.13E-02 2.73E-02 2.54E-03 2.51E-02 1.12E-01 
b1a 6.5 2.39E-03 1.25E-04 2.13E-03 1.11E-03 1.72E-01 2.33E-02 4.43E-03 3.52E-02 1.55E-01 
B2a 5.74 2.02E-03 4.04E-04 3.10E-03 2.27E-03 1.16E-01 3.04E-02 3.65E-03 2.96E-02 1.02E-01 
B3a 6.32 2.05E-03 1.95E-04 1.54E-03 1.14E-03 1.13E-01 4.00E-02 2.93E-03 2.35E-02 1.66E-01 
B4a 6.29 1.88E-03 3.54E-04 2.97E-03 2.32E-03 1.59E-01 4.74E-02 5.69E-03 3.94E-02 1.77E-01 
B5a 6.81 1.73E-03 2.04E-04 2.14E-03 1.17E-03 8.13E-02 2.55E-02 1.48E-03 1.01E-02 1.00E-01 
B7a 6.21 2.39E-03 2.60E-04 1.67E-03 7.10E-04 1.38E-01 2.36E-02 3.60E-03 3.68E-02 1.03E-01 
average 6.57 1.47E-03 1.94E-04 1.78E-03 1.45E-03 9.59E-02 2.96E-02 2.87E-03 2.15E-02 1.01E-01 
SE 0.18 1.45E-04 1.96E-05 1.75E-04 1.46E-04 9.55E-03 2.37E-03 2.99E-04 2.65E-03 9.57E-03 
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 Urine data of white subjects used for theoretical modelling. All units in mol/L 
Lab no pH Cit Ox Ca Mg Na K Urate Phos Cl 
W1a 6.05 9.83E-04 1.66E-04 1.54E-03 1.33E-03 1.05E-01 2.91E-02 4.86E-03 4.12E-02 1.15E-01 
W3a 5.64 1.67E-03 1.37E-04 2.20E-03 1.84E-03 1.51E-01 4.43E-02 1.08E-02 4.52E-02 1.11E-01 
W4a 6.78 1.71E-03 1.79E-04 1.34E-03 9.11E-04 5.39E-02 1.74E-02 4.64E-03 1.54E-02 2.89E-01 
W5a 6.08 1.90E-03 1.19E-04 8.97E-04 8.10E-04 5.28E-02 1.73E-02 2.06E-03 1.21E-02 1.17E-01 
W7a 6.17 1.81E-03 2.16E-04 1.19E-03 9.61E-04 8.76E-02 2.71E-02 3.14E-03 3.81E-02 1.43E-01 
W6A 6.29 1.32E-03 1.94E-04 2.21E-03 1.85E-03 6.08E-02 2.02E-02 2.06E-03 2.08E-02 7.00E-02 
W9A 5.89 1.26E-03 1.64E-04 2.92E-03 2.50E-03 8.15E-02 1.66E-02 2.13E-03 1.76E-02 9.75E-02 
W11A 6.75 2.39E-03 1.22E-04 1.03E-03 2.10E-03 1.03E-01 1.83E-02 2.10E-03 1.28E-02 1.07E-01 
W10A 5.96 2.90E-03 2.41E-04 3.57E-03 1.70E-03 1.18E-01 3.65E-02 2.65E-03 2.55E-02 1.70E-01 
W8A 6.07 1.68E-03 1.90E-04 1.52E-03 1.55E-03 6.21E-02 1.28E-02 2.66E-03 2.51E-02 5.89E-02 
SP1a 6.12 1.39E-03 7.02E-05 1.13E-03 7.48E-04 3.49E-02 1.05E-02 1.57E-03 1.61E-02 5.17E-02 
SP2a 6.19 1.97E-03 1.61E-04 8.14E-04 1.31E-03 1.96E-01 2.73E-02 3.90E-03 2.80E-02 1.85E-01 
SP3a 7.49 1.35E-03 1.09E-04 8.94E-04 4.64E-04 1.04E-01 1.34E-02 1.70E-03 1.05E-02 9.28E-02 
SP4a 6.07 2.14E-03 2.54E-04 9.72E-04 1.18E-03 1.09E-01 1.89E-02 3.24E-03 3.38E-02 1.55E-01 
SP5a 6.25 2.06E-03 1.85E-04 2.07E-03 1.49E-03 2.30E-01 3.13E-02 4.35E-03 3.98E-02 1.80E-01 
SP6a 6.8 1.72E-03 1.72E-04 1.29E-03 1.34E-03 1.27E-01 2.11E-02 3.19E-03 2.50E-02 9.05E-02 
average 6.29 1.77E-03 1.67E-04 1.60E-03 1.38E-03 1.05E-01 2.26E-02 3.44E-03 2.54E-02 1.27E-01 
SEM 0.11 1.18E-04 1.21E-05 1.99E-04 1.35E-04 1.31E-02 2.31E-03 5.54E-04 2.83E-03 1.49E-02 
 
Intergroup comparison of urine data (comparison of means using Unpaired t-test) 
Urine 
parameter 
pH Cit Ox Ca Mg Na K Urate Phos Cl 
P-value 0.21 0.13 0.29 0.62 0.72 0.68 0.045* 0.33 0.37 0.22 
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Appendix 3.2 
Supersaturation of salts in urine of black subjects 
  0.76 µM (black subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
BU1a 6.85E+04 0.44 1.90 9.89 6.75 2.98 5.81 2.18 4.51 9.29 
BU2a 2.54E+12 2360.48 1.73 42953.64 2.14 0.94 1.85 0.69 0.01 1.28 
BU3a 2.01E+05 0.53 1.09 6.15 5.14 2.27 4.43 1.66 0.88 1.87 
BU4a 9.04E+05 1.27 1.35 18.45 6.35 2.81 5.47 2.06 1.10 3.46 
BU5a 9.66E+06 3.52 1.00 37.33 2.00 0.88 1.72 0.65 0.16 1.32 
BU6a 4.02E+08 36.39 2.42 966.05 4.82 2.13 4.16 1.56 0.35 4.98 
BU7a 3.95E+12 1614.36 0.51 8729.71 1.46 0.64 1.26 0.47 0.00 1.17 
BU8a 4.08E+11 972.75 1.70 18155.16 1.36 3.09 2.67 1.00 0.04 4.95 
BU9a 6.07E+07 8.81 0.93 90.57 0.99 0.44 0.86 0.32 0.10 3.12 
BU10a 9.33E+03 0.11 0.90 1.07 3.57 1.58 3.08 1.16 2.14 4.31 
BU11a 3.22E+07 9.20 1.86 192.31 1.41 0.62 1.21 0.45 0.41 5.64 
BU12a 5.37E+03 0.09 1.08 1.05 5.06 2.23 4.37 1.64 2.56 2.47 
B1a 5.30E+07 13.93 2.43 395.37 1.85 0.82 1.59 0.60 0.76 12.71 
B2a 2.11E+05 0.77 2.02 17.46 15.85 7.00 13.68 5.13 2.97 6.10 
B3a 1.56E+06 1.78 1.40 28.51 2.97 1.31 2.56 0.96 0.75 5.60 
B4a 1.25E+08 27.54 3.93 1279.38 8.55 3.78 7.36 2.77 1.51 14.52 
B5a 9.20E+08 49.32 1.94 1047.13 5.70 2.52 4.92 1.85 0.14 2.36 
B7a 9.86E+05 1.57 1.74 30.76 4.06 1.79 3.49 1.31 1.18 8.24 
 
  2.27 µM Phy (black subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
BU1a 6.82E+04 0.44 1.90 9.84 6.73 2.98 5.81 2.18 4.51 9.29 
BU2a 2.48E+12 2328.09 1.72 42169.65 2.13 0.94 1.84 0.69 0.01 1.28 
BU3a 1.99E+05 0.53 1.09 6.10 5.13 2.26 4.42 1.66 0.88 1.87 
BU4a 8.93E+05 1.26 1.35 18.32 6.34 2.80 5.46 2.05 1.10 3.46 
BU5a 9.42E+06 3.48 1.00 36.64 1.99 0.88 1.71 0.64 0.16 1.32 
BU6a 3.97E+08 36.22 2.42 959.40 4.81 2.12 4.15 1.56 0.35 4.98 
BU7a 3.85E+12 1592.21 0.50 8550.67 1.45 0.64 1.25 0.47 0.00 1.17 
BU8a 4.02E+11 963.83 1.70 17947.34 3.08 1.36 2.66 1.00 0.04 4.95 
BU9a 6.08E+07 8.83 0.93 90.78 1.00 0.44 0.86 0.32 0.10 3.12 
BU10a 9.20E+03 0.11 0.90 1.06 3.56 1.57 3.07 1.15 2.14 4.31 
BU11a 3.20E+07 9.18 1.86 191.43 1.40 0.62 1.21 0.45 0.41 5.64 
BU12a 5.32E+03 0.09 1.08 1.04 5.05 2.23 4.36 1.63 2.56 2.47 
B1a 5.27E+07 13.90 2.43 394.46 1.85 0.81 1.59 0.60 0.76 12.71 
B2a 2.10E+05 0.77 2.02 17.42 15.85 7.00 13.65 5.13 2.97 6.10 
B3a 1.55E+06 1.78 1.39 28.38 2.96 1.31 2.56 0.96 0.75 5.60 
B4a 1.25E+08 27.48 3.93 1276.44 8.53 3.77 7.36 2.76 1.51 14.52 
B5a 9.10E+08 48.98 1.94 1039.92 5.69 2.51 4.91 1.84 0.14 2.36 
B7a 9.79E+05 1.56 1.73 30.55 4.05 1.79 3.49 1.31 1.18 8.24 
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  4.45 µM Phy (black subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
BU1a 6.78E+04 0.44 1.89 9.82 6.73 2.90 5.81 2.18 4.51 9.29 
BU2a 2.39E+12 2285.60 1.71 41020.41 2.11 0.93 1.82 0.68 0.01 1.28 
BU3a 1.96E+05 0.52 1.08 6.03 5.12 2.26 4.41 1.66 0.88 1.87 
BU4a 8.79E+05 1.25 1.34 18.07 6.31 2.79 5.45 2.04 1.10 3.46 
BU5a 9.12E+06 3.40 0.99 35.65 1.97 0.87 1.70 0.64 0.16 1.32 
BU6a 3.92E+08 35.89 2.41 948.42 4.80 2.12 4.14 1.55 0.35 4.98 
BU7a 3.71E+12 1555.97 0.50 8298.51 1.44 0.64 1.24 0.47 0.00 1.17 
BU8a 3.92E+11 950.60 1.69 17579.24 3.07 1.36 2.64 0.99 0.04 4.95 
BU9a 6.08E+07 8.83 0.93 90.78 1.00 0.44 0.86 0.32 0.10 3.12 
BU10a 9.06E+03 0.11 0.89 1.04 3.55 1.57 3.06 1.15 2.14 4.31 
BU11a 3.17E+07 9.12 1.86 190.11 1.40 0.62 1.21 0.45 0.41 5.64 
BU12a 5.26E+03 0.09 1.07 1.04 5.04 2.23 4.35 1.63 2.56 2.47 
B1a 5.25E+07 13.87 2.43 393.55 1.85 0.81 1.59 0.60 0.76 12.71 
B2a 2.08E+05 0.77 2.01 17.30 15.81 6.98 13.65 5.12 2.97 6.10 
B3a 1.53E+06 1.77 1.39 28.18 2.96 1.31 2.55 0.96 0.75 5.60 
B4a 1.24E+08 27.42 3.92 1270.57 8.53 3.77 7.36 2.76 1.51 14.52 
B5a 8.97E+08 48.53 1.93 1028.02 5.68 2.51 4.90 1.84 0.14 2.36 
B7a 9.71E+05 1.55 1.73 30.34 4.04 1.78 3.48 1.31 1.18 8.24 
 
  30 µM Phy (black subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
BU1a 6.35E+04 0.42 1.87 9.31 6.65 2.94 5.74 2.15 4.51 9.29 
BU2a 1.60E+12 1790.61 1.57 29716.66 1.96 0.86 1.69 0.63 0.01 1.28 
BU3a 1.63E+05 0.47 1.04 5.19 4.95 2.19 4.27 1.60 0.87 1.87 
BU4a 7.29E+05 1.12 1.29 15.60 6.11 2.70 5.26 1.98 1.10 3.45 
BU5a 6.03E+06 2.65 0.91 25.59 1.82 0.81 1.57 0.59 0.16 1.32 
BU6a 3.29E+08 32.28 2.32 824.14 4.65 2.05 4.00 1.50 0.35 4.97 
BU7a 2.33E+12 1177.61 0.46 5741.16 1.32 0.58 1.13 0.42 0.00 1.17 
BU8a 2.97E+11 803.53 1.60 14092.89 2.90 1.28 2.51 0.94 0.04 4.95 
BU9a 4.98E+07 7.83 0.90 77.27 0.95 0.42 0.82 0.31 0.10 3.11 
BU10a 7.36E+03 0.09 0.86 0.89 3.41 1.51 2.94 1.10 2.14 4.31 
BU11a 2.86E+07 8.57 1.82 174.98 1.37 0.61 1.18 0.44 0.41 5.62 
BU12a 4.55E+03 0.08 1.04 0.92 4.91 2.17 4.24 1.59 2.56 2.47 
B1a 4.97E+07 13.43 2.40 376.70 1.82 0.81 1.57 0.59 0.76 12.71 
B2a 1.91E+05 0.73 1.98 16.11 15.60 6.89 13.43 5.05 2.96 6.10 
B3a 1.40E+06 1.67 1.36 26.24 2.90 1.28 2.51 0.94 0.75 5.60 
B4a 1.17E+08 26.55 3.87 1216.19 8.43 3.72 7.28 2.73 1.51 14.49 
B5a 7.60E+08 44.06 1.87 901.57 5.51 2.43 4.75 1.78 0.14 2.36 
B7a 8.71E+05 1.46 1.69 27.86 3.95 1.75 3.40 1.28 1.18 8.24 
  1.50 mM Phy (black subjects) 
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SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
BU1a 1.04E+04 0.15 1.27 2.32 4.58 2.02 3.95 1.48 4.39 9.04 
BU2a 9.79E+09 82.79 0.49 459.20 0.66 0.29 0.57 0.21 0.01 1.14 
BU3a 1.64E+02 0.01 0.25 0.02 1.23 0.54 1.06 0.40 0.81 1.72 
BU4a 9.98E+03 0.09 0.52 0.51 2.42 1.07 2.08 0.78 1.01 3.20 
BU5a 4.70E+04 0.14 0.31 0.51 0.60 0.27 0.52 0.19 0.15 1.19 
BU6a 1.44E+07 5.00 1.16 67.45 2.39 1.06 2.07 0.77 0.33 4.63 
BU7a 5.81E+10 127.06 0.19 277.97 0.60 0.26 0.51 0.19 0.00 1.05 
BU8a 3.98E+10 240.44 0.96 2703.96 1.82 0.80 1.57 0.59 0.03 4.59 
BU9a 1.05E+07 3.09 0.59 21.63 0.64 0.28 0.55 0.21 0.09 2.89 
BU10a 6.93E+02 0.02 0.51 0.14 1.89 0.84 1.63 0.61 2.02 4.06 
BU11a 9.89E+06 4.61 1.36 75.34 1.00 0.44 0.86 0.32 0.39 5.27 
BU12a 8.07E+01 0.01 0.45 0.04 2.13 0.94 1.84 0.69 2.44 2.36 
B1a 2.16E+07 8.34 1.91 198.61 1.42 0.63 1.22 0.46 0.72 12.13 
B2a 7.60E+03 0.11 1.01 1.28 8.24 3.64 7.10 2.67 2.85 5.85 
B3a 5.43E+05 0.97 1.07 12.71 2.17 0.96 1.87 0.70 0.71 5.32 
B4a 4.76E+07 15.85 3.09 616.60 6.62 2.92 5.70 2.14 1.45 13.93 
B5a 2.33E+07 5.48 0.86 54.95 2.64 1.16 2.28 0.85 0.13 2.19 
B7a 3.05E+05 0.80 1.30 12.50 2.82 1.25 2.44 0.91 1.11 7.78 
 
Supersaturation in urine of white subjects 
 
 
0.76 µM (white subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
W1a 5.96E+05 1.31 2.01 29.51 3.32 1.47 2.86 1.07 2.21 8.17 
w3a 2.11E+04 0.22 1.58 4.02 3.71 1.64 3.20 1.20 10.14 21.23 
W4a 7.94E+06 3.29 0.90 34.67 1.64 0.72 1.41 0.53 0.43 4.31 
W5a 1.43E+03 0.03 0.40 0.12 1.65 0.73 1.42 0.53 0.93 1.91 
W7a 1.19E+05 0.46 1.25 6.53 2.54 1.12 2.18 0.82 1.12 4.49 
W6a 3.85E+07 12.25 2.94 387.26 6.67 2.94 5.74 2.15 0.61 2.34 
W9a 1.08E+06 1.73 2.06 38.90 7.50 3.31 6.47 2.43 1.36 2.82 
W11a 2.92E+06 1.71 0.72 13.68 1.06 0.47 0.92 0.34 0.22 4.11 
W10a 2.59E+06 3.04 2.43 84.72 8.93 3.94 7.71 2.89 1.41 4.82 
W8a 2.28E+05 0.67 1.48 10.57 4.53 2.00 3.90 1.47 1.25 2.93 
SP1a 3.96E+04 0.21 0.89 1.98 1.64 0.72 1.41 0.53 0.70 1.04 
SP2a 2.84E+04 0.18 0.73 1.55 1.29 0.57 1.11 0.42 1.28 12.22 
SP3a 1.32E+08 8.77 0.43 41.30 0.58 0.25 0.50 0.19 0.03 3.51 
SP4a 1.20E+04 0.12 0.84 1.14 2.56 1.13 2.21 0.83 1.40 5.61 
Sp5a 1.10E+07 6.50 2.44 190.99 3.11 1.37 2.69 1.01 1.24 15.78 
Sp6a 5.46E+07 10.76 1.51 181.97 1.67 0.74 1.44 0.54 0.29 7.41 
 
 
2.27uM Phy (white subjects) 
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SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
W1a 5.89E+05 1.297179 2.01 29.24 3.31 1.46 2.85 1.07 2.21 8.17 
W3a 2.10E+04 0.2208 1.58 4.00 3.71 1.64 3.20 1.20 10.14 21.23 
W4a 7.93E+06 3.280953 0.90 34.59 1.63 0.72 1.41 0.53 0.43 4.31 
W5a 1.40E+03 0.027542 0.40 0.12 1.64 0.72 1.42 0.53 0.93 1.91 
W7a 1.19E+05 0.460257 1.25 6.50 2.53 1.12 2.18 0.82 1.12 4.49 
W6a 3.81E+07 12.16186 2.93 353.18 6.65 2.94 5.73 2.15 0.61 2.34 
W9a 1.07E+06 1.725838 2.06 38.73 7.50 3.31 6.46 2.42 1.36 2.82 
W11a 2.89E+06 1.698244 0.72 13.55 1.06 0.47 0.91 0.34 0.22 4.11 
W10a 2.58E+06 3.033891 2.43 84.53 8.93 3.94 7.69 2.89 1.41 4.82 
W8a 2.25E+05 0.660693 1.48 10.47 4.52 2.00 3.89 1.46 1.25 2.93 
SP1a 3.90E+04 0.209411 0.89 1.95 0.72 1.63 1.41 0.53 0.70 1.04 
SP2a 2.83E+04 0.178649 0.73 1.54 1.29 0.57 1.11 0.42 1.28 12.22 
SP3a 1.30E+08 8.709636 0.43 40.93 0.57 0.25 0.50 0.19 0.03 3.51 
SP4a 1.19E+04 0.119674 0.84 1.14 2.56 1.13 2.21 0.83 1.40 5.61 
Sp5a 1.09E+07 6.501297 2.44 190.55 3.11 1.37 2.69 1.01 1.24 15.78 
Sp6a 5.42E+07 10.71519 1.51 180.72 1.67 0.74 1.44 0.54 0.29 7.41 
 
 
4.45uM Phy (white subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
W1a 5.82E+05 1.28825 2.00 28.97 3.30 1.46 2.84 1.07 2.21 8.17 
W3a 2.08E+04 0.219786 1.58 3.98 3.71 1.63 3.19 1.20 10.14 21.23 
W4a 7.89E+06 3.280953 0.90 34.51 1.63 0.72 1.41 0.53 0.43 4.31 
W5a 1.37E+03 0.027102 0.40 0.12 1.63 0.72 1.41 0.53 0.93 1.91 
W7a 1.17E+05 0.458142 1.25 6.46 2.52 1.11 2.18 0.82 1.12 4.49 
W6a 3.77E+07 12.07814 2.92 380.19 6.64 2.93 5.71 2.15 0.61 2.34 
W9a 1.06E+06 1.717908 2.05 38.46 7.48 3.30 6.46 2.42 1.36 2.82 
W11a 2.84E+06 1.682674 0.72 13.40 1.06 0.47 0.91 0.34 0.22 4.11 
W10a 2.56E+06 3.019952 2.42 83.95 8.91 3.94 7.69 2.88 1.41 4.82 
W8a 2.21E+05 0.654636 1.48 10.33 4.50 1.99 3.88 1.46 1.25 2.93 
SP1a 3.80E+04 0.206538 0.88 1.91 1.63 0.72 1.40 0.53 0.70 1.04 
SP2a 2.82E+04 0.178238 0.73 1.54 1.29 0.57 1.11 0.42 1.28 12.22 
SP3a 1.28E+08 8.629785 0.43 40.36 0.57 0.25 0.49 0.18 0.03 3.51 
SP4a 1.18E+04 0.119124 0.84 1.13 2.56 1.13 2.20 0.83 1.40 5.61 
Sp5a 1.09E+07 6.486344 2.44 190.11 3.11 1.37 2.68 1.01 1.24 15.78 
Sp6a 5.36E+07 10.64143 1.51 179.06 1.66 0.74 1.44 0.54 0.29 7.41 
 
 
30 uM Phy (white subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
W1a 5.09E+05 1.19 1.95 26.06 3.21 1.42 2.77 1.04 2.21 8.17 
W3a 1.89E+04 0.21 1.55 3.68 3.63 1.61 3.13 1.17 10.14 21.23 
W4a 7.60E+06 3.21 0.89 33.50 1.62 0.71 1.40 0.52 0.43 4.31 
W5a 1.03E+03 0.02 0.38 0.09 1.55 0.68 1.33 0.50 0.93 1.91 
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W7a 1.06E+05 0.43 1.22 5.96 2.47 1.09 2.13 0.80 1.12 4.48 
W6a 3.27E+07 11.12 2.84 340.41 6.47 2.86 5.58 2.09 0.61 2.34 
W9a 9.64E+05 1.62 2.01 35.65 7.36 3.25 6.35 2.38 1.36 2.82 
W11a 2.38E+06 1.51 0.69 11.59 1.02 0.45 0.88 0.33 0.22 4.10 
W10a 2.38E+06 2.89 2.39 79.25 8.81 3.89 7.59 2.84 1.41 4.82 
W8a 1.82E+05 0.58 1.42 8.81 4.34 1.91 3.74 1.40 1.25 2.92 
SP1a 2.84E+04 0.17 0.83 1.52 1.54 0.68 1.33 0.50 0.70 1.04 
SP2a 2.72E+04 0.17 0.73 1.50 1.28 0.56 1.10 0.41 1.28 12.22 
SP3a 1.07E+08 7.76 0.41 34.99 0.55 0.24 0.48 0.18 0.03 3.51 
SP4a 1.08E+04 0.11 0.82 1.05 2.51 1.11 2.16 0.81 1.40 5.61 
Sp5a 1.05E+07 6.34 2.42 184.08 3.08 1.36 2.66 1.00 1.24 15.78 
Sp6a 4.67E+07 9.82 1.46 160.69 1.62 0.72 1.40 0.52 0.29 7.40 
 
 
 
1.50uM Phy (white subjects) 
SS HAP tCaP brushite OCP CaOx COT COM COD Uric NaUric 
W1a 1.19E+05 0.509331 1.39 8.49 2.15 0.95 1.85 0.68 2.09 7.73 
W3a 3.71E+03 0.080538 1.08 1.06 2.44 1.08 2.10 0.79 9.77 20.51 
W4a 7.89E+06 3.280953 0.90 34.51 1.63 0.72 1.41 0.53 0.43 4.31 
W5a 1.91E+02 0.008492 0.25 0.03 0.93 0.41 0.80 0.30 0.86 1.77 
W7a 5.21E+04 0.289068 1.01 3.52 1.87 0.82 1.61 0.60 1.05 4.23 
W6a 2.30E+05 0.576766 1.00 6.56 2.36 1.04 2.04 0.76 0.57 2.17 
W9a 4.73E+03 0.068077 0.68 0.52 2.76 1.22 2.38 0.89 1.30 2.69 
W11a 5.56E+05 0.638263 0.48 3.60 0.70 0.31 0.61 0.23 0.20 3.83 
W10a 3.73E+05 0.977237 1.59 18.88 5.86 2.59 5.06 1.90 1.35 4.62 
W8a 3.49E+03 0.055208 0.61 0.38 1.77 0.78 1.53 0.57 1.15 2.70 
SP1a 2.00E+02 0.008974 0.29 0.03 0.48 0.21 0.41 0.16 0.63 0.94 
SP2a 1.74E+04 0.137404 0.63 1.09 1.06 0.47 0.92 0.34 1.22 11.72 
SP3a 1.90E+07 2.741574 0.26 8.36 0.35 0.16 0.30 0.11 32.21 3.24 
SP4a 6.07E+03 0.082414 0.70 0.70 1.95 0.86 1.69 0.63 1.33 5.32 
Sp5a 5.71E+06 4.528976 2.04 118.58 2.52 1.11 2.18 0.82 1.20 15.21 
Sp6a 1.23E+07 4.456562 1.03 54.95 1.13 0.50 0.97 0.37 0.27 6.93 
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Appendix 3.3 
Intergroup comparison of urinary SS and chemical speciation (comparison of means 
using Unpaired t-test) 
 
Intergroup comparisons of the SS of each stone-forming salt as well as the concentration of 
each species presented above were made and are reported below. 
No statistically significant difference in the SS of salts was observed between the two groups 
at all concentrations of phytate modelled in the present study as shown below. 
 Comparison of urinary SS: 
 P-value 
SS 0.76 µM 
phytate 
 
2.27 µM  
phytate 
 
4.45 µM 
phytate 
 
30 µM 
phyate 
 
1.50 mM 
phytate 
 
COM 0.24 0.24 0.24 0.24 0.36 
COD 0.24 0.24 0.24 0.24 0.36 
COT 0.17 0.17 0.17 0.17 0.36 
CaOx 0.28 0.28 0.28 0.28 0.36 
Brushite 0.36 0.36 0.36 0.36 0.67 
HAP 0.16 0.16 0.16 0.16 0.15 
OCP 0.14 0.14 0.14 0.14 0.15 
tCaP 0.11 0.11 0.11 0.11 0.11 
Uric acid 0.48 0.48 0.48 0.48 0.21 
Na-Urate 0.45 0.45 0.45 0.45 0.45 
 
In addition to the above, the speciation of calcium, phytate oxalate and phosphate species 
was not significantly different between the two groups (except for that of KOx-1 due to a 
significant difference in urinary potassium between the two groups) at a physiological 
concentration of 0.76 µM phytate or at the non-physiological concentration of phytate (1.50 
mM) as shown in Tables below. 
Comparison of calcium speciation: 
 
Species 
P Values  
0.76 µM phytate 1.50mM phytate 
Ca+2  0.40 0.71 
CaCitPO4-4 0.54 0.57 
CaCit-1 0.56 0.66 
CaHPO4 0.33 0.87 
CaH3(PO4)2-1 0.52 0.38 
CaCl+1 0.93 0.67 
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CaH2PO4+1 0.62 0.55 
CaPO4-1 0.10 0.19 
CaOx 0.23 0.57 
CaH2(PO4)2-2 0.66 0.96 
Ca2Ox+2 0.30 0.59 
CaHCit 0.38 0.34 
CaCit2-4 0.18 0.16 
CaH2Cit2-2 0.21 0.23 
CaHCitPO4-3 0.50 0.22 
Ca2HPhy-7 0.16 0.25 
 
Comparison of phytate speciation: 
 
Species 
P values  
0.76 µM phytate 1.50 mM phytate 
Ca2HPhy-7 0.12 0.65 
HPhy-11 0.36 0.53 
Phy-12 0.75 0.22 
 
Comparison of oxalate speciation: 
 
Species 
P Value  
0.76 µM phytate 1.50 mM phytate 
Ox-2 0.50 0.36 
NaOx-1 0.71 0.65 
MgOx 0.09 0.12 
CaOx 0.24 0.36 
KOx-1 0.03* 0.03* 
Ca2Ox+2 0.30 0.59 
MgHOxPO4-2 0.21 0.22 
HOx-1 0.84 0.76 
MgOxCit-3 0.54 0.76 
CaHOxPO4-2 0.23 0.42 
Mg2Ox+2 0.17 0.20 
MgOx2-2 0.12 0.29 
CaOx2-2 0.20 0.25 
CaOxCit-3 0.98 0.92 
CaHOxCit-2 0.82 0.87 
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Comparison of phosphate speciation: 
 
Species 
P value 
0.76 µM phytate 1.50 mM phytate 
H2PO4
-1 0.17 0.19 
HPO4
-2 0.90 0.87 
H4(PO4)2
-2 0.27 0.22 
HNaPO4
-1 0.91 0.85 
H2NaPO4 0.38 0.38 
HKPO4
-1 0.14 0.18 
CaCitPO4
-4 0.23 0.30 
CaH2PO4
+1 0.93 0.89 
H2KPO4 0.92 0.90 
CaH3(PO4)2
-1 0.59 0.67 
MgH2PO4
+1 0.75 0.86 
HNa2PO4 0.68 0.71 
H3(PO4)2
-3 0.35 0.27 
CaHPO4
+1 0.33 0.87 
MgHPO4 0.25 0.32 
 
Comparison of magnesium speciation: 
 
Species 
P value 
0.76 uM 1.50 mM 
Mg+2 0.35 0.18 
MgHPO4 0.23 0.32 
MgCitric-1 0.10 0.17 
MgH2PO4+1 0.93 0.61 
MgCl+1 0.92 0.97 
MgH3(PO4)2-1 0.52 0.78 
MgOx 0.09 0.12 
MgH2(PO4)2-2 0.29 0.32 
MgCit2-4 0.03* 0.02* 
MgHCitPO4-3 0.45 0.28 
MgHCit 0.68 0.83 
Mg2H2(PO4)2 0.18 0.22 
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Comparison of citrate speciation: 
The concentration of ionized citrate (Cit-3) and MgCit2-4 was significantly lower in the black 
group than the white group in the presence of 1.50 mM phytate as shown below (due to a 
difference in urinary citrate concentration):  
 
Species 
P value 
0.76 µM phytate 1.50 mM phytate 
CaCitPO4-4 0.24 0.30 
CaCit-1 0.56 0.37 
MgCit-1 0.16 0.14 
Cit-3 0.05 (B<W) 0.01* (B<W) 
NaCit-2 0.12 0.07 
Na2Cit-1 0.21 0.22 
HNaCit-1 0.28 0.32 
HCit-2 0.17 0.14 
KCit-2 0.77 0.68 
CaCit2-4 0.27 0.15 
MgCit2-4 0.06 (B<W) 0.02* (B<W)  
CaH2Cit2-2 0.82 0.73 
CaHCit 0.38 0.34 
MgHCitPO4-3 0.40 0.35 
CaHCitPO4-3 0.50 0.22 
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Appendix 4 
 
Appendix 4.1 
Raw data for the practical application of Method 2 (rat study) 
18-Sep-12 
  
[phytate]uM OD 550nm 
log OD 
550nm 
0 1.712 0.234 
2 1.427 0.154 
4 1.231 0.090 
6 1.053 0.022 
8 0.89 -0.051 
10 0.774 -0.111 
12 0.659 -0.181 
14 0.575 -0.240 
 
 
Day 0 
     
rat OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine % recov 
1 1.354 0.132 2.79 0.70   
2 1.403 0.147 2.34 0.58   
4 1.314 0.119 3.18 1.13   
5+6 1.371 0.137 2.63 1.74   
1+2 +IP6 
(1.08uM) 1.109 0.045 5.36 1.46 76 
 
24-Sep-12 
  
[phytate] uM OD 550 nm 
log OD 
550nm 
0 1.762 0.246 
2 1.594 0.202 
4 1.324 0.122 
6 1.107 0.044 
8 0.958 -0.019 
10 0.791 -0.102 
12 0.691 -0.161 
14 0.6 -0.222 
 
 
DAY 6 (IP6 restricted diet) 
    
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine % recov 
1 1.623 0.210 1.334 0.333   
2 1.579 0.198 1.678 0.419   
2+1uM 1.191 0.0759 5.207 1.302 88.2 
4 1.596 0.203 1.544 0.772   
5+6 1.656 0.219 1.082 0.832   
 
y = -0.0338x + 0.226 
R² = 0.9992 
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28-Sep-12 
  [phytate] uM OD logOD 
0 1.686 0.227 
2 1.454 0.163 
4 1.26 0.100 
6 1.097 0.040 
8 0.935 -0.029 
10 0.82 -0.086 
12 0.684 -0.165 
14 0.602 -0.220 
 
 
day10 
     
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine % recov 
1 1.575 0.197 0.976 0.244   
2 1.503 0.177 1.609 0.402   
2+1Um 1.251 0.097 4.092 1.023 62.1 
4 1.572 0.196 1.001 0.741   
5+6 1.552 0.191 1.175 1.034   
 
02-Oct-12 
  
[phytate]uM OD550nm 
log 
OD550nm 
0 1.797 0.255 
2 1.532 0.185 
4 1.316 0.119 
6 1.107 0.044 
8 0.953 -0.021 
10 0.826 -0.083 
12 0.703 -0.153 
14 0.627 -0.203 
 
 
day14 
     
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine % recov 
1 1.675 0.224 0.779 0.195   
2 1.706 0.232 0.538 0.135   
2 + 1um IP6 1.403 0.147 3.104 0.913 77.8 
4 1.745 0.242 0.242 0.060   
5+6 1.712 0.234 0.492 0.123   
 
y = -0.0321x + 0.2286 
R² = 0.9992 
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05-Oct-12 
  
[phytate]uM OD550nm 
log 
OD550nm 
0 1.781 0.251 
2 1.493 0.174 
4 1.287 0.110 
6 1.092 0.038 
8 0.946 -0.024 
10 0.784 -0.106 
12 0.693 -0.159 
14 0.614 -0.212 
 
 
day17 
     
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine % recov 
1 1.673 0.223 0.578 0.144   
2 1.659 0.220 0.687 0.172   
2 + 1um IP6 1.509 0.179 1.919 0.960 78.8 
4 1.653 0.218 0.734 0.184   
5+6 1.659 0.220 0.687 0.286   
 
09-Oct-12 
  
[IP6] uM OD550nm 
log 
OD550nm 
0 1.73 0.238 
2 1.499 0.176 
4 1.245 0.095 
6 1.062 0.026 
8 0.908 -0.042 
10 0.773 -0.112 
12 0.687 -0.163 
14 0.619 -0.208 
 
 
Urine of rats on UAR diet. Day 3 
  
rat ## OD 550nm log OD 550nm 
conc in 
eluate 
conc in 
urine 
1 1.464 0.166 1.987 0.497 
2 1.422 0.153 2.372 0.593 
4 1.535 0.186 1.360 0.654 
5+6 1.534 0.186 1.368 0.342 
 
y = -0.0334x + 0.2428 
R² = 0.9975 
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11-Oct-12 
  
[IP6] uM OD 550nm 
log OD 
550nm 
0 1.705 0.232 
2 1.487 0.172 
4 1.271 0.104 
6 1.075 0.031 
8 0.915 -0.039 
10 0.781 -0.107 
12 0.682 -0.166 
14 0.58 -0.237 
 
 
Day4 (UAR) 
diet 
    
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine 
1 1.387 0.142 2.758 0.690 
2 1.541 0.188 1.405 0.351 
4 1.573 0.197 1.141 0.357 
5+6 1.358 0.133 3.030 0.757 
 
16-Oct-12 
  
[IP6] uM OD 550nm 
log OD 
550nm 
0 1.752 0.244 
2 1.493 0.174 
4 1.282 0.108 
6 1.077 0.032 
8 0.916 -0.038 
10 0.802 -0.096 
12 0.699 -0.156 
14 0.611 -0.214 
 
 
Day10 (UAR) diet 
   
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine 
1 1.287 0.110 3.882 1.142 
2 0.859 -0.066 9.219 2.195 
4 1.366 0.135 3.096 1.248 
5+6 1.181 0.072 5.017 3.484 
 
y = -0.0338x + 0.2353 
R² = 0.9995 
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19-Oct-12 
  
[IP6] uM OD 550nm 
log OD 
550nm 
0 1.637 0.214 
2 1.456 0.163 
4 1.238 0.093 
6 1.06 0.025 
8 0.901 -0.045 
10 0.784 -0.106 
12 0.686 -0.164 
14 0.585 -0.233 
 
 
Day13 (UAR) 
diet         
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine 
1 1.359 0.133 2.674 1.592 
2 1.063 0.027 5.977 1.494 
4 1.51 0.179 1.258 0.873 
5+6 1.358 0.133 2.684 1.459 
 
23-Oct-12 
  
[IP6] uM OD 550nm 
log OD 
550nm 
0 1.797 0.255 
2 1.492 0.174 
4 1.271 0.104 
6 1.077 0.032 
8 0.898 -0.047 
10 0.796 -0.099 
12 0.694 -0.159 
14 0.621 -0.207 
 
 
Day17 (UAR) diet 
   
rat ## OD 550nm 
log OD 
550nm 
conc in 
eluate 
conc in 
urine 
1 1.185 0.074 4.984 1.246 
2 1.247 0.096 4.317 1.079 
4 1.473 0.168 2.138 0.764 
5+6 0.819 -0.087 9.817 4.090 
 
 
 
y = -0.0323x + 0.2196 
R² = 0.9990 
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Appendix 4.2  
Raw data for testing alternative resin 
 
OD 460nm 
   [IP6] 
uM 1 2 3 4 5 average 
   0 1.1616 1.1763 1.1677     1.1685 
   5 1.0968 1.0941 1.0335     1.0955 
   10 0.955 0.9515 0.9529     0.9531 
   20 0.7868 0.7934 0.7984     0.7929 
   
25 0.7198 0.7222 0.721     0.7210 
[IP6] uM in 
eluate 
[IP6] uM 
in AU 
% 
recover
y 
AU 1.1536 1.1586 1.1563 1.1557 1.1559 1.1560 0.55 0.11   
AU + 
1uM 1.0669 1.0677 1.052 1.0558 1.0513 1.0587 5.87 1.17 106 
AU + 
2uM 0.9834 0.9853 1.0036 1.0105 1.004 0.9974 9.22 1.84 87 
 
 
[IP6] 
uM 
OD 550 nm 
logOD    1 2 3 4 5 average 
   0 1.432 1.383       1.4075 0.15 
   2 1.208 1.197       1.2025 0.08 
   4 1.004 1.065       1.0345 0.01 
   6 0.9 0.908       0.904 -0.04 
   8 0.734 0.776       0.755 -0.12 
   10 0.651 0.649       0.65 -0.19 
   
12 0.55 0.552       0.551 -0.26 
IP6 in 
eluate 
IP6 in 
urine 
% 
recover
y 
AU 1.296 1.342 1.376 1.208 1.215 1.2874 0.11 1.20 0.30   
AU+1 1.118 1.131 1.129 1.053 1.062 1.0986 0.04 3.24 0.81 51 
AU+2 0.914 0.93 0.93 0.867 0.908 0.9098 -0.04 5.66 1.41 56 
 
y = -0.0183x + 1.1661 
R² = 0.9894 
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Appendix 5.3 
Particle size distribution plots (artificial urine) 
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Appendix 6 
Appendix 6.1 
 General questionnaire 
General Questionnaire 
General 
Name: _____________________  Tel:_________________ 
Date:_____________________            Cell:________________ 
Date of birth:______                                Gender:    Male                    Race: ___________ 
Nutritional 
Weight:__________                                 Height:_________ 
What foods are you allergic to?____________________________ 
Are you taking any vitamin supplements? __________ 
If yes:  Name of supplement___________          Dose____________ 
                                                                            Frequency_________________ 
Do you take any medication?_______________ 
If yes, please list:           prescription                    over-the counter 
                                 ______________              _______________ 
Lifestyle 
Do you smoke?  _______                 How many a day?___________ 
Do you drink alcohol?  _________   How many a day?___________ 
                                                          How many a week?_________ 
(drink = 1 can beer or 1 glass wine or tot spirits)      
                                                  
Medical history 
Have you had any illnesses recently?  __________________ 
Have you undergone any recent surgery?   ______________ 
What kind of exercise do you do?  __________________     
                            Hours per day? ____________________ 
                            Hours per week? ___________________ 
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Appendix 6.2 
Ethics approval 
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Appendix 6.3 
 urine collection 
Instructions for 24hr urine collections 
 
 On the day on which urine collection begins, do not collect the 1st urine specimen upon 
waking. 
 Thereafter, every urine voiding for the next 24 hours, must be passed into the collection 
bottle. 
 The collection ends when the first voiding upon waking is passed into the bottle, on the next 
day. 
 Because all urine for 24 hours is required, please remember to void into the bottle prior to 
defaecation. 
 During the period of urine collection, the specimen bottle should be kept in a cool place. If 
possible, it should be refrigerated. 
 If you have any queries, please phone: 021 650 2534. 
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Appendix 6.4  
IP6 in oats 
Raw data for determination of IP6 in oats 
 
 
 
 
 
 
 
 
 
Absorbance @ 500nm 
sample OD1 OD2 OD3 OD4 OD5 
Oats 0.393 0.392 0.393 0.395 0.392 
Oats + 600 uM IP6 0.38 0.373 0.372 0.378 0.383 
 
Appendix 6.5 
Raw data for determination of IP6 in urine samples 
[IP6] uM OD1 OD2 OD3 average equation of line 
0 1.2117 1.2300 1.2543 1.242 
  5 1.0767 1.0669 1.0779 1.077 
10 1.0022 0.7318 0.9968 1.036 y = -0.0253x + 1.2404; R2 = 0.9862 
20 0.7388 0.7195 0.7128 0.724 
  25 0.6024 0.6069 0.5997 0.603 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
BU1a 1.095 1.0497 1.0701 5.75 7.54 6.73 1.15 1.51 1.35 1.33 0.10 
BU2a 1.091 1.065 1.078 5.91 6.93 6.42 1.18 1.39 1.28 1.28 0.06 
BU3a 1.0908 1.0514 1.0362 5.91 7.47 8.07 1.18 1.49 1.61 1.55 0.06 
BU4a 1.003 1.0278 1.0253 9.38 8.40 8.50 1.88 1.68 1.70 1.69 0.01 
BU1b 1.027 1.0466   8.43 7.66   1.69 1.53   1.61 0.08 
BU2b 1.0782 1.1528 1.1454 6.41 3.46 3.75 1.28 0.69 0.75 0.72 0.03 
BU3b 1.1611 1.1555   3.13 3.36   0.63 0.67   0.65 0.02 
BU4b 1.009 0.9973 0.9636 9.15 9.61 10.94 1.83 1.92 2.19 1.98 0.11 
BU1c 1.0483 1.081 1.0101 7.59 6.30 9.10 1.52 1.26 1.82 1.53 0.16 
BU2c 1.0838 1.1209 1.0765 6.19 4.72 6.48 1.24 0.94 1.30 1.27 0.03 
BU3c 1.0259 1.0931 1.0768 8.48 5.82 6.47 1.70 1.16 1.29 1.23 0.06 
BU4c 1.1472 1.1013 1.1154 3.68 5.50 4.94 0.74 1.10 0.99 1.04 0.06 
[IP6] uM 
OD1 
(500nm) 
OD2 
(500nm) average Calibration curve: equation of line 
0 0.478 0.47 0.474 
  
7.57 0.425 0.432 0.4285 
15.15 0.385 0.391 0.388 
22.72 0.35 0.351 0.3505 y = -0.0048x + 0.4645; R2 = 0.9961 
30.3 0.31 0.304 0.307 
  
37.88 0.277 0.281 0.279 
45.45 0.245 0.258 0.2515 
53.03 0.212 0.212 0.212 
60.6 0.176 0.173 0.1745 
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[IP6] uM OD1 OD2 OD3 average equation of line 
0 1.14 1.1461 1.1551 1.147 
  5 1.0461 1.045 1.023 1.046 
10 0.9335 0.934 0.9277 0.932 y = -0.0196 + 1.1419; R2 = 0.9981 
20 0.7618 0.7563 0.7422 0.759 
  25 0.642 0.6535 0.652 0.649 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
BU5a 1.1195 1.102 1.0669 1.14 2.04 3.83 0.23 0.41 0.77 0.32 0.09 
BU6a 1.0587 1.0915 1.0722 4.24 2.57 3.56 0.85 0.51 0.71 0.78 0.07 
BU7a 1.0615 1.0752 1.1088 4.10 3.40 1.69 0.82 0.68 0.34 0.75 0.07 
BU8a 1.0281 0.9833 1.0203 5.81 8.09 6.20 1.16 1.62 1.24 1.20 0.04 
BU5b 1.0963 1.0947   2.33 2.41   0.47 0.48   0.47 0.01 
BU6b 1.1016 1.0933   2.06 2.48   0.41 0.50   0.45 0.04 
BU7b 1.1156 1.0618 1.058 1.34 4.09 4.28 0.27 0.82 0.86 0.84 0.02 
BU8b 1.0312 1.0334 1.0259 5.65 5.54 5.92 1.13 1.11 1.18 1.14 0.02 
BU5c 1.0532 1.0558   4.53 4.39   0.91 0.88   0.89 0.01 
BU6c 1.007 1.0175   6.88 6.35   1.38 1.27   1.32 0.05 
BU7c 1.0423 1.0528 0.8996 5.08 4.55 12.36 1.02 0.91 2.47 0.96 0.05 
BU8c 1.0459 1.0623 1.0495 4.90 4.06 4.71 0.98 0.81 0.94 0.96 0.02 
 
[IP6] uM OD1 OD2 OD3 average equation of line 
0 1.1519 1.1591 1.1571 1.156 
  5 1.0487 1.0575 1.0306 1.053 
10 0.9457 0.9452 0.9592 0.945 y = -0.0184 + 1.1454; R2 = 0.9969 
20 0.7938 0.7596 0.7727 0.775 
  25 0.6913 0.6979 0.6945 0.695 
  Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
sample ID 1 2 3 1 2 3 1 2 3 average SE 
BU9a 1.1146 1.141 1.119 1.67 0.24 1.43 0.33 0.05 0.29 0.31 0.02 
BU10a 1.1146 1.1177 1.1103 1.67 1.51 1.91 0.33 0.30 0.38 0.34 0.02 
BU11a 1.0861 1.0876   3.22 3.14   0.64 0.63   0.636 0.01 
BU12a 1.1018 1.1005   2.37 2.44   0.47 0.49   0.48 0.01 
BU9b 1.1166 1.1418 1.0921 1.57 0.20 2.90 0.31 0.04 0.58 0.45 0.13 
BU10b 1.1021 1.1071 1.1363 2.35 2.08 0.49 0.47 0.42 0.10 0.44 0.03 
BU11b 1.1083 1.0909   2.02 2.96   0.40 0.59   0.50 0.09 
BU12b 1.1051 1.0981 1.0766 2.19 2.57 3.74 0.44 0.51 0.75 0.57 0.09 
BU9c 1.1153 1.1092 1.0859 1.64 1.97 3.23 0.33 0.39 0.65 0.46 0.10 
BU10c 1.0997 1.1006 1.0819 2.48 2.43 3.45 0.50 0.49 0.69 0.56 0.07 
BU11c 1.0782 1.09 1.12 3.65 3.01 1.38 0.73 0.60 0.28 0.666 0.06 
BU12c 1.0947 1.0976 1.096 2.76 2.60 2.68 0.55 0.52 0.54 0.54 0.01 
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[IP6] uM OD1 OD2 OD3 average equation of line 
0 1.065 1.1342 1.12 1.127 
  5 1.0085 1.0214 0.9874 1.015 
10 0.921 0.9501 1.0593 0.977 y = -0.0175x + 1.1239; R2 = 0.9893 
20 0.7587 0.7615 0.7639 0.761 
  25 0.6965 0.685 0.7358 0.691 
  Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
sample ID 1 2 3 1 2 3 1 2 3 
averag
e SE 
W1a 1.1082 1.1082 1.104 0.90 0.90 1.14 0.18 0.18 0.23 0.195 0.02 
W2a 1.0943 1.0746 1.0959 1.69 2.82 1.60 0.34 0.56 0.32 0.329 0.01 
W3a 1.1029 1.0617 1.1052 1.20 3.55 1.07 0.24 0.71 0.21 0.227 0.01 
W1b 1.0611 1.099 1.0978 3.59 1.42 1.49 0.72 0.28 0.30 0.291 0.01 
W3b 1.0966 1.0693 1.0716 1.56 3.12 2.99 0.31 0.62 0.60 0.611 0.01 
W3c 1.0362 1.0739 1.0305 5.01 2.86 5.34 1.00 0.57 1.07 1.035 0.03 
W1c 1.0547 1.1457 1.0513 3.95 -1.25 4.15 0.79 -0.25 0.83 0.810 0.02 
 
[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.138 1.126 1.141 1.140 
  5 1.065 1.064 1.069 1.066 
10 0.969 0.972 0.973 0.971 y = -0.0185x + 1.1497; R2 = 0.9983 
20 0.778 0.756 0.773 0.776 
  25 0.687 0.685 0.696 0.686 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
w4a 1.093 1.105 1.1 3.06 2.42 2.69 0.61 0.48 0.54 0.545 0.04 
0
0.5
1
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w5a 1.103 1.101 1.092 2.52 2.63 3.12 0.50 0.53 0.62 0.552 0.04 
w7a 1.124 1.126 1.12 1.39 1.28 1.61 0.28 0.26 0.32 0.285 0.02 
w4b 1.006 1.044 1.034 7.77 5.71 6.25 1.55 1.14 1.25 1.197 0.05 
w5b 1.138 1.131 1.134 0.63 1.01 0.85 0.13 0.20 0.17 0.166 0.02 
w7b 1.136 1.132 1.136 0.74 0.96 0.74 0.15 0.19 0.15 0.163 0.01 
w4c 1.128 1.118 1.14 1.17 1.71 0.52 0.23 0.34 0.10 0.289 0.05 
w5c 1.108 1.141 1.105 2.25 0.47 2.42 0.45 0.09 0.48 0.467 0.02 
w7c 1.104 1.105 1.108 2.47 2.42 2.25 0.49 0.48 0.45 0.476 0.01 
 
 
[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.168 1.178 1.176 1.177 
  5 1.07 1.077 1.069 1.072 
10 0.948 0.945 0.936 0.947 y = -0.0219 +1.1741; R2 = 0.997 
20 0.736 0.72 0.722 0.721 
  25 0.64 0.645 0.625 0.643 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
w6a 1.126 1.06 1.144 2.20 5.21 1.37 0.44 1.04 0.27 0.357 0.08 
 
[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.185 1.154 1.161 1.158 
  5 1.054 1.041 1.01 1.048 
10 0.902 0.916 0.908 0.909 y = -0.0226x + 1.1517; R2 = 0.9965 
20 0.712 0.689 0.687 0.688 
  25 0.583 0.601 0.603 0.602 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
W6b 1.145 1.114 1.111 0.30 1.67 1.80 0.06 0.33 0.36 0.347 0.01 
W8b 1.131 1.119 1.133 0.92 1.45 0.83 0.18 0.29 0.17 0.174 0.01 
 
[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.19 1.288 1.201 1.196 
  5 1.075 1.082 1.074 1.075 
10 0.962 0.961   0.962 y = -0.0213x + 1.185; R2 = 0.9983 
20 0.756 0.746 0.766 0.756 
  25 0.662 0.658 0.664 0.661 
sample ID Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
  1 2 3 1 2 3 1 2 3 average SE 
W6c 1.128 1.126 1.123 2.68 2.77 2.91 0.54 0.55 0.58 0.557 0.01 
W8c 1.11 1.11 1.098 3.52 3.52 4.08 0.70 0.70 0.82 0.742 0.04 
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[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.2 1.184 1.19 1.1913 
  5 1.074 1.082 1.09 1.0780 
10 0.973 0.97 0.968 0.9703 y = -0.0208 + 1.1837; R2 = 0.9977 
20 0.758 0.777 0.754 0.7560 
  25 0.679 0.679 0.675 0.6777 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
W9A 1.143 1.138 1.119 1.96 2.20 3.11 0.39 0.44 0.62 0.415 0.02 
W10A 1.106 1.121 1.084 3.74 3.01 4.79 0.75 0.60 0.96 0.675 0.07 
W11A 1.117 1.123 1.098 3.21 2.92 4.12 0.64 0.58 0.82 0.613 0.03 
 
[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.235 1.219 1.200 1.210 
  5 1.084 1.082 1.078 1.081 
10 0.967 0.963 1.001 0.965 y = -0.0212x + 1.1937; R2 = 0.9962 
20 0.760 0.760 0.770 0.763 
  25 0.672 0.678 0.654 0.675 
sample ID 
Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
1 2 3 1 2 3 1 2 3 average SE 
W8A 1.156 1.148 1.145 1.78 2.16 2.30 0.36 0.43 0.46 0.445 0.01 
W9B 1.113 1.110 1.119 3.81 3.95 3.52 0.76 0.79 0.70 0.752 0.02 
W10B 1.132 1.127 1.151 2.91 3.15 2.01 0.58 0.63 0.40 0.606 0.02 
W11B 1.063 1.058 1.045 6.17 6.40 7.01 1.23 1.28 1.40 1.257 0.02 
 
[IP6] uM OD1 OD2 OD2 average equation of line 
0 1.241 1.239 1.245 1.240 
  5 1.122 1.121 1.140 1.122 
10 1.009 1.018 1.017 1.018 y = -0.0215x + 1.2348; R2 = 0.9996 
20 0.806 0.845 0.810 0.808 
  25 0.696 0.729 0.697 0.697 
  Absorbance at 460nm [IP6] in eluate (uM) [IP6] in urine (uM) 
sample ID 1 2 3 1 2 3 1 2 3 average SE 
W9C 1.166 1.183 1.192 3.20 2.41 1.99 0.64 0.48 0.40 0.507 0.07 
W10C 1.153 1.144 1.187 3.80 4.22 2.22 0.76 0.84 0.44 0.803 0.04 
W11C 1.125 1.110 1.097 5.11 5.80 6.41 1.02 1.16 1.28 1.221 0.06 
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Appendix 6.7 
 
CaOx MSLs 
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Appendix 6.8 
CaOx nucleation and aggregation 
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y = 3.42E-04x - 8.00E-03 
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y = 2.71E-04x - 1.48E-02 
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y = 2.09E-04x - 8.82E-03 
R² = 9.97E-01 
y = -2.94E-05x + 1.13E-01 
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y = 3.78E-04x - 4.36E-02 
R² = 9.99E-01 
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